Design, management and completion of the hypoCOMPaSS RCT evaluating potential for restoration of hypoglycaemia awareness in type 1 diabetes using conventional vs novel technologie : and exploration of potential phenotypes predicting persistent impaired awareness despite study intervention by Little, Stuart Alexander
  
Design, management and completion of the HypoCOMPaSS 
RCT evaluating potential for restoration of hypoglycaemia 
awareness in type 1 diabetes using conventional vs novel 
technologies; and exploration of potential phenotypes 
predicting persistent impaired awareness despite study 
intervention 
 
 
 
Stuart Alexander Little 
 
 
Doctor of Medicine Thesis 
 
 
 
 
Institute of Cellular Medicine 
Newcastle University 
February 2014  
 i 
Abstract  
Aim: To explore the extent to which impaired awareness of hypoglycaemia 
(IAH) can be improved using currently available treatment regimens in 
individuals with long-standing type 1 diabetes mellitus (T1DM), and to 
characterise those individuals whose awareness of hypoglycaemia did not 
improve.  
Methods: A multicentre, 2x2 factorial 24-week RCT (HypoCOMPaSS) 
comparing multiple daily injections (MDI) and continuous subcutaneous insulin 
infusion therapy (CSII) with or without real-time continuous glucose monitoring 
(RT) in a population with T1DM and IAH was designed.  The study was 
undertaken in five UK centres using established and novel outcome measures 
to assess hypoglycaemia awareness, glycaemic control and treatment 
satisfaction.   
A second analysis was undertaken characterising individuals within the 
HypoCOMPaSS population as responders and non-responders.  Complication 
status, autonomic symptom profile and hyperglycaemia avoidance scores were 
assessed.  
Results: Overall, hypoglycaemia awareness improved, and biochemical 
hypoglycaemia, severe hypoglycaemia rate and insulin doses reduced without 
deterioration in HbA1c.  There were no significant differences in awareness 
comparing MDI with CSII; and RT with conventional glucose monitoring.  
Between-group analyses demonstrated comparable reductions in severe 
hypoglycaemia, biochemical hypoglycaemia, fear of hypoglycaemia and insulin 
doses with equivalent HbA1c.  Treatment satisfaction was highest with CSII.  In 
the second study there was a suggestion that longer diabetes duration and 
increased age may impair ability to respond to the interventions but this did not 
correlate with severity of autonomic symptoms.  
Conclusions: Hypoglycaemia awareness can be improved and recurrent 
severe hypoglycaemia prevented in long-standing T1DM without relaxing 
HbA1c.  Similar biomedical outcomes can be attained with conventional MDI 
and SMBG regimens compared with CSII / RT.  All individuals may benefit from 
biomedical interventions to improve awareness of hypoglycaemia.  This 
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research provides a basis for further studies investigating impact of new 
technologies on severe hypoglycaemia and underlines the importance of 
tailoring treatment to avoid biochemical hypoglycaemia without relaxing overall 
control.   
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Chapter 1 
Introduction 
 
 1 
1.1 Content and scope 
The overall objective of this thesis was to explore the potential to improve the 
awareness of hypoglycaemia and prevent severe hypoglycaemia in individuals 
with type 1 diabetes, and identify characteristics of people whose awareness of 
hypoglycaemia did not improve.  This chapter will provide a background to the 
studies including: 
1. The underlying aetiology and drivers of hypoglycaemia 
2. Potential strategies available to prevent hypoglycaemia 
1.2 Introduction 
Diabetes Mellitus is the collective name for a group of disorders characterised 
by a hyperglycaemic state.  The heterogeneous group of disorders can be 
classified on the basis of the pathophysiology leading to the hyperglycaemia.  
Type 1 diabetes mellitus (T1DM) is characterised by insulin deficiency resulting 
from an autoimmune mediated destruction of the beta cells of the islets of 
Langerhans in the pancreas.  Type 2 diabetes mellitus is characterised by 
impaired insulin secretion, reduced insulin sensitivity and increased insulin 
production.   
T1DM is one of the most common childhood metabolic diseases and the 
incidence is increasing.  From 1989 to 2003 the annual increase in incidence in 
children under 15 years of age across Europe was 3.9% with the highest rate of 
increase (5.4%) in the 0-4 years age group (Patterson et al., 2009).  It has been 
estimated that the incidence of T1DM across Europe in this youngest of age 
groups will double between 2005 and 2020 (Patterson et al., 2009).   
Furthermore an inverse relationship has been reported between the overall 
incidence rate and the rise in incidence rate across European centres.  Thus the 
previously low childhood incidence in central and eastern European countries 
may now be catching up with countries with higher incidence.  The increase in 
annual incidence of childhood T1DM is not limited to Europe.  The World Health 
Organisation’s Multinational Project for Childhood Diabetes (DIAMOND, 2006), 
with a population sample of 84 million in 87 different countries, reported that 
between 1990 and 1999 the global annual increase in incidence was 2.8% 
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though the rate was higher (3.4%) during the last 5 years of the study.  Unlike 
the inverse relationship between annual incidence and rate of increased 
incidence between European centres, globally the most significant increases in 
rates were seen in the continents that already have high incidence such as 
Europe.  
A study from 2006 using an epidemiological model suggested that in 2006 there 
were 2,168,000 people with diabetes in England with 165,756 (7.3%) of these 
cases being T1DM (Forouhi et al., 2006).  This suggests an overall prevalence 
of 340 per 100,000 (0.34%).  It was estimated that in the North East of England 
there were 8447 cases of T1DM.  In the 2010-2011 NHS National Diabetes 
Audit the number of registrations of type 1 diabetes was 1,164 (Table 1.1) with 
a prevalence of 0.44% (Table 1.2).  
The factors responsible for the likely T-cell mediated immune destruction of the 
insulin producing beta cells which leads to the clinical presentation of T1DM are 
not fully understood.  Genetic susceptibility to T1DM involves many genes 
though it is thought that polymorphisms of the Human Leukocyte Antigen (HLA) 
genotype are responsible for 40-50% of genetic risk (Pociot and McDermott, 
2002).  Numerous other risk factors have been suggested to be responsible 
including seasonal variation of birth (Padaiga et al., 1999) (Levy-Marchal et al., 
1995), diet (Norris et al., 2003), infectious agents (Hyoty and Taylor, 2002), 
vitamin D deficiency (Bener et al., 2009) and geographical variation (DIAMOND, 
2006).   
In contrast to the hypothesis that there is an as yet unidentified trigger solely 
responsible for the increased incidence in T1DM, the ‘spring harvest’ hypothesis 
has been proposed (Gale, 2005).  This suggests that environmental factors are 
changing the natural history of T1DM disease progression.  Epidemiological 
evidence of earlier disease presentation, increased disease incidence in 
children of previously considered intermediate risk HLA haplotype and the 
prevalence of immune-mediated diabetes not requiring insulin treatment in older 
people and the predecessors of affected children is cited to back up the 
hypothesis of disease acceleration and altered disease penetrance.  
The large registry studies both within Europe and worldwide over recent 
decades have investigated the incidence of T1DM in children only and therefore 
 3 
longitudinal studies with longer term follow up are needed to determine whether 
or not the apparent increase in childhood incidence is associated with increased 
overall lifetime risk.  
  
 4 
Table 1.1 Diabetes registrations by type for Newcastle Primary Care 
Trust 2010-2011 
 
 Number of registrations 
All diabetes 10,581 
Type 1 diabetes 1,164 
Type 2 diabetes 9,323 
 
 
 
 
Table 1.2 Prevalence of diabetes in Newcastle Primary Care Trust 2010-
2011 
 
 Newcastle Primary Care 
Trust 
England 
 
Prevalence 
of diabetes 
(%) 
Percentage 
point 
change 
since 2009-
2010 (%) 
Prevalence 
of diabetes 
(%) 
Percentage 
point 
change 
since 2009-
2010 (%) 
All diabetes 3.97 +0.11 4.57 +0.21 
Type 1 
diabetes 
0.44 -0.01 0.41 0.00 
Type 2 
diabetes 
3.50 +0.12 4.07 +0.20 
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1.3 Aims of treatment in type 1 diabetes 
The results of the landmark Diabetes Control and Complications Trial (DCCT) 
concluded that the improvement of mean glycaemic control to as near normal 
as possible with intensive insulin treatment can delay the onset and slow the 
progression of the microvascular complications associated with T1DM such as 
nephropathy, retinopathy and neuropathy (DCCT, 1993).  The sustained long-
term benefit in reduction in micro-vascular complications was confirmed in the 
Epidemiology of Diabetes Interventions and Complications study (EDIC), which 
was a 17 year follow-up observational study of people with T1DM from the 
DCCT (Nathan et al., 2005).  On the basis of this information national guidelines 
such as that produced by the National Institute for Health and Care Excellence 
(NICE) suggest a target HbA1c of <58mmol/mol (7.5%) for people with T1DM 
(NICE, 2004).  
1.4 Type 1 diabetes and hypoglycaemia 
Type 1 diabetes is fatal unless it is treated with insulin replacement.  Insulin was 
first used as a therapy for humans with diabetes in 1922 by a team from 
Toronto University consisting of Dr. Fredrick Banting, Charles Best, Professor J. 
J. R. Macleod and Dr. James Collip.  In a landmark paper from this pioneering 
group which describes the metabolic outcomes after administration of the 
extract to patients with diabetes, the authors conclude that ‘blood sugar can be 
markedly reduced even to the normal values’ (Banting et al., 1922).  Within the 
same year that this paper was published the problem of iatrogenic 
hypoglycaemia was recognised in the literature (Fletcher and Campbell, 1922).  
For many people with T1DM hypoglycaemia remains one of the most feared 
complications alongside retinopathy and nephropathy (Pramming et al., 1991).  
Indeed, manifest fear of hypoglycaemia (FoH) is a recognised and relatively 
common phenomenon, particularly among those with a recent history of severe 
hypoglycaemia (Gonder-Frederick et al., 2011).  In a review on hypoglycaemia 
Cryer writes: ‘’at the very least an episode of hypoglycaemia is a nuisance and 
a distraction.  It can be embarrassing and cause social ostracism” (Cryer et al., 
2003).  At its worst hypoglycaemia can be even more devastating by causing 
behavioural changes, seizures, coma and in rare but tragic instances even 
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sudden death (Tattersall and Gill, 1991).  Between these two extremes, 
hypoglycaemia reduces emotional well being and impairs quality of life.  It is 
almost inevitably associated with negative mood states (e.g. depressed mood, 
anxiety, irritability) but the relationship is idiosyncratic (Gonder-Frederick et al., 
1989).  Narrative research has found that patients rarely discuss hypoglycaemia 
with others and that it can affect views of themselves and interpersonal 
relationships (Ritholz and Jacobson, 1998).  Loss of spontaneity and 
independence are reported commonly by those with recurrent severe 
hypoglycaemia, as well as other restrictions (e.g. on ability to drive, work, fulfil 
family commitments) that impair quality of life (Speight et al., 2010).  
1.5 Definition of hypoglycaemia 
One of the factors limiting meaningful interpretation of existing literature and 
evidence-based guidelines for optimal clinical management of hypoglycaemia 
has been the lack of universally agreed blood glucose levels by which 
hypoglycaemia is defined.  A clinically useful and globally accepted definition 
used in the Diabetes Control and Complications Trial defines a hypoglycaemic 
episode as ‘mild’ if self treatment is possible and ‘severe’ if external help is 
required for treatment (DCCT, 1993).  Importantly this definition does not take 
into account asymptomatic hypoglycaemia, which is important in the aetiology 
of severe hypoglycaemia.  
The American Diabetes Association (ADA) Workgroup on hypoglycaemia’s 
overarching definition is “all episodes of an abnormally low plasma glucose 
concentration that expose the individual to potential harm” (ADA, 2005).  The 
Workgroup further classifies hypoglycaemia into five categories: severe 
hypoglycaemia, documented symptomatic hypoglycaemia, asymptomatic 
hypoglycaemia, probable symptomatic hypoglycaemia and relative 
hypoglycaemia (Table 1.3).  
The biochemical cut-off (≤ 3.9 mmol/L) proposed by the ADA may artificially 
inflate the amount of hypoglycaemia reported by inclusion of episodes with no 
clinical significance (Swinnen et al., 2009).  This is because the provocation of 
symptoms and cognitive impairment that is associated with low blood glucose 
will rarely be produced at levels between 3.5 - 4.0 mmol/L.   It has therefore 
been argued that a value of 3.5 mmol/L should be used to ensure that only truly 
 7 
significant episodes are recorded in clinical trials (Frier, 2009).  The main 
argument for this is that the evidence suggesting that antecedent plasma 
glucose concentrations of 3.9 mmol/l reduce glucose counter-regulatory 
responses to subsequent hypoglycaemia is from a cohort of non-diabetic 
subjects, and therefore may not be clinically relevant in people with diabetes.  
Primarily this is because the diminished glucagon response seen in non-
diabetic people is unlikely to be relevant because people with insulin treated 
diabetes develop deficient glucagon secretion at an early stage in the T1DM 
disease process.  The alternative view is that a value of ≤ 3.9 mmol/L should be 
used as a cue for action (if not necessarily carbohydrate administration), to give 
patients enough time to take steps to prevent severe hypoglycaemia.  It would 
also allow for some margin of error in the accuracy of blood glucose meters at 
low plasma glucose values (Cryer, 2009).  
Any numerical definition used by healthcare professionals does not however 
reflect the spectrum of disruption hypoglycaemia causes to people with 
diabetes, which may start with mild inconvenience in everyday living but 
extends to a life threatening emergency.  Any biochemical cut-off may be 
deemed arbitrary.   Therefore when investigating hypoglycaemic episodes in 
study populations, which have a high risk of severe hypoglycaemia, it may be 
most appropriate to record low values below a range of thresholds (including all 
≤ 3.9mmol/L) to evaluate impact on clinical outcomes.  
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Table 1.3 ADA working group definitions of hypoglycaemia 
 
Definition 
 
Description 
Severe hypoglycaemia An event requiring the assistance of another person to 
actively administer carbohydrate, glucagon, or other 
resuscitative actions.  These episodes may be associated 
with sufficient neuroglycopaenia to induce seizure or 
coma.  Plasma glucose measurements may not be 
available during such an event, but neurological recovery 
attributable to the restoration of plasma glucose to normal 
is considered sufficient evidence that the event was 
induced by low plasma glucose concentration.   
Documented 
symptomatic 
hypoglycaemia 
An event during which typical symptoms of 
hypoglycaemia are accompanied by a measured plasma 
glucose ≤3.9 mmol/l. 
Asymptomatic 
hypoglycaemia 
An event not accompanied by typical symptoms of 
hypoglycaemia but with a measured plasma glucose 
concentration ≤3.9 mmol/l. 
Probable symptomatic 
hypoglycaemia 
An event during which symptoms of hypoglycaemia are 
not accompanied by a plasma glucose determination (but 
that was presumably caused by a plasma glucose 
concentration ≤3.9 mmol/l). 
Relative hypoglycaemia An event during which the person with diabetes reports 
any of the typical symptoms of hypoglycaemia, and 
interprets those as indicative of hypoglycaemia, but with a 
measured plasma glucose concentration >3.9 mmol/l. 
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1.6 The frequency of hypoglycaemia 
While the ADA Workgroup report provides an extremely valuable framework, 
misreporting remains a risk if data on symptomatic and severe hypoglycaemia 
episodes are not collected meticulously.  As the majority of these episodes 
occur outside times of routine blood glucose monitoring (i.e. before meals and 
bed) care is needed to optimise study protocols, to prevent over-reporting of 
biochemical hypoglycaemia without concomitant reporting of symptoms; or 
under reporting of symptomatic hypoglycaemia / severe hypoglycaemia due to 
the absence of sufficiently robust diary data when glucose levels have not been 
checked or recorded.  
The occurrence of severe hypoglycaemia has a skewed distribution with 
relatively few individuals experiencing the majority of events (Pedersen-
Bjergaard et al., 2004).  This has led to the recommendation that both the 
percentage of individuals affected and event rates (e.g. episodes per 100 
patient years) are reported (ADA, 2005).  Recall of the frequency of severe 
hypoglycaemia is reported to be reliable up to one year (Pramming et al., 1991) 
while the recall of mild or minor events may be inaccurate beyond one week.  
This limitation in recall also contributes to the difficulties in analysing 
hypoglycaemia data.  
In a retrospective epidemiological survey of an unselected population with type 
1 diabetes (defined as a diagnosis of diabetes before the age of 40 years old, 
requiring insulin from the outset) prevalence of severe hypoglycaemia was 
reported to be 37% over a one-year recall period with 130 events occurring per 
100 patient years (Pedersen-Bjergaard et al., 2004).  In this study, 5% of the 
participants experienced 54% of all severe hypoglycaemic episodes, providing 
further evidence for the highly skewed distribution.  The rate of mild 
hypoglycaemia (defined as episodes with symptoms of hypoglycaemia 
manageable by the individual) was reported as two events per week.  In a 
similar study the severe hypoglycaemia rate was reported as 150 events per 
100 patient years with 41% affected over a one-year period (ter Braak et al., 
2000).  
Estimates of the frequency of severe hypoglycaemia when determined in 
prospective population-based studies are likely to be the most reliable. An 
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incidence of severe hypoglycaemia of 115 episodes per 100 patient years was 
reported in one such study from Tayside (Donnelly et al., 2005). A similar 
severe hypoglycaemia rate of 110 events per 100 patient years with prevalence 
of 22% in a patient group with T1DM duration of less than five years was 
reported in a multicentre prospective observational study over 9 - 12 months in 
the UK (UK-hypoglycaemia-studygroup, 2007).  However, the rate rose to 320 
events per 100 patient years with a prevalence of 46% in those with long 
duration diabetes (more than 15 years), indicating that those with a longer 
duration of diabetes are at higher risk of severe hypoglycaemia. 
In the DCCT trial (DCCT, 1997) severe hypoglycaemia rates ranged from 61.2 
events per 100 patient years in the intensively treated group to 18.7 events per 
100 patient years in the conventionally treated group (three fold increase in 
intensively treated group).  However it should be noted that people with type 1 
diabetes and a preceding history of severe hypoglycaemia were excluded from 
the DCCT, which therefore excluded many with impaired awareness of 
hypoglycaemia.  As will be discussed in section 1.9 the majority of clinical trials 
investigating pharmacological interventions in the management of T1DM have 
excluded those with previous recurrent severe hypoglycaemia meaning that 
only limited interpretation of the data concerning SH frequency can be made.  
From a health economic viewpoint there are substantial costs to the NHS in the 
need for the emergency medical treatment of severe hypoglycaemia.  It has 
been suggested that around 10% of episodes of severe hypoglycaemia 
required emergency medical assistance (Donnelly et al., 2005).  
Mild hypoglycaemia has been reported to occur on average twice weekly 
(Pramming et al., 1991; Pedersen-Bjergaard et al., 2004).  
A summary of the epidemiology of severe hypoglycaemia is shown in Table 1.4. 
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Table 1.4 Summary of severe hypoglycaemia epidemiology in type 1 
diabetes mellitus 
Study 
Prevalence of 
severe 
hypoglycaemia (%) 
Incidence of severe 
hypoglycaemia 
(episodes/patient/year) 
Pramming S et al 
(Pramming et al., 
1991) 
36 1.4 
DCCT Research 
group (DCCT, 1997) 
35 (men) 
31 (women) 
0.19-0.62 
Ter Braak E W et al 
(ter Braak et al., 
2000) 
40.5 1.5 
Pedersen-Bjergaard 
U et al (2004) 
(Pedersen-Bjergaard 
et al., 2004) 
36.7 1.3 
UK Hypoglycaemia 
Study Group (UK-
hypoglycaemia-
studygroup, 2007) 
22 (<5 year duration) 
46 (> 15 yrs 
duration) 
1.1 (<5 years duration) 
3.2 (>15 years 
duration) 
 12 
1.7 Hypoglycaemic symptoms 
Hypoglycaemic symptoms can be classified under 3 headings (autonomic, 
neuroglycopenic and other) depending on the aetiology of the symptom (Deary 
et al., 1993).  
(1) Autonomic symptoms are due to secondary activation of the sympatho-
adrenal nervous system).  Some autonomic symptoms are adrenergic 
(catecholamine mediated) such as palpitations, tremor, anxiety; while others are 
cholinergic (acetylcholine mediated) such as sweating, hunger and 
paraesthesia (Cryer et al., 2003). 
(2) Neuroglycopenic symptoms include dizziness, confusion, tiredness, difficulty 
in speaking, drowsiness and headache.  These are secondary to the direct 
effect of glucose deprivation on the brain, particularly cortical function.  Cerebral 
glycopenia affects cognitive performance including processing information and 
decision making.  In experimental studies the performance of working memory 
and simple motor tasks such a finger tapping are more resilient and may 
deteriorate at around 2.4 mmol/L (Holmes et al., 1986), while the performance 
of undertaking tasks requiring reaction times and operation of driving simulators 
are affected at plasma glucose levels of around 2.8 - 3.0 mmol/L (Heller and 
Macdonald, 1996).  This may be due to the regional variations in brain glucose 
metabolism that have been clearly documented (Cranston et al., 1998).  
(3) Other symptoms include hunger, blurred vision and tiredness.  These are 
symptoms that are difficult to reliably attribute to the other physiological 
mechanisms.    
1.8 Aetiology and drivers of severe hypoglycaemia 
1.8.1 Classical drivers 
Fundamentally, low glucose is caused by relative insulin excess.  The 
therapeutic ratio for insulin is extremely small, with doses sufficient to achieve 
normoglycaemia being sufficient also to induce hypoglycaemia in the same 
individual (Little et al., 2011).  Therefore, there is a particularly high risk of 
hypoglycaemia when insulin doses are large or ill-timed.  Hypoglycaemia can 
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also occur when exogenous delivery of glucose is decreased (e.g. missed 
meals); when glucose utilisation is increased (e.g. during physical activity); 
when endogenous glucose production is reduced (e.g. post alcohol); when 
sensitivity to insulin is increased (e.g., weight loss, increased fitness) and when 
insulin clearance is decreased (e.g. renal failure, hypothyroidism) (Cryer et al., 
2003).  However in the Diabetes Control and Complications Trial (DCCT), such 
classical risk factors were not found to be responsible for most severe 
hypoglycaemic events (DCCT, 1991).  Table 1.3 has been adapted from Cryer 
(Cryer, 2008)) and illustrates the causes and risk factors for hypoglycaemia.  
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Table 1.5  Causes and risk factors for hypoglycaemia (adapted from 
Cryer, 2008) 
Causes of relative or absolute therapeutic insulin 
excess 
Risk factors 
Inadequate intake of exogenous carbohydrate 
a) Missed meals 
b) Dieting 
c) Breast feeding 
d) Malabsorption (coeliac disease) 
e) Gastroparesis (autonomic neuropathy) 
 
Impaired awareness of 
hypoglycaemia 
 
History of severe 
hypoglycaemia 
 
Strict glycaemic control 
 
C-peptide negativity 
 
Sleep 
 
Recent antecedent 
hypoglycaemia 
 
Duration of diabetes 
 
Exercise 
 
Loss of glucagon 
secretion 
Increased utilisation of carbohydrate 
a) Unexpected physical exertion 
b) Breast feeding 
c) Social situation; before and after sport, 
new job, travel 
 
Increased sensitivity to insulin 
a) In the middle of the night 
b) Improved fitness 
c) Weight loss 
d) Honeymoon period following treatment in 
newly diagnosed diabetes 
 
Reduced insulin clearance 
a) Renal failure 
b) Hypothyroidism 
 
Change in insulin or insulin pharmacokinetics 
a) New formulation 
b) Dose ill timed or of wrong type 
c) Effects of temperature (e.g. hot bath) 
d) Effects of injection site 
 
Other causes 
a) Concomitant endocrine conditions 
(hypopituitarism, adrenal insufficiency, 
hypothyroidism) 
b) Factitious insulin administration 
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1.8.2 Tight glycaemic control and treat to target studies 
In the DCCT, there was a three fold increase in severe hypoglycaemia in the 
intensive treatment group compared to the conventional treatment group (61.2 
events per 100 patient years vs 18.7 events per 100 patient years) (DCCT, 
1997).  This landmark study has reinforced the dogma that tight glucose control 
is the predominant risk factor for severe hypoglycaemia while revealing that the 
majority of events are not solely due to conventional risk factors but instead 
occur in those with impaired awareness of hypoglycaemia.  In the DCCT, 
predictors of risk of severe hypoglycaemia in the intensive treatment group 
included previous severe hypoglycaemia history, longer duration of diabetes, 
higher baseline HbA1c and lower recent HbA1c (DCCT, 1991).  The DCCT also 
confirmed that the presence of detectable endogenous insulin as measured by 
residual C-peptide secretion is associated with reduced risk of severe 
hypoglycaemia (DCCT, 1997).  It has been postulated that this may be 
mediated by the C-peptide itself, through an as yet unidentified mode of action, 
or simply through hypoglycaemia-induced reduction in residual endogenous 
insulin secretion. 
1.8.3 Biochemical hypoglycaemia and impaired counter regulation  
Biochemical hypoglycaemia at a level associated with cognitive impairment is 
avoided in people without diabetes through a series of counter regulatory 
responses which result in increased endogenous production and reduced 
peripheral utilisation of glucose.  This has been confirmed in seminal studies 
involving stepped hyperinsulinaemic hypoglycaemic clamps, which report 
glycaemic thresholds for counter-regulatory hormone secretion, symptoms of 
hypoglycaemia and cerebral dysfunction (Schwartz et al., 1987; Mitrakou et al., 
1991; Fanelli et al., 1994a).  There is a distinct hierarchy of responses.  As 
insulin secretion ceases, the counter-regulatory hormone glucagon is secreted, 
promoting hepatic gluconeogenesis and glycogenolysis, followed by activation 
of the autonomic nervous system and epinephrine release.  Autonomic 
symptoms precede neuroglycopenic symptoms and progressive deterioration in 
cerebral function.   
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Glucagon secretion occurs first at a blood glucose level of approximately 3.8 
mmol/l.  Epinephrine secretion from the adrenal medulla follows, also increasing 
hepatic gluconeogenesis and glycogenolysis.  Associated activation of the 
sympathetic nervous system stimulates hepatic gluconeogenesis by direct 
neuronal stimulation, which also contributes to autonomic symptoms.  A plasma 
glucose level for increased epinephrine secretion of between 3.6 - 3.8 mmol/l 
has been reported (Schwartz et al., 1987; Mitrakou et al., 1991; Fanelli et al., 
1994a).  In a different study the glucose levels required to trigger epinephrine 
secretion varied between individuals without diabetes from 2.7 - 4.1 mmol/l with 
a mean of 3.5 mmol/L (Amiel et al., 1987).  The same study concluded that the 
rate of glucose decline does not affect the threshold.  This hierarchy of 
response prevents glucose from falling below the threshold for cognitive 
impairment (approximately 3.0 mmol/l) thus averting neuroglycopenic 
symptoms, collapse or need for assistance in administering carbohydrate to 
reverse hypoglycaemia (Mitrakou et al., 1991).   
People with C-peptide negative type 1 diabetes are unable to inhibit insulin 
secretion in the face of biochemical hypoglycaemia, and almost all have 
impaired physiological counter-regulatory hormone responses within a few 
years of diagnosis (Bolli et al., 1983).  The exact mechanism of this is not fully 
understood.  However, the intra-islet hypothesis posits that intra-islet 
hyperinsulinaemia, due to exogenous insulin therapy, during hypoglycaemia 
leads directly to defective alpha-cell regulation (Banarer et al., 2002).  Recent 
animal studies have also suggested that an inhibitory effect of exogenous 
insulin on alpha-cell glucagon secretion may be mediated by the brain at the 
level of the ventromedial hypothalamus (Paranjape et al., 2010).   
Given the absent insulin and diminished glucagon responses in people with 
type 1 diabetes, the sympathoadrenal response is critical in their defence 
against hypoglycaemia (Rizza et al., 1979).  Individuals with reduced 
epinephrine responses including those with longer disease duration are at 
higher risk of severe hypoglycaemia (Fanelli et al., 1994b).  Amiel and 
colleagues reported that in people with tightly controlled T1DM by the means 
then available, the plasma glucose level at which epinephrine response was 
triggered was reduced (blood glucose: 2.6 mmol/L) (Amiel et al., 1988).  
Conversely, the plasma glucose level required for epinephrine release was 
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found to be raised when glycaemic control was sub-optimal, demonstrating that 
thresholds for epinephrine secretion are dynamic. 
In 1988 Amiel and colleagues (Amiel et al., 1988) reported that in people with 
strictly controlled T1DM, treated with an intensive insulin regimen the threshold 
for epinephrine secretion was higher (blood glucose = 2.6 mmol/L) and that the 
epinephrine concentration was reduced at all glucose levels.  In the same study 
the glucose threshold for epinephrine release were found to be lower when 
glycaemic control was poor.  This confirmed that the absolute thresholds for 
epinephrine secretion are dynamic.  
1.8.4 Biochemical hypoglycaemia and hypoglycaemia associated 
autonomic failure (HAAF) 
Hyperinsulinaemic clamp studies in volunteers without diabetes, published in 
the early 1990s, established that short duration antecedent biochemical 
hypoglycaemia reduced both the counter-regulatory hormone and symptom 
response to subsequent hypoglycaemia (Davis and Shamoon, 1991; Heller and 
Cryer, 1991; Widom and Simonson, 1992).  The same finding was reported in 
participants with type 1 diabetes (Dagogo-Jack et al., 1993).  Cryer 
hypothesised that iatrogenic biochemical hypoglycaemia was responsible for 
reduction in the counter-regulatory response to hypoglycaemia thus creating a 
vicious cycle, eventually leading to “hypoglycaemia associated autonomic 
failure” (HAAF) (Cryer, 1992b).  
HAAF in T1DM is a concept that describes two clinical syndromes, the 
mechanisms of which are largely unknown.  The first syndrome is that of 
defective glucose counter-regulation, as defined by a further reduced 
epinephrine response in the setting of an absent glucagon response (Bolli et al., 
1983).  The second is impaired awareness of hypoglycaemia caused by 
reduced autonomic symptom responses associated with a reduced sympathetic 
neural response to lower glucose concentrations.  When the threshold for these 
responses falls to around or below the threshold for cognitive impairment, 
neuroglycopenic symptoms can precede or impair recognition of autonomic 
symptoms leading to a severe event (Sussman et al., 1963).   
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Impaired awareness of hypoglycaemia has been associated with a 6-fold 
increased risk of severe hypoglycaemia over a twelve month period (Geddes et 
al., 2008).  It is thus important that awareness of hypoglycaemia is regularly and 
formally assessed in those with type 1 diabetes.  This includes ascertainment of 
glucose level at which symptoms are first experienced, whether earliest 
symptoms are autonomic or neuroglycopenic and whether these can be 
recognised as a harbinger of hypoglycaemia before others recognise this or 
help in treatment is required.  Recognition of hypogIycaemia associated 
autonomic failure as a dynamic syndrome whereby ‘hypoglycaemia begets 
hypoglycaemia’ (Cryer, 1993) underlines how one episode of severe 
hypoglycaemia is an important risk factor for a further event with risk of being 
unable to detect hypoglycaemia being increased following a single episode of 
sustained biochemical hypoglycaemia (Dagogo-Jack et al., 1993).   
It has been postulated that the sympathetic neural response with subsequent 
increase in norepinephrine and acetylcholine secretion, as opposed to the 
adrenomedullary response with epinephrine secretion, is responsible for the 
majority of autonomic symptoms (Cryer, 2005).  This is supported by evidence 
of maintained autonomic symptoms in patients who have had bilateral 
adrenalectomies (DeRosa and Cryer, 2004).   
1.8.5 Neuroimaging correlates 
Neuroimaging has been used to identify differences in brain responses 
(changes in cerebral blood flow) to hypoglycaemia between those who are 
symptom aware and those with impaired awareness of hypoglycaemia.  The 
normal response to hypoglycaemia results in activation of brain areas important 
in the mediation of autonomic responses (thalamus) (Arbelaez et al., 2008), 
stress (anterior cingulate, insula), food seeking (insula) and altered internal 
homeostasis, with a deactivation in areas involved with memory (hippocampus), 
vision (visual cortex) and reward or pleasure (lateral orbito-frontal cortex) (Teh 
et al., 2010).  This would suggest that hypoglycaemia is perceived as stressful 
and unpleasant.  However, in individuals with impaired awareness of 
hypoglycaemia, there is less activation in the stress areas, with a failure of 
deactivation of the orbito-frontal cortex, consistent with a lack of internal 
motivation to avoid hypoglycaemia (Bingham et al., 2005; Dunn et al., 2007) 
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1.8.6 The role of diabetic autonomic neuropathy 
Classical diabetic autonomic neuropathy (DAN) was traditionally thought to be 
an important factor underlying impaired awareness of hypoglycaemia but the 
evidence to support this is conflicting.  Reported data are difficult to interpret 
due to confounding factors including duration of diabetes, age and glycaemic 
control and the lack of consensus regarding the diagnostic criteria for DAN.  
The reported prevalence of autonomic neuropathy in people with type 1 
diabetes ranges widely, between 0 and 90%, depending upon the study, the 
population under investigation and the number and type of diagnostic tests 
performed (Vinik et al., 2003).  
As Cryer and others have highlighted, although one of the key associations of 
unawareness is loss of sympathoadrenal response (Heller and Cryer, 1991; 
Cryer, 1992a), impaired awareness of hypoglycaemia can be induced by just a 
few hours of mild hypoglycaemia and these changes are reversible, at least in 
part.  Short-term functional changes are not consistent with classical DAN 
caused by slowly accruing and long-standing damage to the autonomic nervous 
system.  Thus the term, hypoglycaemia associated autonomic failure (HAAF) 
(Cryer, 1992a), coined by Cryer to describe impaired physiological protection 
against hypoglycaemia following antecedent episodes, is distinct from any effect 
of classical autonomic neuropathy (Ryder et al., 1990).  
Nevertheless, there are data to suggest that DAN is associated with a modest 
increase in risk of severe hypoglycaemia.  In a large epidemiological study 
comprising 3,248 people with type 1 diabetes, those with at least one episode of 
severe hypoglycaemia (1046 (32%)) within the preceding year were more likely 
to have impaired cardiac autonomic function (126 (13%)) (determined by 
measuring heart rate and blood pressure response to standing) than those 
without (157 (7.7%) p=0.002) (Stephenson et al., 1996).  Even after controlling 
for confounding factors, there was an association between history of severe 
hypoglycaemia and autonomic neuropathy.  There is also evidence that DAN is 
associated with an impaired epinephrine response to experimental 
hypoglycaemia (Polinsky et al., 1980; Hilsted et al., 1981; Bolli et al., 1983; 
Horie et al., 1984; Meyer et al., 1998).  
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However, people with T1DM but without autonomic neuropathy also have an 
attenuated epinephrine response to hypoglycaemia compared to people without 
diabetes.  Studies involving glucose clamps in participants with T1DM with and 
without DAN, have reported reduced epinephrine responses with autonomic 
responses occurring at lower glucose concentrations compared to people 
without diabetes (Dagogo-Jack et al., 1993).  These findings confirm those of a 
previous study, which reported no evidence of DAN in a cohort of people with 
type 1 diabetes and impaired awareness of hypoglycaemia; and no evidence of 
impaired glucose counter-regulation or impaired awareness of hypoglycaemia in 
patients with DAN (Ryder et al., 1990).  A larger observational study (Hepburn 
et al., 1990), however, concluded that 'the precise relationship between diabetic 
autonomic neuropathy and loss of hypoglycaemia awareness remains 
undefined' after finding a positive association between impaired awareness of 
hypoglycaemia and DAN in the study population but not in the sub-group of 
people with type 1 diabetes duration greater than 15 years.   
1.8.7 Psychosocial factors 
The biomedical factors for hypoglycaemia discussed above help to explain the 
aetiology of many episodes of severe hypoglycaemia.  However key studies 
have also reported significant rates of severe hypoglycaemia in patient groups 
with intact awareness of hypoglycaemia (Gold et al., 1994; Clarke et al., 1995a) 
and also in patient groups without many of the key risk factors (DCCT, 1991).  A 
biopsychobehavioural model of risk of severe hypoglycaemia integrating 
psychosocial and behavioural factors in addition to biological processes has 
been described (Gonder-Frederick et al., 1997) to further elucidate severe 
hypoglycaemia risk.  This model emphasises the need for skills based 
education as an intervention to reduce severe hypoglycaemia risk.  With 
education focussed on avoiding high risk behaviour, optimising treatment 
decisions, modifying behaviour and helping to improve detection of 
hypoglycaemia it is suggested that overall risk of severe hypoglycaemia can be 
reduced (Cox et al., 2001; Hermanns et al., 2010).  
A recent large study with 764 participants concluded that the frequency of 
severe hypoglycaemia is the most important factor in the development of fear of 
hypoglycaemia (Anderbro et al., 2010) which is widely accepted as 
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compromising overall glycaemic control and impairing quality of life.  However 
there is very little research on fear of hyperglycaemia, which may be a driver of 
hypoglycaemia in some people with T1DM.  Fear of hyperglycaemia is a 
psychological construct characterised by excessive worry about high blood 
glucose in combination with acceptance (and non-avoidance) of hypoglycaemia 
- as a 'necessary evil' to evade development of long-term complications, such 
as blindness.  It may lead to inappropriate blood glucose lowering behaviours, 
including deliberate overtreatment or overzealous use of insulin, reluctance to 
attend to early symptoms of hypoglycaemia, and inappropriate pursuit of low 
blood glucose despite recurrent hypoglycaemia.  Interviews with people with 
recurrent severe events suggest that fear of hyperglycaemia may be a highly 
relevant determinant of severe hypoglycaemia (Barendse et al., 2012).  The 
'Hyperglycaemia Avoidance Scale' (Singh and al, 2010), assessing phobic 
concerns and behaviours related to hyperglycaemia, has been developed in the 
United States and has been adapted for use in the United Kingdom (Barendse 
et al., 2011).  While the scale shows promise for improving understanding of 
phobic behaviours there are as yet no published data on its use.  
Recent qualitative research with participants who have impaired awareness of 
hypoglycaemia, has identified further attitudes which may prevent people from 
being motivated to regain awareness (Rogers et al., 2012).  These included 
normalising lack of awareness, underestimating its consequences, wanting to 
avoid the 'sick role' by not attending to their hypoglycaemia and, as described 
above, overestimating the consequences of hyperglycaemia.  Another 
qualitative study by Speight et al (submitted) has identified that despite 
experiencing early symptoms of hypoglycaemia, individuals often delay 
intervention (with carbohydrate) due to being distracted, inaccurate assessment 
of risk, embarrassment, worry about rebound hyperglycaemia or unavailability 
of a preferred glucose source.  In addition, use of an inappropriate slow-acting 
glucose (e.g. biscuit or chocolate) compromised prevention of severe 
hypoglycaemia.  
  
 22 
1.9 The prevention of severe hypoglycaemia 
1.9.1 Avoidance of biochemical hypoglycaemia 
As outlined above it is now accepted that antecedent biochemical 
hypoglycaemia is the major factor in the development of impaired awareness of 
hypoglycaemia and, thus, increased risk of severe hypoglycaemia.  A landmark 
study published in the New England Journal of Medicine in 1993 (Mitrakou et 
al., 1993) reported the observation that in patients with insulinomas, recovery of 
counter regulatory hormone response and symptoms to hypoglycaemia was 
seen following surgical resection of the adenoma, demonstrating that in this 
patient group the loss of awareness was reversible.   
The first study (Fanelli et al., 1993) testing this hypothesis in a population with 
T1DM demonstrated that in a study population of 8 with short duration diabetes 
(mean 5 years) and short duration unawareness (mean 1.2 years) 
hypoglycaemia unawareness was reversible.  In this study stepped 
hyperinsulinaemic hypoglycaemic clamps were undertaken two weeks and 
three months after careful hypoglycaemia avoidance.  None of the patients in 
the study had classical diabetic autonomic neuropathy.  At three months the 
threshold for epinephrine secretion normalised to the level of the non-diabetic 
control group although the magnitude of the response remained less.  
Interestingly at three months the glucagon response also improved although the 
threshold remained less with a lower magnitude.  During the three months there 
was a significant reduction in the number of episodes of hypoglycaemia and 
there were no episodes of severe hypoglycaemia.  There was also a significant 
increase in HbA1c from 40mmol/mol (5.8%) to 52mmol/mol (6.9%) suggesting 
that the prevention of hypoglycaemia was achieved at the cost of deterioration 
in overall glycaemic control. 
The finding that awareness of hypoglycaemia could be reversed was also seen 
in a study with participants with longer term diabetes (duration range = 11 - 32 
years) who all had history of impaired awareness (Cranston et al., 1994).  Two 
groups of participants were studied with a total study population of 12.  One 
group had tight glycaemic control (HbA1c < 53mmol/mol (7.0%)); the other had 
variable control (mean HbA1c at baseline of 66mmol/mol (8.2%)).  After a three 
week period in which all self monitored home blood glucose readings were 
 23 
recorded as >3.5 mmol/L, significant reductions in the threshold for the onset of 
both autonomic and neuroglycopenic symptoms were seen in both patient 
groups.  Significantly lower thresholds for epinephrine, norepinephrine and 
growth hormone secretion were also seen in both groups although unlike 
Fanelli’s study (Fanelli et al., 1993) no difference in the threshold to glucagon 
secretion was seen.  There was also no deterioration in overall glycaemic 
control as assessed by HbA1c.  
The concept that absolute biochemical hypoglycaemia avoidance can restore 
awareness has been confirmed in further studies.  In a study with population 
n=21, improved counter regulatory and symptom responses were seen after 
three months of intensified insulin therapy during which meticulous prevention 
of hypoglycaemia was attempted (Fanelli et al., 1994b).  While Dagogo-Jack 
and colleagues (Dagogo-Jack et al., 1994) did report improved symptomatic 
responses to hypoglycaemia after three months of strict hypoglycaemic 
avoidance, no significant reductions in the threshold for epinephrine or glucagon 
release were observed.  The authors concluded that there were differences 
between mechanisms underlying hypoglycaemia awareness and defective 
glucose counter-regulation.  These authors demonstrated that the improvement 
in symptomatic responses seen after only a short period of strict avoidance may 
be sustained with ongoing beneficial effect on hypoglycaemia episode 
frequency (Dagogo-Jack et al., 1999).  
1.9.2 Education and behaviour modification 
A programme termed Blood Glucose Awareness Training (BGAT), which is 
described as a psychoeducational intervention to aid avoidance of both hypo- 
and hyperglycaemia has been developed.  Evaluations of this programme have 
reported significantly improved detection of low blood glucose in people with 
impaired awareness of hypoglycaemia from baseline to 6 months (Cox et al., 
1995) and significantly reduced number of severe hypoglycaemia events from 
baseline to 6 months (Cox et al., 2001).  There is evidence that the mechanism 
for the improvement in awareness may be by reducing the attenuated 
epinephrine response to hypoglycaemia seen in people with intensively treated 
T1DM (Kinsley et al., 1999).  As of 2008 this training programme was made 
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available over the internet (Cox et al., 2008), demonstrating how if successful 
education can be made easily accessible to large numbers of patients.  
An RCT with 111 participants comparing a modified version of BGAT for use in 
a German speaking population with a standard education programme has also 
reported significant reductions of severe hypoglycaemia and significant 
improvement in awareness of hypoglycaemia (Schachinger et al., 2005) in 
favour of BGAT.  
An education programme termed HyPOS has been described in the literature 
and in contrast to BGAT focuses only on hypoglycaemia.  An RCT comparing 
HyPOS (Hermanns et al., 2007) to standard T1DM education with 164 
participants all of whom had either confirmed impaired awareness of 
hypoglycaemia or history of at least one episode of severe hypoglycaemia 
within the preceding year was designed not to detect change in severe 
hypoglycaemia rate, but instead to detect change in awareness to 
hypoglycaemia.   The study found significant improvements in awareness of 
hypoglycaemia as measured by the validated Clarke questionnaire (Clarke et 
al., 1995) and a modified visual analogue scale of the Gold score (Gold et al., 
1994).  No difference was seen in either severe hypoglycaemia rates or overall 
glycaemic control.  The authors comment that in both groups there were 
improvements in awareness suggesting education per se is effective in 
improving awareness.  
There is some evidence to suggest that an educational intervention whose 
content stresses only insulin, food, and exercise would be unlikely by itself to be 
sufficient to reduce the frequency of severe hypoglycaemia.   In a study (Clarke 
et al., 1999) with 93 participants, the preceding management behaviours with 
regards insulin, food and exercise before low blood glucose were predictive of 
hypoglycaemia, but were not different between those who did and did not have 
a history of severe hypoglycaemia.  
The DAFNE (Dose Adjustment For Normal Eating) T1DM education programme 
which was derived from a training programme developed in Dusseldorf 
(Muhlhauser et al., 1983), provides a holistic approach to improving glycaemic 
control.  There is growing evidence suggesting that it reduces severe 
hypoglycaemia and improves hypoglycaemia awareness.  In an audit of 
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participants attending courses in one year, 43% of those with impaired 
awareness at course entry (40% of the total) had restored awareness at one 
year (Hopkins et al., 2012).  In the same study there was also a significant 
reduction in severe hypoglycaemia rate from 1.7 ± 8.5 to 0.6 ± 3.7 
episodes/person/year (p <0.001), within one year of undertaking the 
programme.  In a similar audit in Australia, 28% of 145 DAFNE-trained 
participants reported a decrease in severe hypoglycaemia frequency at one 
year (McIntyre et al., 2010).  In the hub-and-spoke DAFNE study with 63 
participants, there was a significant reduction in frequency of emergency call-
out for severe hypoglycaemia in the year after undertaking the programme, 
though absolute numbers of events were small (Rogers et al., 2009).   
1.9.3 Pharmacology: basal insulin analogues 
Hypoglycaemia has been studied inadequately for both of the commonly used 
long acting insulin analogues.  Most of the large randomised control trials 
comparing long acting insulin analogues with neutral protamine Hagedorn 
(NPH) insulin have been treat to target studies (particularly in terms of lowest 
achievable fasting glucose) powered to detect changes in overall glycaemic 
control as measured by HbA1c and not hypoglycaemia frequency.  In addition 
many of the key comparative studies have excluded participants with history of 
recurrent severe hypoglycaemia; and as a consequence have study populations 
with a mean age usually between 35 and 45 years old and a mean diabetes 
duration usually less than 20 years. The definition of hypoglycaemia in these 
studies is varied with a range from <4.0 mmol/l to 2.0 mmol/l.   
1.9.4 Glargine 
Glargine is a long acting insulin analogue, which is less soluble at physiological 
pH than human insulin.  Because of this glargine precipitates in the 
subcutaneous tissue and therefore the rate of absorption is delayed and 
duration of action extended (Pieber et al., 2000).  There is evidence that 
glargine reduces the risk of nocturnal hypoglycaemia compared to NPH insulin 
when taken either with prandial unmodified human insulin (Pieber et al., 2000; 
Ratner et al., 2000) or rapid acting insulin analogues (Porcellati et al., 2004; 
Rossetti et al., 2003; (Fulcher et al., 2005).   A study comparing the combined 
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analogue regimen of glargine and lispro with NPH insulin and unmodified insulin 
(Ashwell et al., 2006) reports a significant reduction in the monthly rate of 
nocturnal hypoglycaemia (0.66 ± 0.02 vs 1.18 ±0.02 episodes/month, p<0.001) 
in favour of the combined analogue group.  The reduction in nocturnal 
hypoglycaemia in this group was also accompanied by a significant reduction in 
HbA1c and fasting plasma glucose (FPG).   
1.9.5 Detemir 
Insulin detemir is the second most commonly used genetically engineered long 
acting basal insulin.  This insulin has an extended duration of action due to 
molecular features leading to increased albumin binding (Kurtzhals et al., 1996).  
There is evidence that insulin detemir is also associated with reduced nocturnal 
hypoglycaemia (Vague et al., 2003; De Leeuw et al., 2005; Kolendorf et al., 
2006; Bartley et al., 2008).  
One study comparing detemir with NPH insulin was designed and powered to 
detect differences in hypoglycaemia (Kolendorf et al., 2006).  Patients with a 
history of recurrent severe hypoglycaemia and impaired awareness of 
hypoglycaemia were excluded from participation.  No significant reduction was 
seen in severe hypoglycaemia, as total numbers were low and statistical 
analysis could not be done, however the number of episodes of severe 
hypoglycaemia was numerically lower in the detemir group.  There was 
however a significant reduction in rate of total and nocturnal hypoglycaemic 
events per patient per year in favour of detemir (53.3 vs 64.7, p=0.001 and 6.0 
vs 12.0, p<0.0001 respectively).  
1.9.6 Glargine vs Detemir 
One study comparing insulin detemir and insulin glargine has suggested a 
significant reduction in severe hypoglycaemia in favour of detemir (Pieber et al., 
2007).  This study which also excluded those with history of recurrent severe 
hypoglycaemia and impaired awareness of hypoglycaemia, reported low 
absolute numbers of severe hypoglycaemia.  In addition the fasting plasma 
glucose was significantly lower in the glargine group suggesting there may have 
been higher nocturnal glucose levels in the detemir group.  The other head to 
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head comparison of glargine and detemir in the literature reports no difference 
in any hypoglycaemic event frequency (Heller et al., 2009).   
1.9.7 Rapid acting insulin analogues 
Rapid acting insulin analogues were developed in order to better simulate the 
non-diabetic postprandial insulin response.  This entailed the development of 
insulin that was both rapidly available in the circulation but which also had a 
duration of action short enough to minimise the risk of late post prandial 
hypoglycaemia.  The genetically engineered insulin analogue lispro, which is 
exactly the same as human insulin except for the transposition of proline and 
lysine at positions 28 and 29 in the C-terminus of the B chain, was the first 
insulin to demonstrate a more physiological prandial insulin profile as compared 
to unmodified human insulin.  After lispro administration peak insulin 
concentrations are both earlier and greater as compared to human insulin and 
concentrations return to baseline earlier than with unmodified human insulin 
(Torlone et al., 1994).   
The data from the subsequent clinical trials comparing lispro with human insulin 
suggest that the more physiological mode of action described is associated with 
reduced risk of hypoglycaemia.  While there is good evidence that lispro 
significantly reduces the risk of nocturnal hypoglycaemia as compared to 
human insulin (Ahmed and Home, 1998; Heller et al., 1999; Gale, 2000) the 
evidence does not appear to be as strong for reduced risk of severe 
hypoglycaemia.  Holleman and colleagues reported a significantly lower 
incidence of severe hypoglycaemia with lispro than human insulin without 
deterioration in HbA1c during a 6 month cross over trial with 199 participants 
(Holleman et al., 1997).  An experimental study with 10 participants investigated 
whether lispro reduced the development of attenuated counter regulatory 
hormone responses to hypoglycaemia during intensive therapy as compared to 
human insulin (Heller et al., 2002).  The study which reported no difference in 
overall hypoglycaemia rates between groups, also found no difference in 
epinephrine or other counter regulatory hormone response. 
A second commonly used rapid acting insulin analogue is insulin aspart, which 
has also been shown to have a more physiological profile than unmodified 
human insulin (Heinemann et al., 1996).  This genetically modified insulin differs 
 28 
from human insulin in that the amino acid proline is substituted with an aspartic 
acid residue in order to reduce hexameric binding and thus improve absorption.  
Overall evidence for a reduction in severe hypoglycaemia with aspart appears 
lacking.  A multicentre randomised double-blind crossover study with 90 
participants did demonstrate significantly reduced severe hypoglycaemia with 
aspart as compared to human insulin in addition to significantly improved 
postprandial glycaemic control (Home et al., 1998).  However larger randomised 
control trials comparing aspart with prandial human insulin (with basal NPH 
insulin) suggest no significant reduction with severe hypoglycaemia in favour of 
the insulin analogue (Home et al., 2000) (Tamas et al., 2001)).  Both of these 
studies demonstrate significantly improved overall glycaemic control with apsart 
without risk of increased severe hypoglycaemia or overall hypoglycaemia.   
Home and colleagues demonstrated a significant reduction in both nocturnal 
and late post-prandial hypoglycaemia in favour of aspart (Home et al., 1998).  
1.9.8 Continuous subcutaneous insulin infusion (CSII) therapy 
CSII, commonly known as insulin pump therapy, has been recommended by 
several professional organisations (American Diabetes, 2004; NICE, 2008b). 
The National Institute for Health and Care Excellence states that insulin pump 
therapy can be considered if attempts to achieve target haemoglobin HbA1c 
levels with multiple daily injections (MDIs) result in the person experiencing 
disabling hypoglycaemia.  For the purpose of the guidance, disabling 
hypoglycaemia is defined as the repeated and unpredictable occurrence of 
hypoglycaemia that results in persistent anxiety about recurrence and is 
associated with a significant adverse effect on quality of life.’ (NICE, 2008b).   
The majority of systematic reviews have failed to confirm a significant reduction 
in severe hypoglycaemia with CSII in RCTs, possibly due to a number of 
confounding factors such as short trial duration, insufficient study power and 
enrolment of subjects with low baseline rate of hypoglycaemia. A recent 
Cochrane review found no relevant benefit of CSII over multiple daily injections 
(MDI) for reducing non-severe hypoglycaemic events (17 studies) but data 
indicated a possible benefit of CSII over MDI in terms of reducing severe 
hypoglycaemia (15 studies) (Misso et al., 2010).  However, due to the use of 
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different methods for reporting both non-severe and severe hypoglycaemia, no 
meta-analysis was performed.   
The majority of existing trials have not used both short- and long-acting insulin 
analogues in the MDI comparator group.  Two small RCTs that compared 
optimised analogue MDI (with basal insulin glargine) regimens and CSII in 
participants with T1DM with (Thomas et al., 2007) and without (Bolli et al., 
2004)  previous recurrent severe hypoglycaemia showed no significant 
differences in frequency of hypoglycaemia between the two interventions.  A 
short 10-week multicenter randomised, crossover study (Hirsch et al., 2005) 
suggested a lower occurrence of nocturnal minor hypoglycaemic episodes in 
participants treated with CSII than those treated with MDI therapy including 
insulin glargine.  However this study also suggested a higher rate of daytime 
minor hypoglycaemic episodes with CSII.  
A more focused review that only included studies of at least six months duration 
where the rate of severe hypoglycaemia during MDI was >10 episodes/100 
patient years of treatment suggested that CSII is significantly better than MDI in 
reducing the risk of severe hypoglycaemia (Pickup and Sutton, 2008).  This 
review included both RCTs and before/after studies; 10 studies were in children 
or adolescents and 12 studies were in adults.  The pooled severe 
hypoglycaemia event rate during MDI was 62 events per 100 patient years 
(95% CI 22 to 175).  In RCTs, the random effect meta-analysis for severe 
hypoglycaemia rates showed that severe hypoglycaemia was markedly reduced 
during CSII compared with MDI, with a rate ratio of 2.89 (1.45 to 5.76).  In 
before/after studies, the rate ratio for severe hypoglycaemia on MDI versus CSII 
was 4.34 (2.87 to 6.56) and overall rate ratio when all studies were included 
was 4.19 (2.86 to 6.13).  The reduction was greatest in those with the highest 
initial severe hypoglycaemia rates on MDI (p <0.001).  It is worth noting again 
that all studies in this review used insulin isophane or lente based MDI 
regimens rather than modern long-acting insulin analogues and few controlled 
for or used modern methods of teaching patients flexible insulin use in 
structured education programmes.  In view of the advances in delivering MDI, 
there is a need for further studies comparing such modern methods with CSII.   
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1.9.9 Continuous glucose monitoring (CGM) 
Modern blood glucose meters have extended memory capacity and computer 
download facilities.  However despite these advances there remains inadequate 
testing in some people with type 1 diabetes, poor interpretation of the results by 
patients, and on occasion health care professionals, and the need for significant 
patient motivation.  Furthermore this method of blood glucose monitoring omits 
the surveillance of blood glucose while sleeping, variations of which may 
significantly contribute to hypoglycaemia unawareness, as well as being a time 
of high risk of severe hypoglycaemia.  
In recent years, advances in technology have allowed the development of real-
time continuous glucose monitoring (CGM) devices that can be programmed in 
response to falling glucose, or when hypoglycaemia occurs or is predicted.  
These devices measure glucose in interstitial fluid, which lags behind blood 
glucose by 5-15 minutes (Rebrin and Steil, 2000).  The sensitivity and specificity 
of these alarms is between 70 and 80% (Hoi-Hansen et al., 2005), often 
resulting in false alarms and/or missed true hypoglycaemia.   
There are a wide range of in-vivo glucose electrochemical biosensors, with 
variations in needle design, hardware and membrane coatings.  The first 
application of an in-vivo glucose monitoring device was in 1982 (Shichiri et al., 
1982).  Most sensors used commercially are based on the glucose oxidase 
catalyzed oxidation of glucose by oxygen.  The design of the perfect sensor has 
many challenges.  It needs to reliably monitor all glucose variations throughout 
the day with high speed.  Further problems include the risk of immune rejection 
of the sensor by the body, difficulties with stability of the enzyme and 
transducer, the need for calibration and of course the over-riding need for it to 
be convenient and easy to use for the patient.  
The subcutaneous siting of continuous glucose sensors can induce intense 
local inflammatory reactions associated with bacteria and macrophage 
adhesion with subsequent distortion of the glucose concentration next to the 
sensor.  There has been considerable effort to develop sensors that have 
interfaces, which can resist this ‘bio fouling’.   Approaches have included a 
controlled release of nitric oxide, which inhibits platelet aggregation and bacteria 
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using polymeric coating to protect the outer layer of the sensor and use of the 
anticoagulant heparin.  
Another major issue is the need for calibration (i.e. the requirement to transform 
the signal into an estimated glucose concentration) and maintain the calibration 
over the lifetime of the sensor.   
Medtronic Minimed launched the ‘sof-sensor’ in 2008 and reported this glucose 
sensor to be as accurate in days 4 to 6 as in days 1 to 3 (data unavailable).  
The sensor measures the subcutaneous glucose concentration every 5 
minutes, and then by using a transmitter relays the sensor information to an 
insulin pump, which provides the patient-data interface and alarms as required.  
A number of studies have been performed investigating the added benefit of 
CGM in improving glycaemic control.  The Juvenile Diabetes Research 
Foundation funded JDRF-CGM trial randomised 322 participants including 
children and adults with pre-study HbA1c 53 - 86 mmol/mol (7.0 - 10.0%) 
(Tamborlane et al., 2008).  Over 85% of participants used CSII and severe 
hypoglycaemia incidence in the preceding six months was low at 7.5% of 
participants.  Although there was a clinically significant improvement in HbA1c 
of 5 mmol/mol (0.5%) in the adult group, there was no difference in biochemical 
hypoglycaemia measured using CGM between the control and intervention 
groups, and there was no difference in severe hypoglycaemia between groups. 
In the same study, a further 129 adults and children with HbA1c <53 mmol/mol 
(7.0%) were also studied (JDRF-CGM-study-group, 2009).  11% of these had a 
history of severe hypoglycaemia within the preceding six months.  At 26 weeks, 
those with CGM had maintained their HbA1c at a mean of 46 mmol/mol (6.4%), 
with no severe hypoglycaemic events, while there was a significant increase in 
HbA1c in the control group.  The study was designed and powered to detect 
change in time spent with a blood glucose ≤3.9 mmol/L as measured by CGM 
and although at the end of the study there was a reduction in favour of the real 
time CGM group, the difference was not found to be significant.  The study did 
report a significant reduction in time spent with a blood glucose ≤3.3 mmol/L 
and time per day spent between 4.0 mmol/L and 10 mmol/L in favour of the real 
time CGM group.  
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The authors of the above studies also investigated whether there were any 
factors that could be predictive of use of and benefit from real-time CGM use 
(Beck et al., 2009).  The benefit referred to is HbA1c improvement rather than 
severe hypoglycaemia avoidance.  Overall they found that previous history of 
severe hypoglycaemia was not a factor for either CGM use or benefit.  
Interestingly the study also found that baseline psychosocial measures such as 
fear of hypoglycaemia and perceived diabetes associated burden were also not 
predictive of CGM use.  
Other studies have compared real-time CGM integrated with CSII (commonly 
known as sensor augmented pump therapy: SAP) with analogue MDI regimens. 
The STAR-3 study randomised 485 participants with T1DM and sub-optimal 
control (HbA1c 57 - 80 mmol/mol, 7.4 - 9.5%) on MDI to continued MDI or SAP 
(Bergenstal et al., 2010).  Although this study demonstrated a sustained 
reduction in HbA1c with SAP in all age groups, there was no difference in 
severe hypoglycaemia rate - although it is worth noting that incidence in both 
groups was lower than in the DCCT.  Importantly this study excluded those with 
more than two episodes of severe hypoglycaemia over the previous year.  
A smaller RCT with 83 participants compared SAP therapy with MDI in 
participants with suboptimal glycaemic control (baseline HbA1c 66 mmol/mol, 
8.2%) (Hermanides et al., 2011). This study reports a mean difference in 
reduction in HbA1c of 1.1% in favour of the SAP group with no significant 
difference in severe hypoglycaemia frequency or in blinded sensor mean area 
under the curve for hypoglycaemia (<4 mmol/L).  
Only one study has compared outcomes between CSII and SAP in those with 
suboptimal glycaemic control on MDI (Raccah et al., 2009).  Although this study 
did show significant reduction in HbA1c (SAP: -0.96 vs CSII: -0.55, p<0.001) 
without any increase in hypoglycaemia, there was no evidence of reduced 
hypoglycaemia with SAP therapy.  
Although studies of CGM have shown that with this technology, HbA1c can be 
reduced effectively without increasing hypoglycaemia, benefit in terms of 
reduced clinically significant hypoglycaemia has been difficult to demonstrate.  
A six-month prospective study comparing the outcomes of real-time CGM in 
patients using MDI and CSII showed a similar reduction in time spent with blood 
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glucose <3.0 mmol/L in both groups from baseline to endpoint (Garg et al., 
2011).  However severe hypoglycaemia incidence was not reported.  In a multi-
centre randomised study with 120 adults and children with T1DM and a pre-
study HbA1c <7.5% (58 mmol/mol), real-time CGM was associated with 
significantly reduced time spent with a blood glucose <3.5 mmol/L (Battelino et 
al., 2011).  
It is unfortunate that the study design and patient selection criteria of many of 
the major studies with CGM have prevented them from answering the question 
of whether or not CGM can reduce or prevent severe hypoglycaemia.  In one of 
the first RCTs of CGM, there was in fact an increased number of severe events 
in the intervention arm (11 events vs 4 events).  Seven occurred in the same 
individual, all when not wearing the device (Hirsch et al., 2008).  
One of the reasons for lack of severe hypoglycaemia reduction in these studies 
may also be the fact that people sleep through over 70% of the alarms 
(Buckingham et al., 2005).  However, in a recently published paper in a group of 
children with impaired awareness of hypoglycaemia, SAP therapy was shown to 
improve epinephrine response to hypoglycaemia during a stepped 
hypoglycaemia clamp (Ly et al., 2011).  
From the inadequately powered studies published to date there is no RCT 
evidence demonstrating that real-time CGM can prevent severe hypoglycaemia.  
This conflicts with data from studies assessing what patients and, in the case of 
children, carers perceive to be the benefits of this technology.  Hypoglycaemia 
prevention and elimination of fear of hypoglycaemia have been reported to be 
the most common perceived benefits ahead even of improved glycaemic control 
(Cemeroglu et al., 2010).  The trials do suggest that the ability to lower HbA1c 
without increasing hypoglycaemia is enhanced by sensor use but reduction in 
severe hypoglycaemia remains an elusive goal.  
1.9.10 Beta-cell replacement 
While there have been advances in the pharmacological properties of modern 
insulins and in the development of technologies such as real-time CGM, 
complete replacement of normal beta-cell function remains the goal of many 
people with type 1 diabetes, researchers and clinicians.  Only with beta-cell 
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therapy can the unique physiological homeostatic mechanisms of second-to-
second glucose control be restored, entirely avoiding risk of severe 
hypoglycaemia.  
Transplantation of whole pancreas together with its blood supply from a 
deceased donor offers the potential of a ‘cure’ for diabetes in terms of restoring 
normoglycaemia without the need for supplemental exogenous insulin in 
tandem with absolute avoidance of severe hypoglycaemia (White et al., 2009).  
In addition to the need for life-long immunosuppression to prevent allo- and 
auto-immune rejection, pancreas transplantation requires major surgery with 
one-year mortality of 3-5% (Gruessner, 2011).  It is thus largely performed 
together with a kidney transplant given the extremely high mortality of those 
with type 1 diabetes on dialysis, though it clearly has an additional role as a 
solitary transplant in those with truly life-threatening recurrent severe 
hypoglycaemia. 
Allogeneic islet cell transplantation offers beta-cell replacement through 
minimally invasive percutaneous transplantation into the hepatic portal vein 
under radiological guidance.  Under NICE (National Institute for Health and 
Care Excellence) guidance, this is available in the UK within the National Health 
Service for those with type 1 diabetes complicated by recurrent severe 
hypoglycaemia despite optimised insulin therapy, in addition to those already on 
immunosuppression following kidney transplant with on-going sub-optimal 
glycaemic control (NICE, 2008a).  
Arguably the most important factor in the improvement of clinical outcomes post 
islet transplantation over the past decade has been the implementation of the 
Edmonton Protocol (Shapiro et al., 2000).  This treatment regimen uses a 
glucocorticoid free immunosuppressive regimen, which initially comprised 
sirolimus (a potent non-calcineurin inhibitor immunosuppressant), low-dose 
tacrolimus (a calcineurin inhibitor), and daclizumab (a monoclonal antibody 
against the interleukin-2 receptor) with transplantation of an adequate islet cell 
mass for at least short-term attainment of insulin independence (usually 
requiring more than one graft).  The first published study using this protocol 
reported on the clinical outcomes in seven individuals with a mean duration of 
diabetes of 35 years who all had recurrent severe hypoglycaemia (Shapiro et 
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al., 2000).  After a mean follow up period of 11.9 months following 
transplantation all recipients remained insulin independent with reported 
complete absence of severe hypoglycaemia.  
A subsequent international multicentre trial using the Edmonton protocol was 
published in 2006 reporting clinical outcomes following islet cell transplantation 
in 36 participants (Shapiro et al., 2006).  Mean duration of diabetes was 25 
years and 35 of the 36 participants had history of recurrent severe 
hypoglycaemia.  At one-year post final transplant 72% of participants had at 
least partial graft function and no episodes of severe hypoglycaemia were 
reported within this group.  Evidence of severe hypoglycaemia prevention in 
recipients of islet after kidney transplantation has also been published.  One-
year follow-up of seven recipients from the Miami centre reported 86% graft 
function and 30% insulin independence with no episodes of severe 
hypoglycaemia, even in those who were not insulin independent (Cure et al., 
2008).    
In addition to the evidence of severe hypoglycaemia prevention post islet 
transplantation, there is also evidence that hypoglycaemia awareness is 
significantly improved.  A retrospective cohort study reported a significantly 
reduced proportion of patients with impaired awareness of hypoglycaemia post-
transplantation (Leitao et al., 2008).  Strikingly, this reduction was sustained 
even when results were stratified based on islet function meaning that in the 
groups in which function was lost or partially lost, there were significant 
reductions in the proportion of patients with reduced awareness.   
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1.10 Rationale for the studies 
Severe hypoglycaemia is widely acknowledged as the major limiting factor for 
achieving optimised glycaemic control in established C-peptide negative type 1 
diabetes, affecting nearly half of those with disease duration of >15 years every 
year (UK-hypoglycaemia-studygroup, 2007).  It is therefore imperative that there 
are more randomised control trials investigating the use of conventional 
interventions in reversing IAH in populations with type 1 diabetes, and history of 
IAH and severe hypoglycaemia.  This includes studies involving insulin 
analogues, continuous subcutaneous insulin infusion therapy and real time 
continuous glucose monitoring.  Many previous studies involving these 
interventions have actively excluded those individuals at highest risk of severe 
hypoglycaemia.  There is also a need for more research into what 
characteristics of people with type 1 diabetes and IAH may indicate a resistance 
to conventional interventions in improving awareness in order that consideration 
can be made to initiating alternative management plans such as psychological 
interventions or early beta cell replacement. 
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1.11 Aims and objectives of the studies 
1. To establish and write the protocol for an adequately powered multi-
centre peer reviewed principal investigator initiated 24-week randomised 
control trial (HypoCOMPaSS) comparing optimised multiple daily 
injections and continuous subcutaneous insulin infusion with or without 
adjunctive real time continuous glucose monitoring in individuals with 
type 1 diabetes and impaired awareness of hypoglycaemia.   
2. To coordinate the multicentre study and conduct the Newcastle 
component.  The aim of this study is to test the hypothesis that by 
avoiding biochemical hypoglycaemia using routinely available clinical 
interventions, awareness of hypoglycaemia can be improved thus 
reducing risk of severe hypoglycaemia requiring third party assistance.   
3. Using the HypoCOMPaSS study population to undertake a study 
characterising the profiles of the participants with type 1 diabetes and 
impaired awareness of hypoglycaemia and whether these predict 
response and non-response to the trial interventions.  The aim of the 
study is to test the hypothesis that there is a sub-group of patients who 
are resistant to conventional interventions in attempting to reverse 
hypoglycaemia unawareness.  
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 39 
2.1 Objectives of the multicentre study 
2.1.1 Primary objective 
To demonstrate that by optimising conventional management, including the use 
of real-time continuous glucose monitoring (RT), in individuals with type 1 
diabetes complicated by IAH, rigorous prevention of biochemical hypoglycaemia  
will restore awareness and reduce risk of recurrent severe hypoglycaemia.  
2.1.2 Secondary objectives: 
1. To quantify and compare biochemical hypoglycaemia identified by self-
monitored blood glucose (SMBG) and blinded CGM profiles during each 
intervention. 
2. To quantify and compare overall glycaemic control and glucose lability in 
each group by analysis of HbA1c, SMBG and blinded CGM. 
1. To quantify and compare total daily doses of insulin before and after the 
intervention period. 
2. To compare health utility and treatment satisfaction during each 
intervention using validated measures. 
3. To perform secondary analyses of those who continue to experience IAH 
regardless of study intervention, to determine factors associated with 
absence of response.  It was hypothesised that these would include two 
sub-groups: one in whom an absolute focus on avoidance of high 
glucose (evidenced from patient-reported outcome (PRO) measures) 
leads to continued biochemical hypoglycaemia despite the study goals; 
and a second with severe autonomic neuropathy (evidenced from clinical 
history) who are unable to recover autonomic warning symptoms of 
hypoglycaemia despite effective reduction in biochemical hypoglycaemia. 
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2.2 Preparatory work 
The title of the multicentre study was confirmed as ‘Prevention of recurrent 
hypoglycaemia: a definitive RCT comparing optimised MDI and CSII with or 
without adjunctive real-time continuous glucose monitoring’.  
After I drafted the study design consultation began with other investigators 
about specific key aspects of the study.  My role within the overall programme 
of research is outlined in Figure 2.1 
The short title for the study was ‘HypoCOMPaSS’, an acronym for: Comparison 
of Optimised Multiple daily injections and Pumps with or without Sensors in 
Severe hypoglycaemia.  I designed a graphic for branding purposes (Figure 
2.2), which was used on all official study documents including the protocol and 
case report forms (CRFs).  
Key aspects of the study’s design were identified as needing preparatory work 
before commencement.  
2.2.1 The assessment of IAH 
Hypoglycaemic hyperinsulinaemic clamp studies are considered the gold 
standard experimental method of assessing awareness of hypoglycaemia.  
However including this as mandatory in the study protocol would potentially 
mean that many people who were not willing to be clamped, or who had 
cardiovascular disease or other medical comorbidities would be excluded from 
participation.  It was therefore agreed that established and validated patient 
reported measures of hypoglycaemia awareness would be used as primary 
endpoint of the study (while also undertaking hypoglycaemic hyperinsulinaemic 
clamps on eligible participants using separate informed consent procedures).  
However, it was noted that the existing patient reported measures including the 
Gold (Gold et al., 1994)  and Clarke (Clarke et al., 1995a) scores lacked ability 
to detect severity of the IAH and lack some sensitivity of change (Geddes et al., 
2007b).  It was therefore agreed that a new questionnaire would be designed 
and optimised to measure for the detailed characterisation of problematical 
hypoglycaemia, including frequency, severity, impact and awareness of 
hypoglycaemia. 
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 Figure 2.1  My role in the HypoCOMPaSS multicentre study 
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Figure 2.2  The HypoCOMPaSS study graphic 
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2.2.2 Insulin preparations 
Given the lack of RCT evidence for the role of insulin analogues in the 
prevention of severe hypoglycaemia and the call from NICE for more studies 
(NICE, 2002), it was agreed that this study should use the long acting insulin 
analogue glargine and rapid acting insulin analogues.   
2.2.3 Equality between intervention groups 
A recognised major caution in interpreting previous studies in this field has been 
that some of the benefits of pump therapy may have risen from the increased 
attention of the investigator and the possibility that the CSII arm of the trials 
have included ‘non-pump’ elements such as carbohydrate counting and 
education that were not incorporated as vigorously in the MDI intervention 
groups (Pickup and Sutton, 2008).  Therefore the design of the study was 
focussed around ensuring that the number and length of study visits, and the 
investigator, participant contact time and education outwith the subject of the 
insulin delivery advice was equal between intervention groups.  Specific issues 
included: 
1. The need to match the time spent providing education on the use of real-
time continuous glucose monitoring in this intervention group, with the 
time spent providing education on SMBG in this intervention group. 
2. The need to match the time spent providing education on the use of CSII 
with the time spent providing education on the use of an optimised MDI 
regimen. 
3. The need to ensure that MDI participants were not disadvantaged by not 
having access to an easily accessible bolus calculator, which the CSII 
group would have.  It was therefore agreed that all participants would be 
given an insulin pump (even those randomised to MDI) and all would be 
given self monitoring glucose meters, which wirelessly transmit data to 
the pump for bolus calculator use.  
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2.2.4 Standardised education between intervention groups and study 
sites 
It was necessary for all investigators to give standardised advice on avoidance 
and treatment of hypoglycaemia.  Based on the pilot study with influences from 
Blood Glucose Awareness Training (BGAT) (Cox et al., 2001) a participant 
education programme would be required which was standardised as far as 
possible between sites.  
2.2.5 Patient reported outcomes 
We wanted to include patient reported outcomes to meet the following 
objectives: 
1. To undertake a detailed baseline characterisation of hypoglycaemia to 
include psychological evaluation. 
2. To compare health utility and well-being during each intervention using 
validated measures enabling comparison with other interventions. 
3. To perform sub-group analyses of those who continue to experience 
severe hypoglycaemia and IAH despite successful avoidance of 
biochemical hypoglycaemia to evaluate associated risk factors. 
Therefore considerable effort was taken to carefully select appropriate patient 
reported outcomes.  This was undertaken by discussions with Dr Jane Speight, 
Chartered Health Psychologist and Director of AHP Research.  
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2.3 Protocol preparation 
2.3.1 Early development stages of the new hypo-awareness 
questionnaire 
Prior to undertaking this programme of research the established clinical 
methods for identifying IAH involved the use of self-report measures, the ‘Gold 
score’ (Gold et al., 1994) and the ‘Clarke questionnaire’ (Clarke et al., 1995b), 
separately or in combination (Geddes et al., 2007a).  The Gold score comprises 
a single question ‘Do you know when your hypos are commencing?’ with a 7-
point response scale.  Its advantages are its brevity and face validity (the extent 
to which it looks like it measures what is intended).  However, it only enables 
identification of IAH and does not facilitate detailed characterisation.   
Furthermore, its interpretation is problematic.  While scores of ‘1’ and ‘2’ denote 
intact awareness and a score of ≥4 confirms IAH (Gold et al., 1994), the clinical 
relevance and relative risks of scores from 3 through to 7 cannot be determined.  
It was evident that a single-item measure would be inadequate for 
characterising problematical hypoglycaemia and IAH, in our study populations.  
The Clarke questionnaire (Clarke et al., 1995b) comprises eight questions 
characterising exposure to hypoglycaemia and glycaemic threshold for 
symptomatic responses.  It is widely used and provides a detailed assessment 
but it has limitations: the severe hypoglycaemia definition is not that 
recommended by the ADA Hypoglycaemia Workgroup (ADA, 2005); there is a 
lack of consensus for the glycaemic thresholds used; the recall periods are 
inconsistent between questions and with the time periods used in most clinical 
trials; notably, events such as nocturnal hypoglycaemia are not captured.  Thus, 
while both the Gold and the Clarke have good concordance in detecting IAH, 
they share a limited ability to characterise or evaluate severity of IAH and lack 
some sensitivity to change (Geddes et al., 2007a).  
Therefore prior to undertaking the studies described in this thesis there was an 
aim to design a novel, optimised measure for the detailed characterisation of 
problematical hypoglycaemia, including frequency, severity, impact and 
awareness of hypoglycaemia.  
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The limitations of existing IAH measures were discussed.  The Clarke 
Questionnaire informed draft items, which were circulated for comment.  An 
iterative approach was then used, involving several rounds of interviews with 
adults with type 1 diabetes, the results of which we discussed with other 
diabetologists and health psychologists.  Between interview sets, which were 
undertaken by the health psychology team, questionnaire items were redrafted 
and circulated for comment.  Further interviews took place until an optimised 
design was achieved and no further concerns were raised.  In total, ten drafts of 
the HypoA-Q (hypoglycaemia awareness questionnaire) were needed. 
Demographic and other clinical data were collected by self-report with HbA1c 
retrieved from medical records.  National Research Ethics Committee approval 
was in place with site-specific approval at each centre.  All participants were 
registered with one of two UK specialist diabetes centres (Newcastle and 
Manchester).  Eligible participants were adults with type 1 diabetes who had 
experienced problematical hypoglycaemia, including previous severe 
hypoglycaemia and current IAH. 
Each interview was conducted in distinct stages: exploratory; draft 
questionnaire completion; and questionnaire cognitive debriefing.  Exploratory 
interviews took 54 ± 9 minutes.  Following a brief break, participants completed 
the draft HypoA-Q unaided, and then took part in a cognitive debriefing (‘think 
aloud’) interview to determine the questionnaire’s relevance, comprehensibility 
and ease-of-use (Willis, 2005).  
Exploratory interviews were transcribed in full and subjected to a thematic 
analysis.  Following each set of interviews, the health psychology team 
examined the detailed notes and completed questionnaires for relevant issues 
before discussing with me and Professor James Shaw, highlighting items 
needing improvement and agreeing suggestions for circulation to the wider 
specialist group.  Further questionnaire revision was based on group consensus 
and checked with subsequent interviewees until questionnaire design was 
optimised. 
The newly designed questionnaire was named the Hypoglycaemia Awareness 
Questionnaire (HypoA-Q).   A subsequent psychometric validation study was 
then planned to take place in Edinburgh in collaboration with Professor Brian 
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Frier.  A full manuscript regarding the development of this questionnaire has 
recently been submitted to Diabetic Medicine (August 2014).  The HypoA-Q 
questionnaire is included as Appendix 1.  
2.3.2 Development of a brief standardised education programme  
Following experience in the pilot study (Thomas et al., 2007) and informed by 
insights from the qualitative study (described above) a brief education 
programme (with formal curriculum and workbook, referred to as ‘my hypo 
compass), was developed (Little et al., 2012a).  This was to ensure 
standardised education regarding hypoglycaemia avoidance was provided to all 
participants across the five study sites.  
The curriculum was driven by findings from semi-structured interviews with 
people with T1DM and history of severe hypoglycaemia and learnings from the 
Blood Glucose Awareness Training (BGAT) programme (Cox et al., 1995). 
Content was refined through an iterative design process, including: 1) repeated 
reviews by health psychologists, diabetes specialist clinicians and nurse 
educators, and 2) debriefing by patient experts.   
The aim of the education programme was to facilitate discussions and exercises 
targeted specifically at rigorous avoidance of biochemical hypoglycaemia while 
maintaining overall glycaemic control, based around four key elements forming 
the four points of the ‘my hypo compass’ (Figure 2.3) establishing the 
imperatives:  
1. To never delay the treatment of hypoglycaemia and the optimal 
treatments for hypoglycaemia. (North) 
2. To establish the individual’s unique times of increased risk (East) 
3. To recognise hypoglycaemia by the presence of subtle symptoms 
(South) 
4. To be particularly careful (wary) about detecting and preventing nocturnal 
hypoglycaemia.  (West) 
Also included was advice on self-adjustment of insulin doses according to 
carbohydrate intake, SMBG and planned activity and recommendation for 
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oral carbohydrate administration for all glucose levels less than 4 mmol/l.  
The participant and facilitator handbooks for this education programme, 
which I led the design of, are included as Appendices 2 and 3 respectively.  
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Figure 2.3  ‘my hypo compass’ 
  
Now! 
No delay 
Establish your  
Extra risks 
Scan for 
Subtle 
Symptoms 
Wary even 
While asleep 
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2.3.3 Trial management group 
A Trial Management Group (TMG) was established with the following members: 
1. Professor James Shaw (Chief Investigator) 
2. Dr Stuart Little (co-ordinating researcher) 
3. Dr Julia Stickland and Ms Cath Brennand (trial managers from Newcastle 
Clinical Trials Unit) 
4. Dr Thomas Chadwick (statistician) 
5. Professor Sally Marshall (Professor of Diabetes and advisor to the TMG, 
second MD supervisor) 
6. Mrs Ruth Wood (data manager from Newcastle Clinical Trials Unit) 
The study protocol was written with clinical trial management expertise input 
from the Clinical Trials Unit at Newcastle University.  The protocol was signed 
by the Chief Investigator, Professor James Shaw; Principal Investigators at 
each study site; and the Sponsor’s representative, Dr Lesley Hall on behalf of 
Newcastle upon Tyne Hospitals NHS Foundation Trust.    
Permissions were obtained where necessary, for the use of established and 
validated patient reported outcome questionnaires proposed for use in the 
studies.  
Patient Information Sheets and informed consent forms were designed and 
written with the assistance of the Clinical Trials Unit at Newcastle University.   
Paper case report forms were designed for each study visit.  These were then 
transcribed into Power Trial’s Symphony web software system, which was used 
for data collection and management.  This system provided electronic case 
report forms (eCRFs) that allowed remote data entry, source document 
verification, query resolution and audit trail of all entries, compliant with Good 
Clinical Practice (GCP) regulations.  Data was then held on a secure server and 
automated failover and backup was provided.  Only authorised users with 
appropriate access and permissions were able to enter, view and edit data. 
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The protocol for the study was prepared for publication in the journal BMC 
Endocrine Disorders (Little et al., 2012b).  
2.3.4 Study initiation visits 
Initiation visits were undertaken to all participating study sites where the goals 
were: to orientate and train staff on the protocol and study related processes; to 
confirm readiness for study implementation; and to identify additional 
requirements that needed satisfied prior to site activation and participant 
recruitment.  Full day visits to clinical research facilities at each of the five 
participating centres were undertaken in partnership with the trial manager from 
Newcastle Clinical Trials Unit.  
2.4 Obtaining regulatory approvals 
2.4.1 Ethical approval 
I obtained ethical approval for the study after submission of the appropriate 
IRAS (integrated research application system) application forms and attendance 
at the local ethics committee meeting in Sunderland, UK. 
2.4.2 Governance approvals and clinical trial registrations 
Although using established medications under existing licenses the study 
needed the approval of the Medicines and Healthcare products Regulatory 
Agency (MHRA) which I obtained through IRAS application.  Site-specific 
approvals were granted from all participating Acute NHS Trusts’ Research and 
Development Departments.  As this programme of research involved the 
collection of personal (though not identifiable) data outside of the acute trusts 
and onto University I.T. systems, Caldicott approvals were also obtained.  The 
study was adopted by the National Institute of Health Research, a UK 
Government body that provides logistical support to clinical trials undertaken 
within the NHS.  The study was issued with an International Standard 
Randomised Controlled Trial Number (ISRCTN) following registration on the 
clinical trials database (ISRCTN: 52164803).  The study was also issued with a 
EudraCT number following registration on the European Union Drug Regulating 
Authorities Clinical Trials database (EudraCT: 2009-015396-27).  
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2.5 Ethical considerations 
Potential participants were identified from existing clinics and research 
databases held at each centre.  Only participants who fulfilled the inclusion and 
exclusion criteria of the study were invited to take part.  
Potential participants were provided with written information, along with 
opportunity for questions and had a minimum of 24 hours to decide whether or 
not to take part.  All the potential participants were fully informed of the intensive 
requirements of this study.  These included the need for rigorous self blood 
glucose monitoring, the probabilities of being randomised to different treatment 
arms, including the use of real-time continuous glucose monitoring and 
continuous subcutaneous insulin infusion therapy; and the requirement for 
monthly blinded continuous glucose monitoring.  The original signed consent 
form was retained in the investigator site file, with a copy kept in the clinical 
notes and a copy provided to the participant.  The participants were specifically 
consented to their GP being informed of their participation in the study. 
The right to refuse to participate without giving reasons was respected.  
Informed written consent was taken by a member of the research team at each 
site adhering to guidelines of Good Clinical Practice (Commission, 2001).     
All the participants were provided with a 24-hour contact detail for the 
investigator at their site, to use were they have any problems related to the 
study.  
No payments were provided to participants for taking part in this study.  
However, participants did receive expenses for travel costs incurred while 
attending study visits. 
Study files were kept in a locked room in the Clinical Research Facility of each 
respective study site.   Participant confidentiality was maintained by ensuring 
that only participant initials and study number were mentioned in study 
documents.  
The studies were performed in accordance with the principles of the Declaration 
of Helsinki (Association, 2008) and Good Clinical Practice (Commission, 2001) 
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2.6 Study population 
2.6.1 Study centres 
This was a multicentre programme of research and was conducted at the 
following hospitals, all of which are tertiary referral and established academic 
hypoglycaemia centres: 
1. Royal Victoria Infirmary, Newcastle upon Tyne 
2. Royal Bournemouth Hospital 
3. Derriford Hospital, Plymouth 
4. Addenbrooke’s Hospital, Cambridge 
5. Northern General Hospital, Sheffield 
2.6.2 Identification and recruitment 
The target population was 100 participants with each of the five sites having a 
target of recruiting 20 participants.  Participants identified as being potentially 
eligible were approached to give their written informed consent before 
undertaking a screening visit at which time inclusion criteria were checked.  
Potential participants were identified at all study sites except in Newcastle, 
where identification was undertaken at the Newcastle Diabetes Centre, 
Newcastle General Hospital (after approval as a participant identification 
centre).  
2.6.3 Inclusion criteria 
Participants recruited for this programme of research had to meet the following 
criteria for participation in the studies: 
1. Male or female aged 18-74 years inclusive at start of the trial. 
2. Diagnosis of diabetes mellitus according to ADA ('Diagnosis and 
classification of diabetes mellitus,' 2011) and WHO (WHO, 2006) criteria 
and consistent with a clinical diagnosis of type 1 diabetes mellitus. 
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3. Fasting serum C-peptide below the quality assured limit of detection for 
the assay and laboratory at each study site with simultaneous exclusion 
of biochemical hypoglycaemia (glucose <4.0 mmol/L) by laboratory 
glucose level analysis on a sample taken at the same time point. 
4. History of severe hypoglycaemia in the preceding one year ((as defined 
by the American Diabetes Association (ADA, 2005)) (Table 1.3)) and / or 
impaired awareness of hypoglycaemia as confirmed by a score of ≥ 4 in 
the Gold score (Gold et al., 1994).  
2.6.4 Exclusion criteria 
Potential participants presenting with any of the following were not considered 
for inclusion in the studies: 
1. Any condition that in the investigator’s judgement is likely to cause the 
participant to be unable to understand the information in the informed 
consent document or to provide informed consent. 
2. Insufficient proficiency in English, below that to enable the participant to 
understand both verbal and written information during the study.  This 
was due to the complexity of the education programme, the need for 
independent completion of the questionnaire measures, and the degree 
of communication required between participants and clinicians during the 
study. 
3. Unwilling to undertake intensive insulin therapy, including randomisation 
to use of CSII, optimised MDI regimen or real-time CGM.  
4. Unwilling to undertake glucose profiles using the subcutaneous 
continuous glucose monitoring (CGM) equipment.  
5. Unwilling to undertake SMBG at least 4 times daily.  
6. Unwilling to monitor and record signs and symptoms of hypoglycaemia.  
7. A history of intolerance to insulin glargine. 
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2.7 Assessment of hypoglycaemia awareness 
To ensure eligibility criteria were met all potential participants underwent 
assessment of hypoglycaemia awareness using the Gold (Gold et al., 1994) 
and Clarke scores (Clarke et al., 1995a)  (described in 2.2.1).   These measures 
were used at screening to ensure eligibility, baseline study visit and at study 
endpoint.  The hypoA-Q was used in conjunction with the Gold and Clarke 
scores at baseline and endpoint.  
2.8 Blinded / health care professional continuous glucose monitoring 
All participants had a period of professional continuous glucose monitoring 
during the last week of the wash in period and for 1 week between study visits.  
The iPro professional continuous glucose monitoring system (CGMS) is a 
product from Medtronic Minimed.  It involves continuous monitoring of interstitial 
glucose for a period of up to 7 days with the participant unaware of the result 
until such time the data are transferred to a data management system and 
analysed.  
The first such device, ready for use in the clinical setting was the Minimed 
CGMS Physician-Use Glucose Monitoring System which was approved in 
America by the Food and Drug Administration in 1999 (Mastrototaro, 1999).  In 
2003, the CGMS Gold was introduced by Medtronic Minimed.  This device 
captured data in a recorder that was attached to a sensor in the patient’s 
subcutaneous tissue by a cable, which was then downloaded.  The iPro device 
does not use a cable.  Instead the recorder is attached directly to the sensor 
and secured to the patient’s skin.  
2.8.1 Professional CGM hardware and data download  
The iPro CGMS device from Medtronic has three components: 
1. The iPro recorder; a small rechargeable and waterproof device that 
stores the data; 
2. The glucose sensor; 
3. The iPro charger which can recharge the recorder in 20 minutes. 
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The glucose sensor used in the study (Sof sensor, Medtronic) consists of two 
semipermeable membranes that surround an impregnated glucose-oxidase 
enzyme containing material.  When glucose and oxygen pass through the 
semipermeable membrane and react with the glucose oxidase enzyme in the 
presence of glucose, hydrogen peroxide is produced with two hydrogen ions, 
producing an electronic signal.   
After each use of the iPro recorder data were then downloaded using 
Medtronic’s Solutions software without unblinding either the participant or the 
investigator.  
2.9 Self monitoring of blood glucose 
In this programme of research all participants were asked to complete detailed 
paper self-monitored blood glucose diaries.   Specifically participants were 
asked to complete daily 4 point profiles and weekly 8 point profiles, which 
included blood glucose concentrations before and two hours after the main 
meals of the day, before going to bed and at 4 am.  The diaries also asked for 
clinical details of all glucose levels less than 4 mmol/L and symptomatic 
hypoglycaemic events.   
All participants were given the Contour link ®, Bayer Healthcare meter and 
asked to use this meter only for the duration of the studies.  Instructions on the 
use of the meter were provided at the screening visit.  The study teams at each 
study site provided blood glucose testing strips for the meters.   The blood 
glucose meters were calibrated at each 4-weekly follow up visit using Bayer’s 
Contour ® control solutions.   
2.10 Insulin preparations used in the study 
2.10.1 Regulatory requirements 
In accordance with the Medicines for Human Use (Clinical Trials) Regulations 
2004 and Directive 2001/20/EC the insulin preparations used in the study fell 
under the definition of ’investigational medicinal product’ (IMP).  Although the 
insulins used during this trial fell under the definition of IMPs they were used 
only under existing licence agreements. 
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A label was designed for all the study IMPs in accordance with regulatory 
guidelines and all local legal requirements.  Each study centre maintained a 
drug disposition log in which they recorded information regarding the 
administration of study drug and return of unused vials. 
2.10.2 Basal insulin used in MDI arm of study 
All participants randomised to the Multiple Daily Insulin Injection (MDI) regimen 
used insulin glargine (Lantus ®) as basal insulin.   This insulin is a recombinant 
human insulin analogue that is a long acting parenteral blood glucose-lowering 
agent.  Glargine is a clear, colourless aqueous solution for subcutaneous 
injection.  Insulin glargine was provided via the Solostar ® prefilled disposable 
device, which allows dose dialling in one-unit step increments between one unit 
and a maximum of 80 units.  Participants were given boxes of 5 x 3mL 
Solostar® pens each containing glargine (100 units per millilitre).  
2.10.3 Rapid acting insulins used in MDI arm of study 
For the participants randomised to MDI, insulin aspart was the rapid acting 
insulin analogue of choice.  However for those patients who had a history of a 
previous negative experience or adverse effect with insulin aspart the 
alternative of insulin lispro was offered.   
Insulin aspart (Novorapid ®) is a recombinant human insulin analogue that is a 
rapid acting parenteral blood glucose-lowering agent.  Aspart is a clear, 
colourless aqueous solution for subcutaneous injection.  Each millilitre of aspart 
injection contains 100 Units of insulin aspart.  Insulin aspart (Novorapid®) was 
provided via the Novorapid Flexpen ® which is a pre-filled disposable insulin 
delivery device.   This device allows dose dialling in one-unit step increments 
between one unit and a maximum of 60 units.  Participants were given boxes of 
5 x 3mL Novorapid Flexpens® each containing aspart (100 units per millilitre).  
For those participants who had a previous negative experience or adverse 
effect with insulin aspart the alternative of insulin lispro (Humalog ®) was 
offered.  Insulin lispro is a recombinant human insulin analogue that is a rapid 
acting parenteral blood glucose-lowering agent.  Lispro is a clear, colourless 
aqueous solution for subcutaneous injection.  Lispro was provided in the 
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Humalog Kwikpen® which is a pre-filled disposable insulin delivery device for 
use of insulin lispro.  This device allows dose dialling in one-unit step 
increments between one unit and a maximum of 60 units.  Participants were 
given boxes of 5 x 3mL Humalog Kwikpens® each containing lispro (100 units 
per millilitre).  
2.10.4 Insulin used in the CSII arm of the study 
For participants randomised to CSII, insulin aspart (Novorapid®) was the insulin 
of choice.  It was provided in 10 ml vials (100 Units/mL).   
Insulin lispro (Humalog®) was used instead of insulin aspart in the CSII group 
for those participants who had previous negative experience / adverse effect 
with aspart.  Insulin lispro for use in the CSII group was provided in 10ml vials 
(100 Units/mL). 
2.11 Continuous subcutaneous insulin infusion device 
The Paradigm Veo® insulin pump (Medtronic Minimed) was used in the study.  
Two different sizes of pumps  (Paradigm 554 and 754) were available. The 
difference between the two insulin pumps is the size of reservoir each can hold.  
The 754 insulin pump can accommodate either a 3 ml reservoir or a 1.76 ml 
reservoir, which holds 176 units of insulin.  The 554 insulin pump can 
accommodate just the 1.76 ml reservoir.   
The Paradigm Veo® pump has a built in bolus calculator termed the bolus 
wizard®.  This uses the inputted personal settings on insulin: carbohydrate ratio 
(ICR), insulin sensitivity factor (ISF), blood glucose readings, carbohydrate 
intake and active insulin duration to suggest a bolus amount. 
Two different infusion sets were available to participants depending on body 
habitus and personal preference: 
1. Quick-set infusion set; this is inserted at 90 degrees to the skin using a 
spring loaded insertion device. 
2. Silhouette infusion set; this is inserted at 45 degrees to the skin usually 
by hand. 
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2.12 Real-time continuous glucose monitoring device 
The first system integrating CSII with CGM was launched in 2006 by Medtronic 
Minimed and was called the Paradigm Real-time system.  For this study an 
updated version was used: the Paradigm Veo System (Medtronic Minimed) 
using the Veo insulin pump and with an updated calibration algorithm for real-
time continuous glucose monitoring.  
When this study was initiated there were other real time continuous glucose 
monitoring systems available, though no others were integrated with an insulin 
pump.  All available real time glucose monitoring systems approved for use at 
the time of study initiation are listed below.  
1. GlucoDay (A Menarini Diagnostics, Italy) 
2. Free style Navigator Continuous Glucose Monitor (Abbott, USA) 
3. Seven System (Dexcom, USA)   
4. Short term system STS (Dexcom, USA)  
5. Guardian Real-Time System (Medtronic Minimed, USA) 
6. Paradigm Veo System (Medtronic Minimed, USA) 
All of these systems use the implantable needle type electrode described in 
1.10.8 except the Glucoday system which uses microdialysis sampling.  This 
systems use a hollow dialysis fibre, which is implanted in the subcutaneous 
tissue and perfused with isotonic fluid.  The glucose which diffuses from the 
tissue into the fibre is then pumped towards the enzyme electrode.   
2.12.1 Accuracy of the Paradigm Veo system (Medtronic Minimed) 
The numerical accuracy of all continuous glucose monitoring systems including 
real-time CGM can be defined as the closeness between CGM readings and 
corresponding in-time reference blood glucose measurements.  Several 
different measures have been used to assess this accuracy including the mean 
absolute difference (MAD), mean absolute relative difference (MARD), median 
absolute difference (MedAD), median absolute relative difference (MedARD) 
and ISO (International Standards Organisation) criteria.  The ISO criteria refer 
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specifically to the percentage of CGM readings within 0.8 mmol/l from the blood 
glucose when <4.2 mmol/L or within 20% from reference when blood glucose is 
>4.2 mmol/L.  Table 2.1 describes the clinical accuracy of three of the most 
widely available real-time CGM systems.  
The numerical accuracy of different CGM devices has been investigated with 
regards hypoglycaemia detection (Kovatchev et al., 2008).  This has suggested 
that the Navigator as compared to the Guardian and Dexcom systems performs 
best (ISO: % readings within 0.8 mmol/l from reference when reference <4.2 
mmol/l; guardian, 76.5%; Dexcom, 52.9%; Navigator, 79.4%).  
The Paradigm Veo system (Medtronic Minimed) uses a new sensor calibration 
system as compared to the previous Paradigm Real time (PRT) system.  In a 
retrospective analysis of the data from the STAR-1 study, in which sensor 
augmented pump therapy was compared to CSII and conventional monitoring, 
the Paradigm Veo calibration system has been compared to the PRT system 
(Keenan et al., 2010).  This study has shown that as compared to the PRT, 
when blood glucose is 2.2 - 4.4 mmol/L the number of CGM glucose 
measurements with the Veo calibration algorithm within 20% of the blood 
glucose reading is 81% as compared to 73% with PRT.  The MARD for the Veo 
algorithm for blood glucose levels 2.2 - 4.4 mmol/L was 19.5 ± 23.8 as 
compared to 24.8 ± 27.6 with the PRT.  The sensitivity for hypoglycaemic 
events as defined as a single blood glucose measurement <3.9mmol/L was 
82.3% with the Veo and 54.9% with the PRT.   
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Figure 2.4  Example of CSII with integrated real-time continuous glucose 
monitoring (sensor augmented pump therapy (SAP)) 
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Table 2.1  Sensitivity of Paradigm Veo calibration compared to 
Paradigm Guardian calibration algorithm for detecting hypoglycaemic 
events as defined as a single blood glucose <3.9mmol/L (Kovatchev et al., 
2008) 
 
 
 
 
 
 
 
 
 
  
 Paradigm Guardian Paradigm Veo 
Number of blood 
glucose readings 
<3.9mmol/L 
5841 
Sensitivity 54.9 82.3 
Specificity 98.1 96.4 
False positive rate 1.6 2.9 
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Table  2.2 Numerical point accuracy of three real time CGM devices 
(Keenan et al., 2010) 
 
 
 
 
 
 
 
 
 
 
 
 
 
*MAD = mean absolute difference, ∧MARD = mean absolute relative difference, 
**MedARD = median absolute relative difference  
 
 
 Guardian Dexcom Navigator 
Point accuracy: 
euglycaemia (blood 
glucose = 3.9-
10.0mmol/L) 
   
MAD* 0.91 1.24 0.89 
MARD^ 15.2 21.2 15.3 
MedARD (mmol/L)** 13.3 18.4 11.8 
ISO: % readings within 
0.8mmol/L from reference 
when reference 
≤4.2mmol/l 
76.5 52.9 79.4 
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2.13 Patient reported outcomes 
2.13.1 Diabetes treatment satisfaction questionnaire (DTSQ) 
Brief and used previously to evaluate potential benefits of insulin glargine, the 
diabetes treatment satisfaction questionnaire (DTSQ) is a widely used and 
sensitive measure of satisfaction with diabetes treatment (Bradley, 1994).  This 
questionnaire has been used in many trials with proven responsiveness to 
various treatment regimens (DAFNE Study Group, 2002; Ashwell et al., 2008).  
The DTSQ (Appendix 12) is an eight item questionnaire with the Items of 
particular relevance to this programme of research being perceived frequency 
of hypoglycaemia as well as flexibility and convenience of the treatment.  Each 
of the eight items is scored on a scale of 0-6.  
Two versions of the questionnaire are available, the DTSQ status (DTSQs) and 
the DTSQ change (DTSQc).  
2.13.2 Hypoglycaemia fear survey II 
Fear of hypoglycaemia is an important issue for many people with recurrent 
severe hypoglycaemia and can be responsible for severely limiting quality of 
life.  The hypoglycaemia fear survey II (Appendix 14) provides the only known 
measure of this phenomenon and was first developed alongside blood glucose 
awareness training (BGAT) in the United States (Cox et al., 1987).  
2.13.3 Hyperglycaemia avoidance scale 
Fear of hyperglycaemia may be an important determinant of behaviours that 
lead to recurrent severe hypoglycaemia.  The hyperglycaemia avoidance scale 
(HAS) was developed in the United States (Singh and al, 2010) and adapted for 
use in the United Kingdom for use in this study (Barendse et al., 2011).  This 
questionnaire has four subscales: 
I. Worry subscale: items 10, 13, 14, 15, 16, 18, 19, 20, 21, 23, 24.  
II. Immediate action scale: items 1, 2, 4, 5.  
III. Low blood glucose preference scale: items 3, 6, 11, 12, 17.  
IV. Avoid extremes scale: items 7, 8, 9, 22.  
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2.14 Assessment of global autonomic dysfunction 
The autonomic symptom profile is a patient reported outcome questionnaire 
from which the composite autonomic symptom scale (COMPASS) with item- 
weighting was established (with higher scores indicating more or worse 
symptoms).  COMPASS explores a wide range of autonomic domains, 
providing an overall score and sub scores for eleven subscales: orthostatic 
intolerance, secretomotor dysfunction, male sexual dysfunction, bladder 
dysfunction, diarrhoea, constipation, pupillomotor symptoms, vasomotor 
symptoms, reflex syncope, upper GI symptoms and sleep dysfunction.  This 
questionnaire has been validated against the composite autonomic scoring 
scale (CASS) in a population with peripheral neuropathy and neurogenic 
autonomic failure including people with diabetes (Suarez et al., 1999).  CASS is 
derived from the autonomic reflex screen which includes orthostatic blood 
pressure and heart rate responses to tilt; heart rate response to deep breathing; 
the Valsalva ratio; and beat-to-beat blood pressure measurements during the 
Valsalva manoeuvre, tilt, and deep breathing. 
There are a total of 169 questions in this questionnaire, which has a complex 
scoring system.  It yields one total score reflecting overall severity and eleven 
weighted subscale scores.  
1. Orthostatic intolerance subscale: items 18, 20, 19, 25, 22, 37, 38, 39, 40.  
2. Vasomotor symptoms subscale: items 54, 59, 60, 61,62, 55, 56, 57, 58, 
63, 64.  
3. Secretomotor symptoms subscale: items 66, 67, 68, 69, 70, 71, 72, 73, 
74, 75. 
4. Autonomic diarrhoea symptom subscale: items 87, 88, 89, 93. 
5. Constipation symptom subscale: items 94, 95, 96, 97.   
6. Male sexual dysfunction subscale: items 112, 113, 114, 115, 116, 117, 
118, 119, 120, 121, 114, 115, 116, 122, 123.  
7. Bladder dysfunction subscale: items 108, 109, 110.  
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8. Pupillomotor symptoms subscale: items 124, 125, 132, 126, 127, 134, 
135.  
9. Sleep disorder symptoms subscale: items: 136, 137, 138, 139, 140, 141, 
142, 144.  
10. Syncope symptoms subscale:  items 42, 43, 44, 45, 46.  
11.  Upper GI symptoms subscale: items 80, 81, 82, 83, 84.  
12. Under scoring items: 143, 167, 104, 105, 106, 107.  
13. Over scoring items 166, 49, 51, 52, 102, 103.  
2.15 Cardiac autonomic function assessment 
At baseline and at study endpoint all participants also underwent cardiac 
autonomic function testing including: 
1. Baroreceptor sensitivity 
2. Spectral analysis of heart rate variability at rest 
3. Spectral analysis of heart rate variability with paced breathing 
4. Heart rate variability during deep breathing 
5. Heart rate variability during the Valsalva manoeuvre 
Fellow investigators in Sheffield prepared the standard operating procedure for 
this.  Results of this are not presented within this thesis, as analysis of this data 
will be undertaken by my colleagues in Sheffield.  
2.16 Stepped hypoglycaemic hyperinsulinaemic clamp studies 
I established the standard operating procedure (SOP) for undertaking the 
hypoglycaemic hyperinsulinaemic clamp studies.  These were undertaken as 
part of a sub-study with a requirement of separate informed written consent 
from eligible participants.  The SOP included assessment of counter-regulatory 
hormone and symptom response to experimental hypoglycaemia and was 
included as part of the published study protocol.  The SOP I prepared is 
included as Appendix 6.  Results from the clamp studies are not presented 
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within this thesis as analysis of the data was undertaken by fellow investigators 
at Cambridge University.   
2.17 Study visit schedule 
A detailed account of the study visits is given in the published study protocol.  A 
summary is provided below.  Appendix 11 shows the timeline of study visits.  
2.17.1 Screening visit (start of 4-week wash in period) 
Participants attended for a screening visit to ensure that all study inclusion 
criteria were met and ensure that the nature and purpose of the research had 
been fully understood.  At this visit it was ensured that the participant had had 
all their questions about the trial adequately answered.  The following were 
performed at the screening visit: 
1. The hypoglycaemia screening questionnaire comprising of the Clarke 
and Edinburgh hypoglycaemia scores and was completed or results 
reviewed if previously completed (Appendices 4 and 5 respectively). 
2. Written informed consent was obtained if not done so previously.  
3. Participants were issued with their unique trial number for the studies.  
4. Venepuncture was undertaken during the screening visit and blood 
samples from each site were sent to their own respective laboratories for 
c-peptide, glucose and HbA1c. 
5. Patients were provided with a hand-held glucometer (Contour Link®) and 
educated in the use of prospective Self Monitoring Blood Glucose 
(SMBG) / hypoglycaemia diaries to measure daily 4 point profiles and 
weekly 8 point profiles in addition to clinical details of all glucose levels 
less than 4 mmol/L and symptomatic hypoglycaemic events during a 4-
week wash in period. 
2.17.2 Visit 2: CGM sensor placement  
Participants attended for placement of subcutaneous sensor for 7-day blinded 
continuous glucose monitoring (CGM).  
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2.17.3  Visits 3: baseline  (wash-in week 4, end of 28 day wash-in period) 
The participant attended after 7 days blinded CGM and completion of the 4-
week glucose / hypoglycaemia diary 
A full clinical history and examination together with detailed history of severe 
hypoglycaemia number and consequences over the preceding twelve months 
was taken. Modified Clarke and Edinburgh questionnaire was repeated when 
completing study questionnaire pack of patient reported outcomes   
The 4-week glucose / hypoglycaemia paper diary was transcribed into the 
eCRF.   
The validated patient-reported outcome questionnaires (Gold and Clarke) in 
addition to the new instrument designed to be sensitive to change related to 
study interventions (HypoA-Q) were completed  
Blood was taken for HbA1c, U&Es, liver function tests and lipid profile.  
2.17.4       Visit 4: autonomic symptom profiling 
Participants completed the autonomic symptom profile (ASP) questionnaire and 
underwent cardiac autonomic function tests.  
2.17.5       Visit 5: autoimmune disease screening 
Participants attended for a short synacthen test.  This test was performed to 
screen for adrenocortical insufficiency.  2ml of blood was taken to measure 
basal cortisol (0 mins).  This was followed by intravenous 250µg (in 1 ml) 
tetracosactide (synacthen).  2mls of blood was then taken at 30 mins and 60 
mins for cortical analysis.  At this visit a sample was also taken for serum TSH 
(Thyroid Stimulating Hormone) measurement to exclude thyroid disease and for 
anti-endomysial antibody analysis to exclude coeliac disease.  New diagnoses 
of other autoimmune diseases did not preclude participation in the study.  If 
indicated participants with newly diagnosed autoimmune disease were referred 
to an appropriate specialist for further investigation and management. All 
samples were analysed in local hospital laboratories.  
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2.17.6     Visit 6: education session 
The results of the SMBG (self monitoring blood glucose) diary and baseline 
CGM profile were discussed with all participants forming the basis for the 
uniform structured re-education programme undertaken at each site (my hypo 
compass).  
2.17.7 Randomisation 
Participants were allocated by third party concealed randomisation by centre 
and baseline HbA1c (with stratification cut-off of 64 mmol/mol (8%) to 24 weeks 
CSII using insulin aspart (or insulin lispro if previous intolerance / negative 
experience with insulin aspart) or MDI using glargine and insulin aspart (or 
insulin lispro if previous intolerance / negative experience with insulin aspart).  
50% of each of these two groups were randomised to the use of real-time 
continuous glucose monitoring.  Therefore there were four intervention groups 
with 25 participants in each group as detailed below. 
Intervention group 1: CSII with RT 
Intervention group 2: CSII without RT 
Intervention group 3: MDI with RT 
Intervention group 4: MDI without RT 
 
2.17.8     Visit 7: RCT commencement 
All patients had an educational session solely on the technical aspects of the 
insulin administration equipment they were to use during the intervention period.  
The session for participants randomised to CSII was restricted to technical 
aspects of insulin pump management.  The external pump, consumables and 
insulin were provided.  The session for participants randomised to MDI was 
restricted to insulin device (pen) use and injection site care.  
Each participant was provided with his or her appropriate titration regimen.  
(Appendices 8, 9 and 10).  
 
The primary goal of titration throughout for all participants was the absolute 
avoidance of glucose levels <3 mmol/L as determined by CGM and SMBG.  
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This was achieved by setting ‘4 as the floor’ with all glucose levels <4mmol/L 
treated by 15g glucose with repeat SMBG every 15 minutes until glucose 
>4mmol/L in addition to consideration of insulin dose reduction.  
Where attainable without hypoglycaemia, SMBG before breakfast and 4am 
targets were 5 - 7 mmol/L with other pre-prandial targets 4.5 - 7 mmol/L and 
post-prandial targets 6 - 8 mmol/L (Appendix 7).  
During the intervention period all participants were telephoned daily for the first 
week post randomisation for support in starting their new regimen, to review 
SMBG values and offer guidance in initial insulin dose adjustment.  Thereafter 
participants were telephoned weekly for the remainder of the randomised 
control trial period.  Participants had contact numbers for study personnel to 
contact between telephone calls/visits if further advice was needed.    
On this day, study insulin was provided using study specific prescriptions with 
commencement of 24-week RCT of new intervention and 4-week glucose-
monitoring / hypoglycaemia diary.   All participants were telephoned daily over 
the following 6 days for support in starting their new regimen, to review SMBG 
values and offer guidance in initial insulin dose adjustment.   
2.17.9    Visit 8:  review/blood glucose monitoring  
At this visit, one week after RCT commencement, in addition to reviewing 
progress over the first week, using glucose data to achieve the primary goal of 
avoiding biochemical hypoglycaemia was discussed together with reinforcement 
of the other educational tenets of the study.  
All participants randomised to real-time continuous glucose monitoring (RT) 
were given an educational session on the technical aspects of using the real-
time monitors including trend analysis and the use of the hypoglycaemia and 
hyperglycaemia alarms.  They were encouraged to wear the sensor 
continuously (re-siting every 7 days) but flexibly with a minimum of 7 days 
continuous monitoring in the last week of each month.   Participants not 
randomised to RT had an educational session on self-blood glucose monitoring.  
At this visit arrangements for all participants to upload their anonymised data 
onto a central server (Carelink, Medtronic) was discussed to facilitate optimised 
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self-management (with the research team also having access to the data to 
support self management).  Participants did not need to consent to this in order 
to participate in the study.  
2.17.10 Telephone Contact 
Participants were contacted by telephone weekly after visit 8 throughout the 
RCT to reinforce the primary goal of biochemical hypoglycaemia avoidance, 
provide clinical review / support, and ensure diary completion. 
2.17.11 Study follow up 
Participants attended for a study visit every four weeks during the RCT for 
collection of SMBG/hypoglycaemia diary and HbA1c.  One week prior to each 
visit participants had a blinded CGM sensor fitted and these data were 
downloaded at the visit.  Participants had their weight measured at each follow 
up visit and this, along with details of insulin dosage, was recorded on visit 
specific CRFs.  Both investigator and participant remained blinded to the results 
of the blinded CGM data during the RCT period.  Clinical review at each follow 
up visit reinforced the primary goal of biochemical hypoglycaemia avoidance.  
At each follow up visit information was collected on any episodes of 
hypoglycaemia experienced, duration of RT usage and RT alarm settings. 
2.17.12 End of RCT visit 
At week 24, participants attended for the primary RCT completion visit.  This 
included blinded CGMS data download, collection of SMBG/hypoglycaemia 
diary, and HbA1c.  Participants were also asked to complete the ‘end of RCT’ 
study-specific questionnaire booklets assessing hypoglycaemia experience and 
other PROs (Section 2.13).  
On the same day, eligible participants were invited to attend for ‘end of RCT’ 
stepped hyperinsulinaemic hypoglycaemic clamp.  
At the end of this intervention period, participants were asked to attend for 
repeat detailed cardiac autonomic function testing and to complete the 
autonomic symptom profile questionnaire.  
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2.18 Statistical analysis 
The principal analysis examined the factorial structure of the treatment and 
monitoring regimen effects on the difference in IAH (Gold score) at 24 weeks 
using analysis of covariance (ANCOVA).  Baseline IAH (Gold score) and 
stratification (centre and baseline HbA1c) variables were included among the 
covariates considered in addition to suitable summaries of questionnaire scores 
and glucose monitoring data collected at baseline prior to randomisation.  The 
glucose monitoring data collected included time spent for the following separate 
ranges: <2.5 mmol/l, <3 mmol/l, <4 mmol/l, >7 mmol/l, >10 mmol/l, between 4 
and 7 mmol/l and between 3 and 10 mmol/l.  The inclusion of baseline HbA1c 
as a covariate enabled the examination of possible interactions between effects 
observed and these values. 
Further analyses were undertaken concerning IAH to corroborate the Gold 
score; the Gold score was compared with scale and subscale scores derived 
from the Clarke questionnaire and the hypoglycaemia awareness questionnaire 
(HypoA-Q) at 24 weeks. 
These measures were also subject to analysis as for the primary outcome.  
Additionally, a binary indicator of IAH response (defined as a Gold Score of <4 
or ≥4) at 24 weeks) was analysed using logistic regression making use of the 
covariates used for the primary outcome analysis. 
There was also an additional analysis of the (paired) change in IAH (Gold 
score) over the 24-week duration of the trial using the t-test without 
consideration of the intervention or monitoring groups in order to evaluate the 
effect of undergoing any intervention or monitoring over the 24-week period. 
Outcomes were assessed at baseline and 24 weeks.  Analysis methods were 
generally similar to that described for the primary analysis but alternative 
techniques such as McNemar’s test and logistic regression were used as 
appropriate. 
Further analyses were undertaken using HbA1c and the separate continuous 
glucose monitoring measures (time spent in the following separate ranges: <2.5 
mmol/l, <3 mmol/l, <4 mmol/l, >7 mmol/l, >10 mmol/l, between 4 and 7 mmol/l 
and between 3 and 10 mmol/l) as outcome variables. 
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Similar analyses were undertaken on scores from all PRO measure scores.  
A number of measures relating to severe hypoglycaemia (ADA criteria) were 
analysed: number of episodes of severe hypoglycaemia at 24 weeks, change in 
severe hypoglycaemia between baseline and 24 weeks (reported as difference 
in annualised rate pre and post-intervention), change in severe hypoglycaemia 
between baseline and 24 weeks (reported as the proportion of participants with 
reduction in number of severe hypoglycaemia events compared between the 
timepoints) and change in proportion without severe hypoglycaemia between 
baseline and 24 weeks. 
Changes in weight, total daily dose of insulin, and in glucose lability were 
subject to analysis in a similar manner to the primary outcome. 
Wherever possible participants who elected to withdraw from the study were 
followed up so that final outcome data were obtained, enabling their inclusion in 
an Intention to Treat (ITT) analyses.  This formed the analysis groups for the 
analyses described above. 
Analyses restricted to those participants who were allocated to use RT were 
undertaken, in order to allow use of the further covariate of low or high RT use 
(defined by consideration of a pre-defined cut-off value) throughout the 24-week 
period.  Variables analysed in this manner included IAH (Gold score), episodes 
of severe hypoglycaemia, HbA1c and several of the glucose monitoring 
measures. 
Significance levels were set at α = 0.05 throughout. 
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3 Chapter 3 
A multicentre 2x2 factorial randomised control trial 
comparing insulin pump with multiple daily injections, and 
continuous with conventional glucose self-monitoring  
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3.1 Introduction 
Within months of the introduction of insulin therapy for type 1 diabetes (T1DM) 
in 1922, the potential for dangerous low glucose reactions was reported 
(Fletcher and Campbell, 1922).  Over ninety years later, severe hypoglycaemia 
requiring the assistance of another person for recovery, remains the most 
feared complication of insulin therapy (Pramming et al., 1991).  Prevalence 
increases with diabetes duration, annually affecting nearly half of those with 
type 1 diabetes for more than 15 years (UK-hypoglycaemia-studygroup, 2007). 
The landmark DCCT trial provided the incontrovertible evidence that intensive 
treatment of type 1 diabetes with either MDI or CSII reduces microvascular 
complications.  The intensive therapy was, however, associated with increased 
risk of severe hypoglycaemia.  Hypoglycaemia precludes the maintenance of 
euglycaemia and the subsequent associated vascular benefits.  Furthermore, 
hypoglycaemia compromises physiological defences against further 
hypoglycaemia, further increasing the risk. 
Single-centre studies in participants with T1DM and severe hypoglycaemia 
have shown that rigorous biochemical hypoglycaemia avoidance can restore 
awareness (Cranston et al., 1994; Fanelli et al., 1994b).  A 24-week pilot study 
for this programme of research, comparing education alone with analogue MDI 
and CSII, demonstrated prevention of recurrent severe hypoglycaemia in >70% 
with all interventions, together with better overall glycaemic control in MDI and 
CSII groups than with education alone (Thomas et al., 2007).  
A meta-analysis comparing CSII with MDI has however countered the argument 
that intensive treatment with CSII is always associated with increased risk of 
severe hypoglycaemia (Pickup and Sutton, 2008).  Pickup’s study showed that 
with CSII, as compared to MDI, there was a mean 2.9 fold reduction in severe 
hypoglycaemia in the randomised control trials included.  This was only based 
on studies using MDI regimens consisting of isophane and lente insulins.  A 
Cochrane review comparing MDI and CSII therapy has concluded that there 
was no proven additional benefit with CSII (Misso et al., 2010).  Both of these 
reviews have highlighted the need for studies comparing CSII with MDI 
regimens based on short and long acting analogue insulins.  
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The use of real time continuous glucose monitoring in people with type 1 
diabetes and IAH may be of benefit by alerting them to looming hypoglycaemia 
and provide them with an alternative awareness mechanism to replace the loss 
of the normal physiological mechanism.  However, although with this technology 
a lower HbA1c has been seen, it has not been associated with a reduction in 
severe hypoglycaemia (Tamborlane et al., 2008; Bergenstal et al., 2010).   
Large-scale intervention trials in T1DM generally focus on attainment of optimal 
HbA1c using a ‘treat-to-target’ approach (Little et al., 2011).  Despite the desire 
to show that new treatments carry less hypoglycaemia risk, trials have not been 
powered robustly to evaluate impact on significant hypoglycaemia, often 
excluding those with IAH or severe hypoglycaemia. 
Informed by this, the aim of this study was to undertake the first ever multi-
centre RCT in participants with established C-peptide negative T1DM 
complicated by IAH designed to determine robustly whether awareness can be 
restored and recurrent severe hypoglycaemia prevented through rigorous 
prevention of biochemical hypoglycaemia without worsening overall glycaemic 
control.  CSII was compared with optimised analogue MDI; and adjuvant RT 
with conventional glucose self-monitoring.  
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3.2 Aims 
The primary objective of this study was to investigate whether optimised MDI as 
compared to CSII with or without real-time CGM improves awareness of 
hypoglycaemia as measured by the validated Gold score in a high risk 
population.  
The secondary objectives were: 
1. To compare the rate of severe hypoglycaemia achieved by the 
interventions. 
2. To compare the frequency of biochemical hypoglycaemia identified by 
blinded CGM during each intervention. 
3. To compare the overall glycaemic control as assessed by HbA1c by 
each intervention. 
4. To compare total daily insulin doses between each intervention. 
5. To compare treatment satisfaction with each intervention. 
6. To compare awareness of hypoglycaemia using a new novel measure 
(the HypoA-Q) before and after the intervention.  
7. To compare the change in IAH (Gold score) and other markers of 
glycaemic control over the 24-week duration of the trial without 
consideration of the intervention or monitoring groups.  
 
3.3 Study design 
This was a 2 x 2 factorial, multi-centre, randomised control trial carried out at 
five UK tertiary referral centres, all routinely offering structured T1DM education 
with expertise in hypoglycaemia assessment / management and use of CSII / 
RT (Addenbrookes Hospital, Cambridge; Bournemouth Royal Hospital; Royal 
Victoria Infirmary, Newcastle upon Tyne; Derriford Hospital, Plymouth; Northern 
General Hospital, Sheffield).  Eligible participants were aged 18-74 years with 
C-peptide negative T1DM and IAH confirmed by Gold score ≥4 (Gold et al., 
1994).  After a four-week wash-in period during which a period of blinded CGM 
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was undertaken, a baseline study visit took place.  At this visit a full clinical 
history and detailed history of severe hypoglycaemia was undertaken and self 
reported outcome measures were completed.  Hypoglycaemia awareness was 
re-evaluated at baseline using validated Gold (Gold et al., 1994) and Clarke 
(Clarke et al., 1995a) questionnaires.  To improve sensitivity to change over a 
short period, the hypoglycaemia awareness questionnaire (HypoA-Q) was 
utilised.  Screening was undertaken for undiagnosed thyroid, Addison’s and 
coeliac disease.  
Prior to randomisation, all participants attended brief standardised education 
with formal curriculum and workbook, referred to as ‘my hypo compass’ (Little et 
al., 2012a).  
Following randomisation, number of study visits was the same for all 
participants, tailored for each group to technical aspects of their insulin 
administration and glucose monitoring intervention.   All participants, whether 
randomised to aspart insulin delivery by CSII (Medtronic Paradigm Veo insulin 
pump) or MDI (aspart / glargine) were given an insulin pump enabling benefit 
from direct transmission of SMBG levels to bolus calculator.  Those randomised 
to RT (REAL time continuous glucose monitor, Medtronic) were trained on 
sensor insertion, calibration and use of monitor including trend analysis and 
hypo- / hyper-glycaemia alarms.   Participants were able to individualise alarm 
settings but did not use the low-glucose-suspend feature.  Continuous RT use 
was encouraged but not mandatory. 
Participants were asked to record all episodes of severe hypoglycaemia 
prospectively and were recalled four weekly up to 24 weeks.  They were given 
identical written guidance on insulin titration primarily targeted towards absolute 
avoidance of biochemical hypoglycaemia (Appendix 7).  Glargine was 
administered before bed with addition of a second dose before breakfast in 
those with consistent glucose >7.0 mmol/L before evening meal or highly 
variable glucose levels between breakfast and evening meal.  Each study visit 
was preceded by 7-day CGM profile, with participant and investigator blinded to 
data until study completion.   Between study visits, all participants were 
telephoned weekly to encourage use of insulin titration guidelines, with 
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maintained focus on hypoglycaemia avoidance.  An outline of the study 
timetable can be seen in Appendix 11.  
 
3.4 Randomisation 
Using Newcastle University Clinical Trials Unit’s web based system, participants 
were randomly allocated on an equal allocation basis, stratified by baseline 
HbA1c (<64 and ≥ 64 mmol/mol, 8.0%) and by centre, to one of four groups: 
MDI with SMBG; MDI with SMBG and RT; CSII with SMBG; CSII with SMBG 
and RT.   
3.5 Statistical analysis 
Informed by the pilot study, (Thomas et al., 2007) recruitment of 100 
participants was planned to give 80% power at a significance level of 0.05 to 
detect a difference of 1.1 between the 24-week Gold score of the 50 
participants randomised to either of the groups allocated CSII and the 50 
randomised to either of the groups allocated MDI.  Results were analysed using 
SPSS version 21.0 for Windows (SPSS, IBM, New York, USA).  A general 
linear model (ANCOVA) was used with baseline IAH (Gold score) and 
stratification variables (centre and baseline HbA1c) included among the 
covariates.  A p-value <0.05 was considered to be significant for all analyses.  
3.6 Results 
110 individuals with IAH (defined as Gold score ≥4) were recruited.  Figure 3.1 
shows the trial profile.  Prior to randomisation: 93 (97%) were using MDI 
regimens (pre-prandial insulin: aspart/ lispro 90 (94%), human soluble 3 (3%), 
porcine soluble 3 (3%); basal insulin: glargine 45 (50%); detemir 36 (40%), 
human isophane 6 (7%); porcine isophane 3 (3%)). Three (3%) were using 
insulin aspart / lispro as part of a CSII regimen.  
Ninety-six participants were randomised, all with long-standing (mean duration 
29 years) C-peptide negative (<50 pmol/l in all except two: 87; 103 pmol/l) 
T1DM.  Baseline demographic and clinical characteristics were similar in all 
intervention groups and are seen in Table 3.1.   
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Baseline HbA1c was <64mmol/mol (8.0%) in just under half of the study 
population at 43%, with the mean HbA1c of the population being 66 ± 12 
mmol/mol (8.2%).  The majority of the study population was female (74%). The 
mean pre-study total daily dose of insulin was 0.64 units/kg.    
In the overall study population the baseline annualised severe hypoglycaemia 
rate over the preceding six months was high at 8.9 episodes per patient-year.  
77% of participants were affected over the preceding 6 months and 92% over 
the preceding 12 months (Table 3.4). 
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Figure 3.1  Trial profile 
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Table 3.1 Baseline characteristics of the study population 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Data are number of patients (%) or mean±SD. †Stratification variable. 
*Excludes participants with data missing for indicated variable (number missing: 
(HbA1c, one; duration of diabetes, one; body weight, one; BMI, one; insulin 
dose, two). 
  
 
 Insulin 
comparison 
Monitoring 
comparison 
All MDI CSII SMBG RT 
†Site -       
Bournemouth 16 (17%) 
8   
(16%) 
8 
(17%) 
7  
(15%) 
9 
(19%) 
Cambridge 21   (22%) 
11 
(22%) 
10 
(22%) 
11 
(23%) 
10 
(21%) 
Newcastle 22 (23%) 
12 
(24%) 
10 
(22%) 
11 
(23%) 
11 
(23%) 
Plymouth 17 (18%) 
10 
(20%) 
7 
(15%) 
9  
(19%) 
8 
(17%) 
Sheffield 20 (21%) 
9   
(18%) 
11 
(24%) 
10 
(21%) 
10 
(21%) 
†Baseline HbA1c       
<64 mmol/mol 41 
(43%) 
22 
(44%) 
19 
(41%) 
21 
(44%) 
20 
(42%) 
≥64 mmol/mol 55 (57%) 
28 
(56%) 
27 
(59%) 
27 
(56%) 
28 
(58%) 
*HbA1c (mmol/mol) 66±12 66±13 66±12 67±13 66±11 
Age (years) 48.6 ±12.2 
47.0 
±12.3 
50.3 
±12.0 
47.1 
±11.8 
50.1 
±12.6 
Male 35 (36%) 
16 
(32%) 
19 
(41%) 
20 
(42%) 
15 
(31%) 
*Diabetes duration  
(years) 
28.9 
±12.3 
29.5 
±12.5 
28.2 
±12.2 
26.7 
±12.1 
31.0 
±12.2 
*Body weight  
(kg) 
74.7 
±14.2 
74.9 
±13.9 
74.5±
14.6 
74.5 
±14.6 
75.0 
±13.9 
*BMI (kg/m2) 26.5 ±4.4 
26.7 
±4.6 
26.3 
±4.4 
26.1 
±4.3 
26.9 
±4.7 
*Insulin dose  
(units/kg/24 hr) 
0.64 
±0.23 
0.63± 
0.21 
0.66   
±0.26 
0.61   
±0.19 
0.68  
±0.27 
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3.6.1 Results for the study cohort 
In the overall study population, biochemical hypoglycaemia assessed by blinded 
CGM was significantly reduced according to all pre-specified criteria (table 3.2).  
The percentage of time spent ≤3.0mmol/L equates to a reduction by more than 
half from 53 minutes per 24 hours at baseline to 24 minutes at endpoint. This 
was achieved rapidly over the first four weeks and maintained throughout the 
study as illustrated in Figure 3.2.  
This reduction in biochemical hypoglycaemia was accomplished in tandem with 
a sustained 8-unit reduction in mean total daily insulin dose with mean total 
daily dose falling from 0.64 to 0.53 units/kg (Figure 3.7).  Other aspects of 
glycaemic control were assessed by HbA1c, 8 point SMBG mean and CGM 
mean glucose (Table 3.3).  There was improvement in glucose variability 
determined by CGM standard deviation (Tables 3.2).  HbA1c remained within 
target (<64 mmol/mol (8.0%)) in those with a value below this cut-off at 
baseline; with a non-significant 3 mmol/mol (0.3%) improvement in HbA1c in 
those with baseline HbA1c ≥64 mmol/mol (Figure 3.3).   
Across the study population awareness of hypoglycaemia improved, with 
significant reductions in Gold, Clarke and HypoA-Q IAH subscale scores (table 
3.4).  Gold score (primary study outcome measure) was significantly reduced at 
24 weeks as compared to baseline (Figure 3.4).  Clarke and HypoA-Q scores 
showed strong correlations (r=0.53 - 0.74) with Gold score at baseline and 
study endpoint.  Annualised severe hypoglycaemia rate fell more than 10-fold, 
with 20% of participants experiencing severe events during the RCT in 
comparison to 77% over the preceding 6 months (Figure 3.5).   
Fear of hypoglycaemia (Figure 3.8) and treatment satisfaction (Figure 3.9) 
improved significantly across the study population from baseline to endpoint 
(Table 3.5).
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Table 3.2 Biochemical parameters of CGM in study population 
 
 
 
 
 
 
 
 
 
 
 
 
Data are mean ± SD. * Paired t-test (complete pairs only) between week 24 endpoint and baseline. 
 
Trial Period  
Baseline Week 4 Week 8 Week 12 Week 16 Week 20 Week 24 
(endpoint) 
P 
value* 
CGM analysis (n=84) (n=84) (n=80) (n=76) (n=85) (n=80) (n=83) (n=82) 
Biochemical hypoglycaemia  (% 
time spent below threshold)  
       
≤2.5 mmol/l 
 
2.1 
±3.2 
1.1 
±2.2 
1.0 
±1.7 
1.1 
±2.8 
1.1 
±1.8 
1.1 
±1.9 
0.77 
±2.2 
0.01 
≤3.0 mmol/l 
 
3.7 
±4.4 
2.1 
±3.7 
2.0 
±2.7 
1.8 
±3.7 
2.1 
±3.1 
2.3 
±3.6 
1.7 
±3.9 
<0.01 
<4.0 mmol/l 
 
8.5 
±7.1 
5.4 
±6.3 
5.6 
±5.1 
5.5 
±5.9 
5.7 
±5.8 
7.0 
±7.8 
5.7 
±7.1 
0.01 
Glucose mean (mmol/l) 9.4 
±2.0 
9.3 
±1.7 
9.1 
±1.3 
9.3 
±1.7 
9.2 
±1.8 
9.1 
±1.7 
9.4 
±1.9 
0.81 
Glucose SD (mmol/l) 3.9 
±1.0 
3.4 
±0.9 
3.4 
±0.8 
3.4 
±0.9 
3.3 
±0.8 
3.4 
±0.9 
3.4 
±0.8 
<0.01 
% time 4.0-6.9 mmol/l 
 
25.9 
±13.2 
25.9 
±14.0 
27.1 
±11.4 
25.9 
±11.8 
26.2 
±13.6 
28.4 
±13.9 
25.3 
±13.9 
0.37 
% time 4.0-9.9 mmol/l 
 
52.1 
±16.4 
56.8 
±17.7 
58.6 
±13.6 
57.2 
±16.7 
56.9 
±18.2 
56.7 
±17.9 
54.6 
±18.5 
0.62 
% time 3.1-9.9 mmol/l 
 
57.1 
±17.9 
60.2 
±18.4 
62.2 
±14.6 
60.8 
±18.0 
60.4 
±19.7 
61.4 
±19.5 
58.8 
±19.8 
0.84 
% time ≥7.0 mmol/l 
 
65.6 
±17.2 
68.7 
±17.2 
67.3 
±14.0 
68.6 
±14.6 
68.1 
±17.0 
64.6 
±18.1 
69.0 
±17.4 
0.04 
% time ≥10.0 mmol/l 
 
39.4 
±19.0 
37.8 
±18.9 
35.8 
±15.4 
37.3 
±18.2 
37.4 
±20.3 
36.3 
±20.1 
39.6 
±20.2 
0.56 
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Figure 3.2 Percentage time with glucose <3.0 mmol/L during monthly blinded continuous glucose monitoring in the 
overall study population. *Paired t-test (complete pairs only between week 24 endpoint and baseline (P=0.004)). 
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Table 3.3 Parameters of glycaemic control in overall study population over time 
 
 
 
 
 
 
 
  
 
 
Data are mean ± SD. * Paired t-test (complete pairs only) between week 24 endpoint and baseline.  
 
 
 Trial Period  
 Baseline Week 4 Week 8 Week 12 Week 16 Week 20 Week 24 
(endpoint) 
P 
value* 
8 point SMBG mean 9.5     
±2.8 
(n=66) 
9.4    
±1.8 
(n=78) 
9.5   
±2.2 
(n=78) 
9.3     
±2.2 
(n=78) 
9.1     
±1.7 
(n=76) 
9.3         
±2.1 
(n=72) 
8.8          
±1.9 
(n=56) 
0.16 
(n=41) 
HbA1c (mmol/mol) 
 
66±12 
(n=95) 
66±10 
(n=90) 
66±9 
(n=87) 
66±10 
(n=86) 
65±10 
(n=85) 
65±10 
(n=89) 
65±10 
(n=89) 
0.42 
(n=89) 
Weight (kg) 
 
74.7± 
14.2 
(n=95) 
74.8  
±13.8 
(n=88) 
75.4 
±13.7 
(n=82) 
74.3 
±13.4 
(n=86) 
74.3 
±13.6 
(n=82) 
74.0     
±14.8 
(n=84) 
75.3      
±13.6 
(n=87) 
0.75 
(n=86) 
Total daily insulin dose 
(units) 
48.6 
±21.3 
(n=95) 
38.7 
±14.3 
(n=90) 
40.4 
±15.3 
(n=87) 
39.6 
±16.1 
(n=90) 
40.4 
±15.9 
(n=89) 
40.1     
±16.0 
(n=97) 
40.0      
±16.5 
(n=90) 
<0.001 
(n=89) 
Total daily insulin dose 
(units/kg) 
0.64 
±0.23 
(n=94) 
0.51 
±0.14 
(n=86) 
0.52 
±0.15 
(n=79) 
0.52 
±0.16 
(n=86) 
0.53 
±0.17 
(n=82) 
0.56     
±0.34 
(n=82) 
0.53      
±0.17 
(n=87) 
<0.001 
(n=85) 
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Figure 3.3 Mean HbA1c over time in the overall study population stratified by baseline value <64mmol/mol and ≥ 
64mmol/mol (8.0%). 
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Table 3.4 Severe hypoglycaemia and hypoglycaemia awareness in 
overall study population at baseline and 24-week endpoint.  
 Baseline Week 24 
(Endpoint) 
*P 
value 
Severe hypoglycaemia 
 
   
Annualised rate (patient-
year) 
8.9±13.4 0.8±1.9 <0.001 
 4 [2-7] 0 [0-0] (n=90) 
 (n=96) (n=90)  
    
Proportion affected (%) 77 20 <0.001 
 (n=96) (n=90) (n=90) 
    
Impaired awareness of 
hypoglycaemia 
   
Gold score 5  4 <0.001 
 [4-6] [3-5] (n=85) 
 (2-7) (1-7)  
 5.1±1.1 4.1±1.6  
 (n=96) (n=85)  
    
Clarke score 5  3 <0.001 
 [4-6] [2-4] (n=74) 
 (1-7) (0-7)  
 4.1±1.6 3.2±1.7  
 (n=87) (n=80)  
    
HypoA-Q 14  9.5  <0.001 
 [11-16] [6-12] (n=80) 
 (5-20) (0-19)  
 13.4±3.4 9.1±4.2  
 (n=92) (n=84)  
 
Data are median [interquartile range] (range) or mean ± SD. Number with 
available data denoted by n number in brackets. * Paired t-test (complete pairs 
only) between week 24 endpoint and baseline.  
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Table 3.5 Fear of hypoglycaemia and treatment satisfaction at baseline 
and 24-week study endpoint  
 
 
 
 
 
 
 
 
 
 
Data are median [interquartile range] (range) or mean±SD. Number with 
available data denoted by n number in brackets. * Paired t-test (complete pairs 
only) between Week 24 endpoint and baseline.  
 
  
 Baseline Week 24 
(Endpoint) 
*P 
value 
HFS  II – Total 58 
±26 
(n=94) 
45 
±24 
(n=87) 
<0.001 
(n=85) 
HFS II - Behaviour 
 
 
24 
±11 
(n=94) 
20 
±10 
(n=87) 
<0.001 
(n=85) 
HFS II - Worry 
 
 
35 
±17 
(n=96) 
24 
±17 
(n=87) 
<0.001 
(n=87) 
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Figure 3.4 Gold score (primary endopoint) in the overall study 
population.  *Paired t-test (complete pairs only between week 24 endpoint 
and baseline (P<0.001)). 
 
 
Figure 3.5 Severe hypoglycaemia events in the overall study population.  
*Paired t-test (complete pairs only between week 24 endpoint and baseline 
(P<0.001)). 
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Figure 3.6 HbA1c in the overall study population between week 24 
endpoint and baseline. Paired t-test (complete pairs only between week 24 
endpoint and baseline (P=NS)). 
 
 
 
 
Figure 3.7 Mean total daily dose insulin in the overall study population. 
*Paired t-test (complete pairs only between week 24 endpoint and baseline 
(P<0.001)).  
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Figure 3.8 Fear of hypoglycaemia in the overall study population.  
*Paired t-test (complete pairs only between week 24 endpoint and baseline 
(P<0.001)).  
 
  
Figure 3.9 Treatment satisfaction in the overall study population.  
*Paired t-test (complete pairs only between week 24 endpoint and baseline 
(P<0.001)).  
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3.6.2 Comparisons of MDI vs CSII at 24-week study endpoint 
This study has demonstrated that there was no difference in the improvement in 
hypoglycaemia awareness at 24 weeks between those randomised to optimised 
MDI and those randomised to CSII as assessed by the mean (±SD) Gold score 
((MDI: 4.1 ± 1.6 vs CSII: 4.2 ± 1.7) (p=0.76)) (Figure 3.10).   This was reflected 
in the accompanying measures of hypoglycaemia awareness used, the Clarke 
score (MDI 3.3 ± 1.8 vs CSII 3.0 ± 1.6 (p=0.31)) and the new measure the 
Hypoglycaemia Awareness Questionnaire (MDI 8.9 ± 4.3 vs CSII 9.4 ± 4.2 
(p=0.60)).  
Reductions in annualised rate of severe hypoglycaemia were also comparable 
in the MDI and CSII groups (MDI 1.0 ± 2.1 vs CSII 0.6 ± 1.7 (p=0.34)) and 
proportions of participants affected were also not statistically different (Figure 
3.11 and Table 3.6).  
Other metabolic secondary outcome measures were also equivalent in MDI and 
CSII groups with comparable percentage time spent in biochemical 
hypoglycaemia as assessed by CGM.  Time spent (%) ≤3.0 mmol/L was 1.4 ± 
2.5 in the MDI group as compared to 2.0 ± 4.9 in the CSII group (p=0.48).  
HbA1c was lower in the CSII group at 64 ± 9 mmol/mol as compared to 67 ± 11 
mmol/mol in the MDI group though this was not significant (Figure 3.12).  
There was an overall reduction in total daily dose of insulin seen in the study 
population however no difference was seen between MDI and CSII groups 
(Figure 3.13).  Total daily dose comparisons at 24 weeks were (units/kg/24 
hours) 0.51 ± 0.15 in the MDI group as compared to 0.55 ± 0.18 in the CSII 
group (p=0.31).  
Fear of hypoglycaemia was reduced equally (Figure 3.14) as were perceived 
frequency of hypoglycaemia and hyperglycaemia (Table 3.9).  Overall treatment 
satisfaction was, however, higher in those randomised to CSII (Figure 3.15).  
The mean endpoint DTSQ score for the MDI groups was 29 ± 6 in comparison 
to 32 ± 3 in the CSII group (p<0.001) (Table 4). 
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Table 3.6 Severe hypoglycaemia and hypoglycaemia awareness in MDI 
vs CSII at 24 week endpoint 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Data are median [interquartile range] (range) or mean ± SD. Number with 
available data denoted by n number in brackets. * 2 sample t-test between 
groups at week 24 except, ** Chi square test.  
  
 Insulin comparison 
MDI CSII *P 
value 
Severe hypoglycaemia    
    
Proportion affected (%) 23 16 0.399** 
 (n=47) (n=43)  
    
Annualised rate 1.0 0.6 0.34 
 ±2.1 ±1.7  
 0 [0-0] 0 [0-0]  
 (n=47) (n=43)  
Impaired awareness of 
hypoglycaemia 
   
    
Gold 4 4 0.756 
 [3-5] [3-5.5]  
 (2-7) (1-7)  
 4.1±1.6 4.2 ±1.7  
 (n=45) (n=40)  
    
Clarke 3 3 0.305 
 [2-5] [2-4]  
 (0-7) (0-6)  
 3.3±1.8 3.0±1.6  
 (n=41) (n=39)  
    
HypoA-Q 9 10 0.601 
 [5.5-12] [6-12.5]  
 (0-19) (0-18)  
 8.9±4.3 9.4±4.2  
 (n=44) (n=40)  
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Table 3.7 Biochemical parameters of CGM analysis in MDI vs CSII at 24-
week endpoint 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Data are mean ± SD. * 2 sample t-test between groups at 24 weeks.  
  
 Insulin comparison 
MDI 
(n=41) 
CSII 
(n=42) 
P value* 
Biochemical 
hypoglycaemia on CGM 
(% time spent) mmol/l 
 
   
≤2.5 mmol/l 
 
 
0.5 
±1.1 
1.0 
±3.0 
0.40 
≤3.0 mmol/l 
 
 
1.4 
±2.5 
2.0 
±4.9 
0.48 
< 4.0 mmol/l 
 
 
5.7 
±6.1 
5.8 
±8.0 
0.96 
Glucose mean (mmol/l) 
 
 
9.4 
±2.0 
9.5 
±1.8 
0.85 
Glucose SD (mmol/l) 
 
 
3.3 
±0.7 
3.5 
±0.8 
0.32 
% time 4.0-6.9 mmol/l 
 
 
25.5 
±14.3 
25.1 
±13.7 
0.89 
% time 4.0-9.9 mmol/l 
 
 
55.0 
±19.1 
54.3 
±18.1 
0.88 
% time 3.1-9.9 mmol/l 
 
 
59.4 
±20.9 
58.3 
±18.8 
0.80 
% time ≥7.0 mmol/l 
 
 
68.8 
±18.1 
69.1 
±16.9 
0.93 
% time ≥10.0 mmol/l 
 
 
39.4 
±21.5 
39.9 
±19.1 
0.91 
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Table 3.8 Biochemical parameters of glycaemic control in MDI vs CSII 
at 24-week endpoint 
 
 
 
Insulin comparison 
MDI 
 
CSII P value* 
8 point SMBG mean 8.9 ±1.6 8.7 ±2.2 0.80 
 (n=28) (n=28)  
HbA1c (mmol/mol) 67 ± 11 64 ± 9 0.26 
 (n=46) (n=43)  
Total daily insulin dose 
(units/kg body weight) 0.51 ±0.15 0.55 ±0.18 0.31 
 (n=44) (n=43)  
 
Data are mean ± SD. * 2 sample t-test between groups at 24 weeks.  
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Table 3.9 Fear of hypoglycaemia and treatment satisfaction outcomes 
in MDI vs CSII comparisons at 24-week endpoint 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Data are median [interquartile range] (range) or mean±SD. Number with 
available data denoted by n number in brackets. Number completing DTSQ2 
and DTSQ3 in each group are the same as those completing DTSQ – total 
satisfaction questions. * 2 sample t-test between groups at Week 24.  
  
 Insulin 
comparison 
 
MDI CSII *P 
value 
Fear of 
hypoglycaemia  
   
HFS II – Total 
 
 
45±25 
(n=46) 
 
44±23 
(n=41) 
0.824 
HFS II – Behaviour 21±10 
(n=46) 
 
20±10 
(n=41) 
0.613 
HFS II – Worry 25 ±17 
(n=46) 
24 ±17 
(n=41) 
0.985 
Treatment 
satisfaction 
   
DTSQ – Total 
satisfaction 
 
 
DTSQ2 Perceived 
frequency of 
hyperglycaemia 
 
DTSQ3 Perceived 
frequency of 
hypoglycaemia 
 
29±6 
(n=45) 
 
 
3±1.29 
 
 
 
3±1.13 
32±3 
(n=39) 
 
 
3±1.01 
 
 
 
3±1.25 
<0.001 
 
 
 
0.248 
 
 
 
0.240 
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Figure 3.10 Gold score (primary endpoint) in MDI vs CSII.  2 sample t-test 
(comparison between groups at week 24 (P=NS)). 
 
 
Figure 3.11 Severe hypoglycaemia events in MDI vs CSII.  2 sample t-test 
(comparison between groups at week 24 (P=NS)). 
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Figure 3.12 HbA1c in MDI vs CSII.  2 sample t-test (comparison between 
groups at week 24  (P=NS)). 
 
 
Figure 3.13 Mean total daily dose insulin in MDI vs CSII.  2 sample t-test 
(comparison between groups at week 24 (P=NS)). 
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Figure 3.14 Fear of hypoglycaemia in MDI vs CSII.  2 sample t-test 
(comparison between groups at week 24 (P=NS)).  
 
 
Figure 3.15 Treatment satisfaction in MDI vs CSII.  *2 sample t-test 
(comparison between groups at week 24 (P<0.001)). 
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3.6.3 Comparisons of RT vs SMBG at 24-week study endpoint 
In this 2x2 factorial study comparisons of the SMBG and RT groups similarly 
were equivalent with regards IAH scores and all other secondary outcomes.  
Gold scores (mean ± SD) at study endpoint in the SMBG and RT groups were 
4.3 ± 1.6 and 4.0 ± 1.7 respectively (p=0.42) (Figure 3.16).   Clarke and HypoA-
Q scores were also equivalent (Table 3.10).  
Reductions in annualised rate of severe hypoglycaemia were equivalent in the 
SMBG and RT groups (SMBG 1.0 ± 2.1 vs RT 0.6 ± 1.7 (p=0.34)) and 
proportions of participants affected were also not statistically different (Figure 
3.17 and Table 3.10).  
Other metabolic secondary outcome measures were also equivalent in MDI and 
CSII groups with comparable percentage time spent in biochemical 
hypoglycaemia as assessed by CGM (Table 3.11).  Time spent (% ± SD) 
≤3.0mmol/L was 1.4 ± 2.5 in the MDI group as compared to 2.0 ± 4.9 in the CSII 
group (p=0.48).  HbA1c was similar on both groups (Figure 3.18) as was total 
daily dose of insulin at study endpoint (Figure 3.19).   
When patient reported outcomes were compared for SMBG and RT, fear of 
hypoglycaemia was reduced equally (Figure 3.20), as were perceived frequency 
of hypoglycaemia and hyperglycaemia (Table 3.13).  Unlike the comparison of 
MDII and CSII, no difference was seen in overall treatment satisfactions 
between these interventions (Table 3.13 and Figure 3.21).  
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Table 3.10 Severe hypoglycaemia and hypoglycaemia awareness in 
SMBG vs RT at 24-week endpoint 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Data are median [interquartile range] (range) or mean ± SD. Number with 
available data denoted by n number in brackets. † Mann Whitney U Test, * 2 
sample t-test between groups at Week 24 except, ** Chi square test.  
  
 Monitoring comparison 
SMBG RT *P value 
Severe hypoglycaemia    
Annualised rate 
 
0.9 
±2.1 
0 [0-0] 
(n=44) 
0.8 
±1.8 
0 [0-0] 
(n=46) 
0.95 
 
0.92† 
 
 
Proportion affected (%) 
 
 
21 
(n=44) 
 
 
20 
(n=46) 
 
 
**0.92 
Impaired awareness of 
hypoglycaemia 
 
   
*Gold 
 
 
 
4 
[3-5] 
(1-7) 
4.3 
±1.6 
(n=42) 
4 
[3-6] 
(1-7) 
4.0 
±1.7 
(n=43) 
0.42 
 
Clarke 
 
 
 
 
3 
[2-4] 
(0-6) 
3.3 
±1.6 
(n=39) 
 
3 
[2-4] 
(0-7) 
3.1 
±1.8 
(n=41) 
 
0.83 
 
HypoA-Q 
 
 
 
 
10 
[5-12] 
(0-16) 
9.2 
±4.1 
(n=40) 
 
9 
[6-12] 
(3-14) 
9.0 
±4.4 
(n=44) 
 
0.83 
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Table 3.11 Biochemical parameters of CGM analysis in SMBG vs RT at 
24-week endpoint 
 
 
 
 
 
 
 
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Data are mean ± SD. * 2 sample t-test between groups at 24 weeks.  
 
  
 Monitoring comparison 
 
SMBG 
(n=41) 
RT 
(n=42) 
P value* 
Biochemical 
hypoglycaemia on CGM 
(%time spent) mmol/l 
 
   
≤2.5 mmol/l 
 
 
0.7 
±1.4 
0.8 
±2.9 
0.71 
≤3.0 mmol/l 
 
 
1.3 
±2.1 
2.1 
±5.1 
0.36 
< 4.0 mmol/l 
 
 
5.2 
±4.2 
6.3 
±9.1 
0.47 
 
Glucose mean (mmol/l) 
 
 
9.5 
±1.7 
9.4 
±2.1 
0.73 
Glucose SD (mmol/l) 
 
 
3.4 
±0.7 
3.4 
±0.8 
0.81 
% time 4.0-6.9 mmol/l 
 
 
24.7 
±13.6 
25.9 
±14.4 
0.72 
% time 4.0-9.9 mmol/l 
 
 
54.0 
±17.8 
55.3 
±19.3 
0.75 
% time 3.1-9.9 mmol/l 
 
 
57.9 
±19.4 
59.7 
±20.3 
0.69 
% time ≥7.0 mmol/l 
 
 
70.1 
±16.1 
67.9 
±18.7 
0.56 
% time ≥10.0 mmol/l 
 
 
40.8 
±19.3 
38.4 
±21.2 
0.59 
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Table 3.12 Biochemical parameters of glycaemic control in SMBG vs RT 
at 24-week endpoint 
 
 
 
 
 
 
 
 
 
 
 
 
Data are mean ± SD. * 2 sample t-test between groups at 24 weeks.  
 
 
 
  
 
 
Monitoring comparison 
 
SMBG RT P value* 
8 point SMBG mean 
 
 
9.1 
±2.2 
(n=27) 
 
8.5 
±1.6 
(n=29) 
0.32 
HbA1c (mmol/mol) 
 
 
65 
±9 
(n=43) 
66 
±11 
(n=46) 
0.80 
 
 
 
Total daily insulin dose 
(units / kg body weight) 
0.51 
±0.16 
(n=44) 
 
0.55 
±0.17 
(n=43) 
0.32 
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Table 3.13 Fear of hypoglycaemia and treatment satisfaction outcomes 
in SMBG vs RT comparisons at 24-week endpoint 
 
Monitoring comparison 
SMBG RT P value* 
Fear of 
hypoglycaemia  
   
HFS II - Total 
 
 
45±24 
(n=42) 
45±25 
(n=45) 
 
0.96 
HFS II - Behaviour 21 ±9 
(n=42) 
20 ±11 
(n=45) 
 
0.94 
HFS II - Worry 25 ±17 
(n=42) 
24 ±17 
(n=45) 
 
0.98 
Treatment 
satisfaction 
   
DTSQ - Total 
satisfaction 
 
30±5 
(n=41) 
30±5 
(n=43) 
0.79 
 
 
DTSQ2 Perceived 
frequency of 
hyperglycaemia 
3 ±1.17 
 
3±1.18 
 
0.70 
 
DTSQ3 Perceived 
frequency of 
hypoglycaemia 
3 ±1.09 3±1.27 0.75 
 
Data are median [interquartile range] (range) or mean ± SD. Number with 
available data denoted by n number in brackets. Number completing DTSQ2 
and DTSQ3 in each group are the same as those completing DTSQ – total 
satisfaction questions. * 2 sample t-test between groups at week 24.  
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Figure 3.16 Gold score (primary endpoint) in SMBG vs RT.  2 sample t-
test (comparison between groups at week 24  (P=NS)). 
 
Figure 3.17 Severe hypoglycaemia events in SMBG vs RT.  2 sample t-
test (comparison between groups at week 24 (P=NS)).  
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Figure 3.18 HbA1c in SMBG vs RT.  2 sample t-test (comparison between 
groups at week 24 (P=NS)).  
 
Figure 3.19 Mean total daily dose insulin in SMBG vs RT.  2 sample t-test 
(comparison between groups at week 24 (P=NS)). 
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Figure 3.20 Fear of hypoglycaemia in SMBG vs RT.  2 sample t-test 
(comparison between groups at week 24 (P=NS)).  
 
 
Figure 3.21 Treatment satisfaction in SMBG vs RT.  2 sample t-test 
(comparison between groups at week 24 (P=NS)). 
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3.7 Compliance with RT 
RT participants wore sensors for a median of 57% of time in study with sensor 
usage >80% in 17 individuals (Figure 3.21).  Outcomes were not significantly 
different in those who used sensors for >50% of time, compared with less 
frequent users (Table 3.14).  However higher users showed trends towards 
greater reduction in biochemical hypoglycaemia as defined as % time spent <4 
mmol/L, ≤3 mmol/L and ≤2.5 mmol/L (Table 3.14).  There was also a trend 
towards improved glycaemic control with the group using RT >50% of the time 
having an HbA1c (mean ±SD) of 64 ± 10 mmol/mol as compared to 68 ± 12 
mmol/mol in the group using RT <50% of the time.  
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Figure 3.22 Histogram of percentage time the RT-continuous 
subcutaneous glucose monitor was worn during the study in those 
allocated to this intervention.  Frequency represents the number of 
individuals using RT for each percentage time range. 
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Table 3.14 Comparison of participants who used RT <50% of time with 
those who used it ≥50% of time at 24-week endpoint.   
 
 
Real time CGM use  
<50% ≥50% P* value 
 
CGM analysis 
 
(n=17) 
 
(n=25) 
 
Biochemical hypoglycaemia 
on CGM (% time spent) 
 
   
≤2.5 mmol/l 
 
 
1.4 
±4.4 
0.4 
±1.0 
0.28 
≤3.0 mmol/l 
 
 
3.7 
±7.6 
1.1 
±1.7 
0.10 
<4.0 mmol/l 8.1 
±12.7 
5.1 
±5.4 
0.31 
3.1-9.9 mmol/l 
 
 
53.9 
±22.5 
63.6 
±18.1 
0.13 
≥10.0 mmol/l 
 
 
42.7 
±24.3 
35.5 
±18.7 
0.28 
HbA1c (mmol/mol) 
 
 
68 
±12 
(n=20) 
64 
±10 
(n=25) 
0.24 
Impaired awareness of 
hypoglycaemia 
   
Gold 
 
 
Clarke 
 
 
HypoA-Q 
 
 
Severe hypoglycaemia 
 
Annualised rate (patient-year) 
 
 
Proportion affected (%) 
4.1 
±1.6 
(n=17) 
3.3 
±1.9 
(n=17) 
9.2 
±4.3 
(n=17) 
 
 
0.5 
±1.7 
(n=20) 
10 
 
4.0 
±1.8 
(n=26) 
2.9 
±1.8 
(n=23) 
8.8 
±4.6 
(n=26) 
 
 
1.0 
±1.9 
(n=26) 
30 
 
0.71 
 
 
0.47 
 
 
0.74 
 
 
 
 
0.43 
 
 
**0.15 
    
 
Data are mean ± SD.  * 2 sample t-test between groups at 24 weeks.  **Chi 
squared test.  
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3.8 ANCOVA analysis 
ANCOVA adjusted for indicated covariates supported absence of influence of 
insulin treatment (Tables 3.15, 3.16, 3.17) or monitoring group (Tables 3.18, 
3.19, 3.20) on primary and the majority of secondary outcome measures, either 
through analyses of change over the study period or explicit adjustment for 
baseline values.  The analysis of the proportion of participants experiencing a 
reduction in severe hypoglycaemia was undertaken by logistic regression rather 
than ANCOVA.  
Comparing the insulin regimens, the CSII group experienced a significantly 
larger increase in treatment satisfaction than MDI participants across all three 
fitted models (Tables 3.15, 3.16, 3.17).  
Comparing adjuvant RT and conventional SMBG groups (tables 3.19, 3.19, 
3.20), there was a significantly larger decrease in annualised severe 
hypoglycaemia rate (RT: 11.3 events per patient-year at baseline reduced to 0.8 
events per patient-year at 24 weeks; SMBG: 6.4 vs 0.8 events).  This was 
driven by baseline differences in severe hypoglycaemia rate between the 
monitoring groups.  Interaction between insulin and monitoring regimen was 
considered for primary outcome analysis but found to be non-significant. 
Similar analyses (Tables 3.21, 3.22, 3.23) were conducted for the subgroup 
allocated to RT use, dichotomised by use of RT (≥50% or <50% time).  Higher 
RT use was associated with significantly larger decrease in time ≤3.0 mmol/L 
but without evidence of impact on IAH scores or severe hypoglycaemia.  
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3.9 Safety data 
There were no hospital admissions related to severe hypoglycaemia or injection 
/ cannula / sensor site infections throughout the RCT.  There were three 
episodes of diabetic ketoacidosis requiring hospitalisation: two in participants 
randomised to CSII without RT and one in a participant randomised to MDI 
without RT.  All resolved without adverse sequelae.  Seven other serious 
adverse events (SAEs) were reported in the CSII group and 4 in the MDI group.  
These include episodes of acute-angle closure glaucoma, pneumonia, 
gastroenteritis, fractured radius and need for intravenous antibiotics for pre-
existing neuropathic foot ulceration.  None were deemed related to trial 
intervention.  
After 4 weeks intervention, 50% of participants in the MDI arm were injecting 
glargine twice daily, increasing to 68% at 24 weeks. 
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Table 3.15 Analysis of covariance results comparing insulin regimen 
groups model 1: insulin regimen group only considered as covariate 
  
 
 
 
Significant p-values show a significant difference between groups following adjustment 
for other model covariates.  Beta values show the relative difference between the 
groups (the value being the fitted difference for membership of the CSII group relative 
to MDI).  24-week change values are calculated as the value at baseline subtracted 
from the value at week 24. 
* P-value taken from F test (unless otherwise noted).  
$ Odds ratio reported in place of beta (logistic regression used).  
$$ p-value from logistic regression model 
 
 
  
Outcome Model 1 
 n beta se(beta) Wald*, p 
24-week Gold score 85 0.11 0.36 0.10 (1,83 df), p=0.76 
24-week Clark score  80 -0.39 0.38 1.07(1,78 df), p=0.30 
24-week hypo AQ score 84 0.49 0.93 0.28 (1,82 df), p=0.60 
Severe hypoglycaemia data 
 
    
Number of events at 24 weeks  90 -0.19 0.19 1.01 (1,88 df), p=0.32 
24-week change in annualised rate 90 0.27 2.77 0.01 (1,88 df), p=0.92 
Proportion with reduction  
 
90 0.89 $ 0.42 p=0.80 $$ 
24-week change in HbA1c  89 -1.94 1.86 1.09(1,87 df), p=0.30 
24-week change in weight 86 -0.14 0.82 0.03(1,84 df), p=0.87 
24-week change mean insulin 85 -0.003 0.04 0.01(1,83 df), p=0.94 
24-week change in HFS-II score 85 1.45 4.10 0.12 (1,83 df), p=0.73 
24-week change in DTSQ score 84 4.79 1.36 12.36 (1,82 df), p<0.01 
CGM data: 24-week change     
% time ≤3.0 82 1.83 1.21 2.29 (1,80 df), p=0.13 
% time 3.1-9.9 82 2.52 4.63 0.30 (1,80 df),p=0.59 
% time ≥10.0 82 -4.31 4.61 0.88 (1,80 df), p=0.35 
Glucose (Sensor) SD 82 -0.03 0.24 0.02 (1,80 df), p=0.90 
Glucose (Sensor) mean 82 -0.46 0.44 1.06 (1,80 df), p=0.31 
8 point SMBG mean 41 -0.59 0.92 0.41 (1,39 df), p=0.53 
 115 
Table 3.16  Analysis of covariance results comparing insulin regimen 
groups model 2: in addition to insulin regimen group, adjusted for 
stratification factors at randomisation (site, HbA1c group) 
 
Significant p-values show a significant difference between groups following adjustment 
for other model covariates.  Beta values show the relative difference between the 
groups (the value being the fitted difference for membership of the CSII group relative 
to MDI).  24-week change values are calculated as the value at baseline subtracted 
from the value at week 24.  
* P-value taken from F test (unless otherwise noted).  
$ Odds ratio reported in place of beta (logistic regression used).  
$$ p-value from logistic regression model. ~ 1 site (Bournemouth) predicts reduction 
perfectly: data from this site excluded from this analysis.  
^^ Not adjusted for HbA1c stratification factor (as baseline value is considered within 
24-week change) 
  
Outcome Model 2 
 n beta se(beta) Wald*, p 
24-week Gold score 85 0.18 0.35 0.28(1,78 df), 
p=0.60 
24-week Clark score  80 -0.35 0.37 0.86(1,73 df), 
p=0.36 
24-week hypo AQ score 84 0.67 0.91 0.54 (1,77 df), 
p=0.47 
Severe hypoglycaemia data 
 
    
Number of events at 24 weeks  90 -0.19 0.19 0.99 (1,83 df), 
p=0.32 
24-week change in annualised rate 90 0.37 2.73 0.02 (1,83 df), 
p=0.89 
Proportion with reduction  
 
75~ 0.73 $ 0.39 P=0.55 $$ 
24-week change in HbA1c  ^^ 89 -1.95 1.77 1.21(1,83 df), 
p=0.27 
24-week change in weight 86 -0.20 0.82 0.06(1,79 df), 
p=0.81 
24-week change mean insulin 85 -0.004 0.04 0.01(1,78 df), 
p=0.92 
24-week change in HFS-II score 85 0.94 4.13 0.05 (1,78 df), 
p=0.82 
24-week change in DTSQ score 84 4.63 1.31 12.42 (1,77 df), 
p<0.01 
CGM data: 24-week change     
% time ≤3.0 82 1.86 1.24 2.26 (1,75 df), 
p=0.14 
% time 3.1-9.9 82 4.12 4.39 0.88 (1,75 df), 
p=0.35 
% time ≥10.0 82 -5.93 4.30 1.91 (1,75 df), 
p=0.17 
Glucose (Sensor) SD 82 -0.05 0.24 0.05 (1,75 df), 
p=0.83 
Glucose (Sensor) mean 82 -0.64 0.41 2.47 (1,75 df), 
p=0.12 
8 point SMBG mean 41 -0.31 1.02 0.09 (1,34 df), 
p=0.76 
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Table 3.17  Analysis of covariance results comparing insulin regimen 
groups model 3: in addition to insulin regimen group, adjusted for site, 
baseline Gold score, age, presence or absence of treated autoimmune 
thyroid disease 
 
 
Significant p-values show a significant difference between groups following adjustment 
for other model covariates.  Beta values show the relative difference between the 
groups (the value being the fitted difference for membership of the CSII group relative 
to MDI).  24-week change values are calculated as the value at baseline subtracted 
from the value at week 24.  
* P-value taken from F test (unless otherwise noted).  
$ Odds ratio reported in place of beta (logistic regression used).  
$$ p-value from logistic regression model. ^ Also adjusted for baseline value of 
outcome measure (baseline annualised rate in case of number of severe 
hypoglycaemia events) 
 
Outcome Model 3 
 n beta se(beta) Wald*, p 
24-week Gold score 85 0.12 0.27 0.20(1,76 df), 
p=0.66 
24-week Clark score ^ 74 -0.06 0.37 0.03(1,64 df), 
p=0.86 
24-week hypo AQ score^ 80 0.02 0.73 <0.01 (1,70 df), 
p=0.97 
Severe hypoglycaemia data 
 
    
Number of events at 24 weeks ^ 90 -0.16 0.17 0.90 (1,80 df), 
p=0.35 
24-week change in annualised 
rate 
90 0.15 2.61 <0.01 (1,81 df), 
p=0.95 
Proportion with reduction ^ 
 
75~ 0.68 $ 0.37 P=0.48 $$ 
24-week change in HbA1c   89 -2.33 1.77 1.73(1,80 df), 
p=0.19 
24-week change in weight 86 -0.09 0.82 0.01(1,77 df), 
p=0.91 
24-week change mean insulin 85 -0.003 0.04 <0.01(1,76 df), 
p=0.95 
24-week change in HFS-II score 85 0.42 4.16 0.01 (1,76 df), 
p=0.92 
24-week change in DTSQ score 84 5.05 1.31 14.94 (1,75 df), 
p<0.01 
CGM data:  24-week change     
% time ≤3.0 82 2.05 1.24 2.73 (1,73 df), 
p=0.10 
% time 3.1-9.9 82 4.05 4.43 0.84 (1,73 df), 
p=0.36 
% time ≥10.0 82 -6.05 4.34 1.95 (1,73 df), 
p=0.17 
Glucose (Sensor) SD 82 -0.08 0.24 0.11 (1,73 df), 
p=0.74 
Glucose (Sensor) mean 82 -0.67 0.40 2.79 (1,73 df), 
p=0.10 
8 point SMBG mean 41 -0.61 1.01 0.37 (1,32 df), 
p=0.55 
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Table 3.18  Analysis of covariance results comparing glucose 
monitoring groups model 1: monitoring regimen group only considered as 
covariate 
 
Significant p-values show a significant difference between groups following adjustment 
for other model covariates.  Beta values show the relative difference between the 
groups (the value being the fitted difference for membership of the RT group relative to 
the group without RT).  24-week change values are calculated as the value at baseline 
subtracted from the value at week 24. 
* P-value taken from F test (unless otherwise noted)  
$ Odds ratio reported in place of beta (logistic regression used) 
$$ p-value from logistic regression model 
Outcome Model 1 
 n beta se(beta) Wald*, p 
24-week Gold score 85 -0.29 0.36 0.65, p=0.42 
24-week Clark score   80 -0.21 0.38 0.30(1,78 df), p=0.59 
24-week change in Hypo-AQ 
score 
84 -0.20 0.93 0.05 (1,82 df), p=0.83 
Severe hypoglycaemia data 
 
    
Number of events at 24 
weeks  
90 -0.04 0.19 0.04 (1,88 df), p=0.84 
24-week change in 
annualised rate 
90 -5.42 2.70 4.02 (1,88 df), p=0.048 
Proportion with reduction  90 2.71 $ 1.36 P=0.046 $$ 
24-week change in HbA1c   89 1.52 1.87 0.66(1,87 df), p=0.42 
24-week change in weight 86 -0.14 0.82 0.03(1,84 df), p=0.87 
24-week change in mean 
insulin 
85 -0.06 0.04 1.99(1,83 df), p=0.16 
24-week change in HFS-II 
score 
85 1.84 4.09 0.20 (1,83 df), p=0.65 
24-week change in DTSQ 
score 
84 0.07 1.46 <0.01 (1,82 df), p=0.96 
CGM data:  24-week change     
% time ≤3.0 82 0.86 1.22 0.49 (1,80 df), p=0.49 
% time 3.1-9.9 82 3.79 4.62 0.67 (1,80 df), p=0.41 
% time ≥10.0 82 -4.44 4.61 0.93 (1,80 df), p=0.34 
Glucose (Sensor) SD 82 -0.16 0.24 0.46 (1,80 df), p=0.50 
Glucose (Sensor) mean 82 -0.31 0.46 0.49 (1,80 df), p=0.49 
8 point SMBG mean 41 -0.01 0.94 <0.01 (1,39 df), p=0.99 
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Table 3.19  Analysis of covariance results comparing glucose 
monitoring groups model 2: in addition to monitoring regimen group, 
adjusted for stratification factors at randomisation (site, HbA1c group) 
 
Significant p-values show a significant difference between groups following adjustment 
for other model covariates.  Beta values show the relative difference between the 
groups (the value being the fitted difference for membership of the RT group relative to 
the group without RT).  24-week change values are calculated as the value at baseline 
subtracted from the value at week 24 
* P-value taken from F test (unless otherwise noted)  
$ Odds ratio reported in place of beta (logistic regression used) 
$$ p-value from logistic regression model 
^^Model not adjusted for HbA1c stratification factor (as baseline value is considered 
within 24 week change) 
~ 1 site (Bournemouth) predicts reduction perfectly: data from this site excluded from 
this analysis 
  
Outcome Model 2 
 n beta se(beta) Wald*, p 
24-week Gold score 85 -0.25 0.34 0.53(1,78 df), 
p=0.47 
24-week Clark score   80 -0.21 0.37 0.32(1,73 df), 
p=0.57 
24-week change in Hypo-AQ 
score 
84 -0.17 0.91 0.04 (1,77 df), 
p=0.85 
Severe hypoglycaemia data 
 
    
Number of events at 24 weeks  90 -0.04 0.19 0.04 (1,83 df), 
p=0.84 
24-week change in annualised 
rate 
90 -5.06 2.66 3.61 (1,83 df), 
p=0.06 
Proportion with reduction  75~ 3.01 $ 1.67 P=0.046 $$ 
24-week change in HbA1c  ^^ 89 1.57 1.78 0.78(1,83 df), 
p=0.38 
24-week change in weight 86 -0.01 0.82 <0.01(1,79 df), 
p=0.99 
24-week change in  mean insulin 85 -0.05 0.04 1.71(1,78 df), 
p=0.20 
24-week change in HFS-II score 85 2.13 4.10 0.27 (1,78 df), 
p=0.60 
24-week change in DTSQ score 84 0.14 1.40 0.01 (1,77 df), 
p=0.92 
CGM data:  24-week change     
% time ≤3.0 82 0.85 1.24 0.46 (1,75 df), 
p=0.50 
% time 3.1-9.9 82 5.07 4.34 1.36 (1,75 df), 
p=0.25 
% time ≥10.0 82 -5.70 4.27 1.78 (1,75 df), 
p=0.19 
Glucose (Sensor) SD 82 -0.19 0.24 0.64 (1,75 df), 
p=0.43 
Glucose (Sensor) mean 82 -0.45 0.41 1.25 (1,75 df), 
p=0.27 
8 point SMBG mean 41 -0.32 1.00 0.10 (1,34 df), 
p=0.75 
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Table 3.20  Analysis of covariance results comparing glucose 
monitoring groups model 3: in addition to monitoring regimen group, 
adjusted for site, baseline Gold score, age, presence or absence of treated 
autoimmune thyroid disease 
Significant p-values show a significant difference between groups following adjustment 
for other model covariates.  Beta values show the relative difference between the 
groups (the value being the fitted difference for membership of the RT group relative to 
the group without RT).  24-week change values are calculated as the value at baseline 
subtracted from the value at week 24.  
* P-value taken from F test (unless otherwise noted)  
$ Odds ratio reported in place of beta (logistic regression used) 
$$ p-value from logistic regression model 
^ Model also adjusted for baseline value of outcome measure (baseline annualised rate 
in case of number of severe hypoglycaemia events) 
~ 1 site (Bournemouth) predicts reduction perfectly: data from this site excluded from 
this analysis 
Outcome Model 3 
 n beta se(beta) Wald*, p 
24-week Gold score 85 -0.09 0.27 0.10(1,76 df), 
p=0.76 
24-week Clark score  ^ 74 -0.09 0.36 0.06(1,64 df), 
p=0.80 
24-week change in Hypo-AQ score^ 80 -0.18 0.73 0.06 (1,70 df), 
p=0.81 
Severe hypoglycaemia data 
 
    
Number of events at 24 weeks ^ 90 -0.24 0.18 1.82 (1,80 df), 
p=0.18 
24-week change in annualised rate 90 -5.93 2.58 5.28 (1,81 df), 
p=0.02 
Proportion with reduction ^ 75~ 5.13 $ 3.33 P=0.01 $$ 
24-week change in HbA1c  89 1.45 1.83 0.63(1,80 df), 
p=0.43 
24-week change in weight 86 0.17 0.84 0.04(1,77 df), 
p=0.84 
24-week change in  mean insulin 85 -0.04 0.04 1.04(1,76 df), 
p=0.31 
24-week change in HFS-II score 85 1.68 4.26 0.16 (1,76 df), 
p=0.69 
24-week change in DTSQ score 84 0.32 1.47 0.05 (1,75 df), 
p=0.83 
CGM data: 24-week change     
% time ≤3.0 82 1.24 1.29 0.93 (1,73 df), 
p=0.34 
% time 3.1-9.9 82 7.44 4.50 2.73 (1,73 df), 
p=0.10 
% time ≥10.0 82 -8.45 4.41 3.68 (1,73 df), 
p=0.06 
Glucose (Sensor) SD 82 -0.37 0.25 2.20 (1,73 df), 
p=0.14 
Glucose (Sensor) mean 82 -0.80 0.41 3.84 (1,73 df), 
p=0.053 
8 point SMBG mean 41 -0.15 1.13 0.02 (1,32 df), 
p=0.90 
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Table 3.21 Analysis of Covariance results comparing sub-groups 
defined by level of RT use (those randomised to RT only) model 1: RT use 
group only considered as covariate 
 
Significant p-values show a significant difference between groups following adjustment 
for other model covariates. 
Beta values show the relative difference between the groups (the value being the fitted 
difference for membership of the RT>=50% group relative to the <50% group). 
24-week change values are calculated as the value at baseline subtracted from the 
value at week 24.  
* P-value taken from F test 
 
 
  
Outcome Model 1 
 n beta se(beta) Wald*, p 
24-week Gold Score 43 -0.19 0.53 0.13 (1,41 df), 
p=0.72 
24-week Clarke Score  40 -0.42 0.59 0.52 (1,38 df), 
p=0.47 
Severe hypoglycaemia data 
 
    
Number of events 24 weeks  46 0.19 0.25 0.60 (1,44 df), 
p=0.44 
24-week change in HbA1c   45 -3.38 2.57 1.73 (1,43 df), 
p=0.20 
CGM data – 24-week change 
 
    
% time ≤3.0 42 -3.96 1.88 4.44 (1,40 df), 
p=0.04 
% time 3.1-9.9 42 5.78 6.32 0.84 (1,40 df), 
p=0.37 
% time ≥10.0 42 -2.13 6.41 0.11 (1,40 df), 
p=0.74 
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Table 3.22 Analysis of Covariance results comparing sub-groups 
defined by level of RT use (those randomised to RT only) model 2: in 
addition to RT use group, adjusted for stratification factors at 
randomisation (site, HbA1c group) 
 
 
 
Significant p-values show a significant difference between groups following adjustment 
for other model covariates. 
Beta values show the relative difference between the groups (the value being the fitted 
difference for membership of the RT>=50% group relative to the <50% group). 
24-week change values are calculated as the value at baseline subtracted from the 
value at week 24. 
^^ Not adjusted for HbA1c stratification factor (as baseline value is considered within 24 
week change). 
* P-value taken from F test. 
 
 
  
Outcome Model 2 
 n beta se(bet
a) 
Wald*, p 
24-week Gold Score 43 -0.06 0.54 0.01 (1,36 df), 
p=0.92 
24-week Clarke Score  40 -0.18 0.58 0.09 (1,33 df), 
p=0.77 
Severe hypoglycaemia data 
 
    
Number of events 24 weeks  46 0.29 0.26 1.24 (1,39 df), 
p=0.27 
24-week change in HbA1c  ^^ 45 -1.26 2.47 0.26 (1,39 df), 
p=0.61 
CGM data: 24-week change 
 
    
% time ≤3.0 42 -5.31 1.97 7.26 (1,35 df), 
p=0.01 
% time 3.1-9.9 42 3.53 5.66 0.39 (1,35 df), 
p=0.54 
% time ≥10.0 42 1.43 5.79 0.06 (1,35 df), 
p=0.81 
 122 
Table 3.23 Analysis of Covariance results comparing sub-groups 
defined by level of RT use (those randomised to RT only) model 3: in 
addition to RT use group, adjusted for site, baseline Gold score, age, 
presence or absence of treated autoimmune thyroid disease 
 
 
Significant p-values show a significant difference between groups following adjustment 
for other model covariates. 
Beta values show the relative difference between the groups (the value being the fitted 
difference for membership of the RT>=50% group relative to the <50% group). 
24-week change values are calculated as the value at baseline subtracted from the 
value at week 24. 
^ Also adjusted for baseline value of outcome measure (baseline annualised rate in 
case of number of severe hypoglycaemia events). 
* P-value taken from F test 
Outcome Model 3 
 n beta se(beta) Wald*, p 
24-week Gold Score 43 0.35 0.41 0.73 (1,34 df), 
p=0.40 
24-week Clarke Score ^ 37 0.22 0.65 0.11 (1,27 df), 
p=0.74 
Severe hypoglycaemia data 
 
    
Number of events 24 weeks ^ 46 0.13 0.26 0.26 (1,36 df), 
p=0.61 
24-week change in HbA1c  45 -1.68 2.69 0.39 (1,36 df), 
p=0.54 
CGM data: 24-week change 
 
    
% time ≤3.0 42 -4.80 2.04 5.52 (1,33 df), 
p=0.02 
% time 3.1-9.9 42 4.41 6.38 0.48 (1,33 df), 
p=0.49 
% time ≥10.0 42 0.04 6.47 <0.01 (1,33 df), 
p=>0.99 
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3.10 Discussion 
These results show that currently available modern multiple daily insulin 
injection (MDI) regimens and conventional glucose monitoring (SMBG), when 
optimised, can improve awareness of hypoglycaemia as effectively as 
continuous subcutaneous insulin infusion therapy (CSII) and real-time 
continuous glucose monitoring (RT).  This is important given the global lack of 
availability and cost of these technologies.   
These equivalent biomedical outcomes were matched with equivalent reduction 
in fear of hypoglycaemia with conventional MDI and SMBG regimens compared 
with CSII / RT.  However, treatment satisfaction was higher in CSII users, a 
finding that is consistent with previous randomised controlled trials (Bolli et al., 
2009).  Treatment satisfaction in those randomised to RT was no greater than in 
those continuing on conventional SMBG, in keeping with other studies reporting 
both benefits and hassles with RT (Tansey et al., 2011).   
Statistically significant improvement in IAH from baseline but absence of 
difference in the primary outcome measure between groups at study end-point 
has been confirmed in this adequately powered study in those at highest risk.   
Although caution is required when considering the data regarding overall 
improved hypoglycaemia awareness in the study population given the lack of a 
control group, the reduced biochemical hypoglycaemia and reduced severe 
hypoglycaemia incidence would suggest this finding is real.  Thus, these results 
show that hypoglycaemia awareness can be improved and recurrent severe 
hypoglycaemia prevented through strategies targeted at rigorous avoidance of 
biochemical hypoglycaemia without relaxation of overall glycaemic control in 
adults with long standing T1DM and IAH.  
Due to hypothesised relative insensitivity of the Gold score to change, a second 
validated IAH score and a newly designed measure were also included.  The 
latter showed good correlation with existing measures but with much greater 
magnitude of clinical improvement at endpoint.   
Biochemical hypoglycaemia was rapidly reduced in all groups within the first 
four weeks with this reduction sustained throughout the trial.  It is striking that 
insulin dose reduction (a familiar correlate with insulin pump initiation) was also 
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seen in those remaining on MDI.  Also of interest is the fact that this dose 
reduction was not associated with worsening of glycaemic control. 
All except one individual randomised to CSII who commenced the intervention 
remained on it throughout the trial reporting greater treatment satisfaction than 
those remaining on MDI.  All those who commenced RT following 
randomisation also continued to use the intervention, although improvement in 
treatment satisfaction was no greater than in those continuing on conventional 
glucose monitoring.  The very high baseline rate of severe hypoglycaemia in 
those randomised to RT led to an apparent greater incremental benefit 
compared to the conventional monitoring group but without a difference 
between groups at study end-point.  Those using RT for more than 50% of time 
were most successful in avoiding biochemical hypoglycaemia and in achieving 
best overall glycaemic control in keeping with published studies in those without 
IAH (JDRF-CGM-study-group, 2009; Battelino et al., 2011; Garg et al., 2011).  
However the larger reductions in % time spent in biochemical hypoglycaemia 
were not associated with differences in improved awareness of hypoglycaemia 
scores.  
In this study use of RT did not translate to greater improvement in IAH and 
reduction in severe hypoglycaemia in this very high-risk group.   Uninterrupted 
use of RT was not achieved and this may be viewed as a limitation given the 
established correlation between more regular use and clinical benefit (JDRF-
CGM-study-group, 2009).   
Other potential limitations of this study are that although multiple questionnaires 
were used to document hypoglycaemia awareness at baseline including the 
widely used and validated measures, the subjective nature of such methods 
may be considered a weakness.  There also may be the potential for 
contamination in that my learnings from the use of the technology interventions, 
particularly the use of RT may have impacted on my work with the SMBG 
group.  It is possible that the technology was more useful but that its benefits 
were spread across the whole group.  However the fact that the reduction in 
biochemical hypoglycaemia happened so quickly suggests strongly that the 
education, training and professional support was what made a difference.   
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Another potential criticism of the study may be that the technology was not used 
to full potential in terms of: 
a) The use of RT downloads and their interpretation which was not 
mandatory for all participants; 
b) The patterns of use of unique features of insulin pump therapy - e.g. data 
regarding changes in basal patterns, configurated versus other basal 
patterns and of temporary basal features have not been analysed.  
 
However, as another example of the study design ensuring congruent support 
was provided to all participants across the insulin intervention groups, It is 
important to state that everyone had access to an insulin pump in order that all 
could use the on board bolus calculator.   Similarly with the monitoring groups, 
the same pre-prandial and 2 hour post-prandial targets were set with primary 
goal again being avoidance of glucose <4 mmol/l - whether adjuvant RT was 
available or not.  The weekly 8 point SMBG profiles including 4 am checks were 
another important factor in ensuring equivalence for SMBG group. 
In this study there was an absolute focus on ensuring congruent education, 
support, attention and therapeutic targets for all groups.  There was a focus to 
ensure that those individuals randomised to CSII or RT were not provided with 
extra ‘non technology’ education such as carbohydrate counting support as 
compared to those randomised to those in the MDI and SMBG groups.  This is 
a strength of this RCT as compared to other studies investigating the impact of 
CSII and RT.  
While blinded CGM was used before each study follow up visit for all 
participants, investigators and participants were blinded to this until the end of 
the study and therefore would not have had an impact on insulin titration and 
hypoglycaemia avoidance.  This is an important point to emphasise when 
considering the potential implications for this work in clinical practice where 
blinded CGM may not always be easily accessible.  
The relative impact of ‘my hypo compass’ and the treatment algorithms driving 
insulin dose changes cannot be determined from this study though it is noted 
that the reduction in biochemical hypoglycaemia was immediate from the start 
of the study interventions.   
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The results from this study suggest that through the use of conventional self-
management and novel technologies supported by education achievable in the 
specialist clinical setting, restoration of hypoglycaemia awareness and 
avoidance of recurrent severe hypoglycaemia can be achieved in the majority of 
individuals without relaxation of overall glycaemic control. 
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4 Chapter 4                                                             
Characterisation of individuals with type 1 diabetes      
complicated by impaired awareness of hypoglycaemia: 
responders vs non-responders to conventional 
interventions 
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4.1  Introduction 
The DCCT trial revealed that the majority of severe hypoglycaemia events 
occur in those individuals with type 1 diabetes who have impaired awareness of 
hypoglycaemia (IAH) (DCCT, 1997).  IAH is one of the two components of 
hypoglycaemia associated autonomic failure (HAAF) and is caused by reduced 
autonomic symptom responses associated particularly with a reduced 
sympathetic neural response to lower glucose concentrations (Cryer, 1992b).   
Avoidance of biochemical hypoglycaemia has been shown in experimental 
studies to reverse impaired awareness by providing higher blood glucose levels 
for the onset of autonomic and neuroglycopenic symptoms (Fanelli et al., 1993; 
Cranston et al., 1994).   
It should therefore follow that clinical interventions aimed specifically at avoiding 
biochemical hypoglycaemia should improve awareness in all people with type 1 
diabetes and IAH.  However, in clinical practice this does not appear to be the 
case: avoiding biochemical hypoglycaemia does not seem to be enough to help 
all people regain awareness.  
Given our understanding of the key role that biochemical hypoglycaemia 
avoidance has in regaining awareness perhaps those who are unable to do so 
could be classified into two groups: 
1. Those who despite the intervention do not avoid biochemical 
hypoglycaemia; 
2. Those who do avoid biochemical hypoglycaemia but whose awareness 
does not respond due to an additional pathology.  
 
What may be the underlying drivers in both these two groups?  As discussed in 
chapter one while the concept of fear of hypoglycaemia is well recognised fear 
of hyperglycaemia is a psychological construct characterised by excessive 
worry about high blood glucose in combination with acceptance (and non-
avoidance) of hypoglycaemia - as a 'necessary evil' to evade development of 
long-term complications, such as blindness (Singh and al, 2010).  It could be 
hypothesised that people with this excessive worry over high glucose may 
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demonstrate acceptance of biochemical hypoglycaemia and continue to have 
impaired awareness with any treatment regimen.  
With regards those who do successfully avoid biochemical hypoglycaemia but 
cannot regain awareness perhaps there is a role for the presence of diabetic 
autonomic neuropathy (DAN).  While the data surrounding the role of DAN’s 
role in severe hypoglycaemia is conflicting there are epidemiological studies 
suggesting a link between cardiac autonomic dysfunction and risk of severe 
hypoglycaemia (Stephenson et al., 1996).  Other risk factors may include the 
presence of microvascular complications and chronic kidney disease.  The risk 
of hypoglycaemia has been shown to be higher in individuals with diabetes and 
chronic kidney disease.  Indeed the risk of death in such individuals is increased 
within 48 hours of a hypoglycaemic event (Moen et al., 2009).  
If health care professionals were able to identify the clinical characteristics of 
patients who are not likely to respond to conventional interventions, then early 
consideration could be made to assessment of suitability for alternative 
interventions such as psychological / motivational approaches; or even more 
invasive treatments, such as beta cell replacement options including islet cell 
and whole pancreas transplantation.   
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4.2 Aims 
The first aim was to characterise the phenotype of the group of people with type 
1 diabetes recruited to the HypoCOMPaSS study, all of whom had impaired 
awareness of hypoglycaemia and were at high risk of severe hypoglycaemia.  
The second aim was to perform secondary analyses of those who continued to 
experience IAH regardless of study intervention, to determine factors 
associated with absence of response.  
This study was driven by the hypotheses that there would be two sub-groups:  
1. Those in whom an absolute focus on avoidance of high glucose 
(evidenced from patient-reported outcome (PRO) measures) leads to 
continued biochemical hypoglycaemia despite the study goals; 
2. Those with severe autonomic neuropathy (evidenced from clinical 
history) who are unable to recover autonomic warning symptoms of 
hypoglycaemia despite effective reduction in biochemical hypoglycaemia. 
4.3 Research design and methods 
Using the HypoCOMPaSS study population within the context of the 
randomised clinical controlled trial described in chapter 2, sub group analysis 
was undertaken of those who continued to experience IAH despite any study 
intervention.  
4.3.1 Participants 
All participants had c-peptide negative type 1 diabetes and had baseline Gold 
score ≥4, confirming impaired awareness of hypoglycaemia and increased risk 
of severe hypoglycaemia.  All participants were randomised to one of four 
intervention groups as previously described for the 24-week RCT.  
Intervention group 1: CSII with RT 
Intervention group 2: CSII without RT 
Intervention group 3: MDI with RT 
Intervention group 4: MDI without RT 
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4.3.2 Characteristics on history and clinical examination 
At the baseline study visit all participants had a detailed clinical history.  In 
addition to baseline hypoglycaemia awareness status, details of the presence or 
absence of retinopathy, atherosclerotic disease, treated thyroid disease, 
symptoms of gastroparesis, bladder dysfunction, sweating regulation problems 
and sexual function were taken.  
A clinical examination was carried out checking for features of peripheral 
neuropathy and postural hypotension.  Peripheral neuropathy was checked for 
by an examination using a 10g monofilament, testing at four sites (1st, 3rd, and 
5th metatarsal heads and plantar surface of distal hallux) on each foot.  Loss of 
sensation at one or more site was taken as evidence of peripheral neuropathy 
(Boulton et al., 2008).   
Postural hypotension was undertaken by performing lying and standing blood 
pressures. Postural hypotension was considered present if a reduction in blood 
pressure (≥20 mm Hg in systolic, ≥10 mm Hg in diastolic) was sustained at or 
beyond three minutes (Parry and Tan, 2010).   
4.3.3 Laboratory tests 
A blood test was taken for creatinine concentration and a urine sample for 
microalbuminuria.  Participants were given a sterile universal container for 
collection of a first morning void (Witte et al., 2009).  The blood and urine 
samples were analysed at all local site laboratories.   
4.3.4 The hyperglycaemia avoidance scale 
At the baseline study visit all participants were asked to complete the 
Hyperglycaemia Avoidance Scale (Singh and al, 2010) before study 
randomisation (Appendix 13).   
4.3.5 The autonomic symptom profile questionnaire 
At visit 4, prior to randomisation all participants were asked to complete the 
validated Autonomic Symptom Profile Questionnaire which takes approximately 
15 minutes to complete (Suarez et al., 1999).  See section 2.14 for details on 
scoring.  A copy of this questionnaire is included as Appendix 15.   
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4.4 Definitions of response and resolution 
In the HypoCOMPaSS randomised control trial a range of interventions were 
used with the same common goal: avoid biochemical hypoglycaemia to regain 
hypoglycaemia awareness.  Therefore I decided to look at the entire study 
cohort and determine who did and who did not manage to achieve this goal.   
To do this I compared awareness of hypoglycaemia as assessed by the Gold 
score in the entire study population at the end of the study against scores at 
baseline.  This was used as a surrogate marker of ‘response’ to any intervention 
used in the study.   
The population was compared firstly by responders vs non-responders and in a 
second analysis by resolution vs non-resolution.  
1. Those who responded to any of the interventions used were defined by 
having 24-week Gold score < baseline Gold score.  
2. Those who did not respond to any of the interventions used were defined 
by having 24-week Gold score ≥ baseline Gold score. 
3. Those who had ‘resolution’ of IAH at 24 weeks were defined by having 
24-week Gold score <4.   
4. Those who did not have resolution of IAH at 24 weeks were defined by 
having Gold score ≥ 4.  
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4.5 Statistical analysis 
Data were analysed on an intention-to-treat basis retaining ineligible 
participants and protocol violators in their randomised groups.  Data were 
assessed for normality.  Normally distributed variables are expressed as mean 
values (SD) with differences between groups analysed with parametric 
statistical tests (unpaired student’s t-test).  Categorical variables are expressed 
as proportions (%) with differences between groups analysed using Chi-
squared test.   
Data analysis took the form of a complete case analysis.  Missing data were not 
deemed sufficient to justify imputation of values.  Significance levels were set at 
α = 0.05 throughout.  
4.6 Results  
4.6.1 Overall response and resolution 
Of the 96 study participants who were randomised to one of the 4 study 
interventions complete data for these analyses was available for 85 individuals.  
Fifty (58.8%) of the participants were defined as responders as defined as 
having a Gold score at 24-week study end point less than at study baseline.  
Thirty three individuals (38.8%) were said to have had resolution of impaired 
awareness of hypoglycaemia as defined as 24-week gold score <4.  
4.6.2 Clinical characteristics of the population 
In the overall study population the mean (± SD) diabetes duration was 28.9 ± 
12.4 years with a mean participant age of 48.6 ± 12·2 years.   The majority of 
the population (two thirds) had diabetic retinopathy with other micro- / 
macrovascular complications less common (Table 4.1).  Injection site 
lipohypertrophy was frequent at 38% of the population.  Postural hypotension 
was also frequent at 27% of the population.   29% had treated thyroid disease, 
3% coeliac disease and one was taking corticosteroid replacement for primary 
adrenal insufficiency.   
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4.6.3 Clinical characteristics of responders  
Analyses of responders vs non-responders can be seen in Table 4.1.  
Responders were younger than non-responders (45.0 ± 12.8 vs 53.3 ± 8.8 
years) and also had shorter duration diabetes (26.7 ±12.1 vs 31.7 ± 12.8 years).  
Neither of these differences were found to be significant.  Responders had a 
higher baseline HbA1c than non-responders (68 ± 13 mmol/mol, 8.4% vs 64 ± 
10 mmol/mol, 8.0%), though again this was not statistically significant.  
Baseline creatinine in the responders was lower than non-responders (70·3 ± 
12.9 vs 80.0 ± 28.2), as was the frequency of microalbuminuria (18% of 
responders vs 31% non-responders) though these were both non-significant.  
There was no difference in rate of retinopathy but history of previous 
photocoagulation was lower in the responders group (18% responders vs 34% 
non-responders) though not significantly so.   
4.6.4 Clinical characteristics of those with resolution of impaired 
awareness   
Analyses of those with resolution of impaired awareness as compared to those 
without are seen in Table 4.2.  In line with responders, those with resolution 
were younger (46.1 ±13.4 vs 49.8 ±10.9 years) and had shorter duration 
diabetes (25.9 ± 12.1 vs 30.5 ± 12.6 years) though neither of these differences 
were statistically significant.   Frequency of retinopathy and baseline creatinine 
were both lower (non-significantly) in the resolution group (Table 4.2).    
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Table 4.1 Clinical characteristics: responders v non-responders 
 
Data are number of patients (%) or mean ± SD.  *2-sample t-test (response v non-response) 
**Chi square test (response v non-response). 
 
Response (n=85) 
24-week Gold < Baseline 
P 
value* 
 All (n=96) No (n=35) Yes (n=50)  
Baseline HbA1c (mmol/mol) 66±12 64±10 68±13 0.18 
Age (years) 48·6 ±12·2 53·3 ±8·8 45·0 ±12·8 0.17 
Male 35 (36%) 18 (51%) 13 (26%) 0.02** 
Diabetes duration (years) 28·9 ±12·3 31·7 ±12·8 26·7 ±12·1 0.10 
Body weight (kg) 74·7 ±14·2 76·6 ±14·5 73·7±14·8 0.62** 
BMI (kg/m2) 26·5 ±4·4 26·7 ±4·6 26·4 ±4·7 0.88** 
Insulin dose (units/kg/24 hr) 0·64 ±0·23 0·69±0·29 0·63±0·19 0.32 
Smoking status    0.65** 
Current Smokers 21 (22%) 6 (17%) 11 (22%)  
Ex-smoker 26 (28%) 9 (26%) 15 (31%)  
Never smoked 47(50%) 20(57%) 23(47%)  
Alcohol consumers 62 (65%) 24 (69%) 32 (65%) 0.75** 
Lipohypertrophy 35 (38%) 15 (45%) 17 (35%) 0.36** 
Retinopathy 61 (64%) 23 (66%) 31 (63%) 0.82** 
Laser photocoagulation 24 (25%) 12 (34%) 9 (18%) 0.09** 
Microalbuminuria 22 (24%) 10 (31%) 9 (18%) 0.18** 
Creatinine (micromol/L) 74·4 ±20·5 80·0 ±28·2 70·3 ±12·9 0.30 
Peripheral neuropathy 18 (19%) 9 (26%) 7 (14%) 0.17** 
Atherosclerotic disease 13 (14%) 7 (20%) 5 (10%) 0.19** 
Treated thyroid disease 28 (29%) 12 (34%) 11 (22%) 0.21** 
Postural Hypotension 26 (27%) 10 (29%) 14 (28%) 0.89** 
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Table 4.2 Clinical characteristics: resolution vs non-resolution  
 
Data are number of patients (%) or mean ± SD.  *2-sample t-test (resolution v non-resolution) 
**Chi square test (resolution v non-resolution). 
 
  
 Resolution (n=85) 
24-week Gold < 4 
P 
value* 
 All (n=96) No (n=52) Yes (n=33)  
Baseline HbA1c (mmol/mol) 66±12 65±12 68±11 0.18 
Age (years) 48·6 ±12·2 49·8 ±10·9 46·1 ±13·4 0.17 
Male 35 (36%) 19 (37%) 12 (36%) 0.99** 
Diabetes duration (years) 28·9 ±12·3 30·5 ±12·6 25·9 ±12·1 0.10 
Body weight (kg) 74·7 ±14·2 74·3 ±14·3 75·9 ±15·5 0.62 
BMI (kg/m2) 26·5 ±4·4 26·5 ±4·4 26·6 ±4·6 0.88 
Insulin dose (units/kg/24hr) 0·64 ±0·23 0·64±0·25 0·69±0·21 0.32 
Smoking status    0.76** 
Current Smokers 
Ex-smoker 
Never smoked 
21 (22%) 
26 (28%) 
47 (50%) 
9 (18%) 
15 (29%) 
27 (53%) 
8 (24%) 
9 (27%) 
16 (49%) 
 
Alcohol consumers 62 (65%) 34 (67%) 22 (67%) 1.00** 
Lipohypertrophy 35 (38%) 23 (47%) 9 (28%) 0.09** 
Retinopathy 61 (64%) 35 (67%) 19 (59%) 0.46** 
Laser photocoagulation  24 (25%) 13 (25%) 8 (24%) 0.94** 
Microalbuminuria  22 (24%) 12 (25%) 7 (21%) 0.69** 
Creatinine (micromol/L) 74·4 ±20·5 76·1  ±24·4 71·3 ±13·8 0.30 
Peripheral neuropathy 18 (19%) 12 (23%) 4 (12%) 0.21** 
Atherosclerotic disease 13 (14%) 9 (17%) 3 (9%) 0.29** 
Treated thyroid disease 28 (29%) 16 (31%) 7 (21%) 0.33** 
Postural Hypotension 26 (27%) 14 (27%) 10 (30%) 0.78** 
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4.6.5 Hyperglycaemia avoidance scale (HAS) 
The HAS score has a total score and four sub scales: 
1. Worry about high glucose; 
2. Immediate action for high glucose; 
3. Preference for low blood glucose; 
4. Action taken to avoid extremes. 
The total (mean ± SD) score for the population was 39.9 ± 13.4.  The total score 
for the non-responders was 38.2 ± 13.8 as compared to 41.1 ± 13.2 in the 
responders (Table 4.3).  There were no significant differences in the sub-scale 
scores between responders and non-responders.  Total and sub-scale scores 
were also similar in the resolution vs non-resolution analyses (Table 4.2).  
Figure 4.1 shows a normal distribution of scores across the entire study 
population.   
Figures 4.2 and 4.3 show the distribution of scores across the non-responders 
and responders respectively.  
Figures 4.4 and 4.5 show the distribution of scores across the non-resolution 
and resolution groups respectively.  
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Table 4.3 Hyperglycaemia avoidance scale scores in responders vs non-responders and resolution vs non-
resolution comparisons 
 
 
 
 
 
 
 
 
 
 
 
 
Data are mean ± SD and (range).  * 2-sample t-test (response v non-response, resolution v non-resolution)
 All 
(n=96) 
Response (n=85) 
24-week Gold < Baseline 
P 
value* 
Resolution (n=85) 
24-week Gold < 4 
P 
value* 
No (n=35) Yes (n=50)  No (n=52) Yes (n=33)  
 
Total score 
 
 
39.9±13.4 
 
38.2±13.8 
(11.9-66.0) 
 
 
41.1±13.2 
(17.4-70.6) 
  
39.7±14.5 
(11.9-70.6) 
 
40.3±11.8 
(14.7-64.2) 
 
Worry about high 
glucose 
 
25.0±9.2 23.5±9.8 25.6±8.7 0.29 24.5±9.9 25.1±8.1 0.79 
Immediate action for 
high glucose 
 
9.0±3.3 8.8±3.4 9.3±3.2 0.46 8.8±3.4 9.7±3.1 0.22 
Low glucose preference 
 
6.3±3.6 5.9±3.7 6.2±3.6 0.69 6.2±3.8 5.8±3.3 0.56 
Avoid extremes 
 
3.7±2.9 3.3±2.6 3.6±3.2 0.64 3.6±3.2 3.4±2.5 0.75 
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Figure 4.1 Histogram of hyperglycaemia avoidance scale total scores 
across the study population.  The count is the number of individuals with 
a score within any given quantile.  
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Figure 4.2 Histogram of hyperglycaemia avoidance scale total scores 
across the non-responders.  The count is the number of individuals with a 
score within any given quantile. 
 
 
Figure 4.3 Histogram of hyperglycaemia avoidance scale total scores 
across the responders.  The count is the number of individuals with a 
score within any given quantile.  
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Figure 4.4 Histogram of hyperglycaemia avoidance scale total scores 
across the non-resolution group.  The count is the number of individuals 
with a score within any given quantile.  
 
Figure 4.5 Histogram of Hyperglycaemia Avoidance Scale total scores 
across the resolution group.  The count is the number of individuals with 
a score within any given quantile 
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Figure 4.6 Histogram of hyperglycaemia avoidance scale worry 
subscale score across the study population.  The count is the number of 
individuals with a score within any given quantile.  
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Figure 4.7 Histogram of hyperglycaemia avoidance scale worry 
subscale score across the responders.  The count is the number of 
individuals with a score within any given quantile.  
 
Figure 4.8 Histogram of hyperglycaemia avoidance scale worry 
subscale score across the non-responders.  The count is the number of 
individuals with a score within any given quantile.  
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Figure 4.9 Histogram of hyperglycaemia avoidance scale low glucose 
preference subscale score across the study population.  The count is the 
number of individuals with a score within any given quantile.  
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Figure 4.10 Histogram of hyperglycaemia avoidance scale low glucose 
preference subscale score across the responders.  The count is the 
number of individuals with a score within any given quantile. 
 
Figure 4.11 Histogram of hyperglycaemia avoidance scale low glucose 
preference subscale score across the non-responders.  The count is the 
number of individuals with a score within any given quantile.   
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4.6.6 Autonomic symptom profile (ASP) results 
The total scores for the non-responders and responders were (mean ± SD) 20.8 
± 17.7 and 21.2 ± 18.4 respectively.  There were no differences between any of 
the subscale scores (Table 4.4).  Total and sub-scale scores were similar for 
the resolution vs non-resolution analyses (Table 4.5).  All groups scored highly 
on the orthostatic intolerance score, which is in keeping with the high frequency 
of postural hypotension as identified in Table 4.1.  
Figure 4.12 is a histogram of the total ASP scores for the whole study 
population.   
Figures 4.13 and 4.14 show the distribution of scores across the non-
responders and responders respectively.   
Figures 4.15 and 4.16 show the similar distribution of scores across the non-
resolution and resolution groups respectively.  Of note there was no one in the 
resolution group in the top 3 quantiles of ASP questionnaire score.  
There was no correlation between ASP total scores and either participant age 
or diabetes duration as the histograms in Figures 4.17 and 4.18 respectively 
demonstrate.   
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Table 4.4 Autonomic Symptom Profile questionnaire scores: 
responders v non-responders 
 
 
Data are mean ± SD.  * 2-sample t-test (response v non-response) 
 
  
 
Response (n=85) 
24-week Gold < Baseline 
 
No (n=35) Yes (n=50) P* 
Total 20.8±17.7 21.2±18.4 0.92 
Orthostatic intolerance symptoms 9.1±9.3 8.8±9.5 0.91 
Vasomotor symptoms 0.4±1.3 0.6±1.7 0.51 
Secretomotor symptoms 2.1±3.0 2.4±2.9 0.70 
Upper gastrointestinal symptoms 0.7±1.2 1.0±2.0 0.52 
Autonomic diarrhoea symptoms 2.5±4.0 2.2±4.0 0.75 
Constipation 0.9±1.8 0.9±1.8 0.87 
Autonomic bladder dysfunction 2.1±2.9 2.4±3.3 0.67 
Pupillomotor symptoms 1.3±1.3 1.1±1.2 0.58 
Sleep disorder symptoms 1.1±1.3 1.5±1.6 0.23 
Syncope symptoms 0.0±0.0 0.1±0.6 0.42 
Erectile/Sexual dysfunction (Males 
only) 
6.6±5.9 7.1±6.3 0.82 
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Table 4.5 Autonomic symptom profile questionnaire scores resolution 
vs non-resolution 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Data are mean ± SD.  * 2-sample t-test (resolution v non-resolution) 
 
 
 
 
  
 
Resolution (n=85) 
24-week Gold < 4 
 
No (n=52) Yes (n=33) P* 
Total 21.3±18.8 20.8±16.6 0.91 
Orthostatic intolerance symptoms 8.7±9.7 9.3±9.1 0.77 
Vasomotor symptoms 0.6±1.6 0.5±1.5 0.77 
Secretomotor symptoms 2.4±3.1 2.2±2.7 0.75 
Upper gastrointestinal symptoms 0.8±1.7 0.9±1.8 0.72 
Autonomic diarrhoea symptoms 2.6±4.7 1.9±2.7 0.42 
Constipation 0.8±1.7 1.0±1.8 0.62 
Autonomic bladder dysfunction 2.7±3.5 1.6±2.4 0.15 
Pupillomotor symptoms 1.2±1.2 1.1±1.2 0.75 
Sleep disorder symptoms 1.4±1.6 1.3±1.3 0.86 
Syncope symptoms 0.0±0.0 0.1±0.7 0.22 
Erectile/Sexual dysfunction (Males 
only) 
5.9±6.1 8.0±5.7 0.37 
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Figure 4.12 Histogram of the autonomic symptom profile questionnaire 
scores for the entire study population.  The count is the number of 
individuals with a score within any given quantile.  
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Figure 4.13 Histogram of the autonomic symptom profile questionnaire 
scores for the non-responders.  The count is the number of individuals 
with a score within any given quantile.  
 
 
Figure 4.14 Histogram of the autonomic symptom profile questionnaire 
scores for the responders.  The count is the number of individuals with a 
score within any given quantile.  
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Figure 4.15 Histogram of autonomic symptom profile questionnaire 
scores for the non-resolution group.  The count is the number of 
individuals with a score within any given quantile.  
 
Figure 4.16 Histogram of autonomic symptom profile questionnaire 
scores for the resolution group.  The count is the number of individuals 
with a score within any given quantile.  
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Figure 4.17 Scatter plot of participant age (years) and ASP questionnaire 
total scores 
 
 
 
Figure 4.18 Scatter plot of diabetes duration (years) and ASP 
questionnaire total scores 
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4.7 Discussion 
These results show that while there were no significant differences in the clinical 
characteristics of those who responded as compared to those who did not 
respond, there was a suggestion that longer duration diabetes and advanced 
age may impair the ability to regain awareness.   Of interest was that the 
creatinine level was also higher in the non-responders and non-resolution 
groups.  It is known that people with chronic kidney disease (CKD) are more at 
risk of hypoglycaemia due to multiple factors such as impaired renal 
gluconeogenesis, reduced degradation of insulin in peripheral tissues (Snyder 
and Berns, 2004) and poor nutrition, leading to reduction in glycogen stores 
(Horst et al., 1968).  These factors, in conjunction with the failure to replicate the 
physiological replacement of insulin, make it even more difficult for people with 
CKD to avoid biochemical hypoglycaemia as necessary to improve their 
awareness of hypoglycaemia.  
The reason why people with longer duration diabetes and advanced age may 
be less likely to respond was not answered by this study.  The study’s 
hypothesis that there would be a group of people identified who were not able 
to regain awareness with severe autonomic neuropathy, as evidenced by 
clinical symptoms, has not been proven.  It may be that the methods used in 
this study (the autonomic symptom profile questionnaire) were not good enough 
to identify those with true diabetic autonomic neuropathy.  Further work is 
required in identifying why age and diabetes duration may impair ability to 
respond to the interventions.    
The autonomic symptom profile questionnaire, at the time of undertaking the 
study, was the only validated measure of autonomic symptoms available.  While 
it is a comprehensive validated measure consisting of 169 items in 11 domains, 
and does relate findings to an established protocol of autonomic tests (Suarez 
et al., 1999), it has a fairly complex layout and weighted scoring system.  In 
previous validation studies of this questionnaire symptoms in people with 
diabetes (type 1 and type 2) have been significantly higher than control 
populations (Low et al., 2004).  The symptoms identified in the subscales of this 
questionnaire are clinically relevant and important to identify in a diabetes 
review consultation.  For example the orthostatic intolerance domain identifies 
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symptoms of cerebral hypoperfusion on standing independently or after meals, 
physical exertion or with additional heat.  The secretomotor sub-scale identifies 
symptoms of heat intolerance, specific and general changes in body sweating 
and dryness of eyes and mouth.  The urinary sub-scale identifies symptoms of 
impaired voiding or control.  The subscales focusing on gastrointestinal 
symptoms evaluate gastroparesis (bloating/nausea/vomiting) as well as 
diarrhoea and constipation.  The pupillomotor subscale identifies symptoms 
such as photophobia, difficulty focusing and blurring in order to detect impaired 
neural control of the pupils.  
However there are no previous publications on the scores of the ASP 
questionnaire in a population with impaired awareness of hypoglycaemia.  It is 
therefore of some interest that the orthostatic intolerance subscale scores were 
noticeably higher in the population described in this study as compared to data 
on other populations with type 1 diabetes published by other groups (mean 
standardised score 0.13) (Low et al., 2004).  
The Hyperglycaemia avoidance scale scores were also similar between the 
different groups.   There were individuals identified with high scores who may 
have excessive worry about high glucose levels.  However in this study even 
some of these high scorers were responders, suggesting that people with 
excessive worry should not be excluded from trying the different insulin and 
glucose monitoring regimens used in this RCT as a mechanism to reduce 
biochemical hypoglycaemia and improve awareness.  
The Gold score was used as a surrogate marker of ‘response’ and ‘resolution’. 
This has its weaknesses.  It is known that the Gold score is insensitive to 
change and is subject to variability around the score of 4 (Geddes et al., 
2007b).  Nevertheless it is the current most widely accepted measure of 
awareness (out-with experimental hypoglycaemia clamp studies).  The new 
measure of hypoglycaemia awareness, the HypoA-Q, may be a measure more 
sensitive to change.  For this reason I plan to reanalyze the data concerning 
response and non-response once this score’s validation studies have been 
published.  
This study was not powered to detect differences between groups.  Larger 
studies need to be carried out in this high-risk population.   
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5.1 Introduction 
In recent years there has been an increasing body of literature seeking to 
elucidate the underlying pathophysiology and risk factors for severe 
hypoglycaemia (DCCT, 1997; Cryer, 2005; Dunn et al., 2007).  While patients, 
relatives and physicians are aware of the anguish caused by severe 
hypoglycaemia there has been a lack of interventional trials in high risk 
populations with the specific goals of addressing these factors, reducing risk 
and preventing further severe events. 
Contemporary approaches to type 1 diabetes management include structured 
education; psychosocial behavioural strategies supporting self-management; 
optimised insulin multiple daily injection regimens; CSII therapy; real-time CGM; 
SAP systems; and beta-cell replacement strategies (pancreas or islet 
transplantation).  Although these have all been justified, at least in part, by their 
potential impact on reducing severe hypoglycaemia, there is little adequately 
powered RCT evidence supporting these claims.   
5.2 Rationale of the studies in thesis 
Of high clinical importance to clinicians providing care for people with T1DM is 
the lack of randomised control trials comparing widely used analogue multiple 
daily insulin injection regimens and insulin pump therapy.  Previous studies 
comparing CSII and MDI, arguably have not been optimally designed to assess 
impact on severe hypoglycaemia.  Furthermore there is a possibility that those 
randomised to pump therapy have received additional ‘non-pump’ education 
(Pickup and Sutton, 2008).  Despite several trials assessing the impact of real-
time CGM, at the time these studies were initiated no previous trials 
investigating this intervention had recruited high risk populations with IAH, or 
been powered around their potential to reduce risk of severe hypoglycaemia.  
The unique studies in this thesis have investigated the potential for the currently 
widely available insulin regimens and different methods of monitoring glucose to 
improve impaired awareness of hypoglycaemia and reduce risk of severe 
hypoglycaemia in a high risk population.  As set out in the methods chapter the 
RCT in chapter 3 was designed meticulously to provide identical levels of 
education and professional support to all intervention groups.  The study in 
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chapter 4 has explored the characteristics of a previously under-studied 
population: one with impaired awareness of hypoglycaemia.  The study 
investigated factors potentially increasing resistance to conventional 
interventions.  This information, if available, could help clinicians develop more 
holistic care plans, tailored to the needs of the patient.    
5.3 Comparison of MDI and CSII 
The RCT in chapter 3 compared the outcomes of CSII and MDI in a high-risk 
population.  Baseline rates of severe hypoglycaemia were high and few 
participants had used pump therapy before.  All participants were given 
equivalent education and support and uniquely those randomised to MDI had 
access to the same bolus calculator as used by those randomised to CSII.  
There were no differences in the primary endpoint of Gold score at 24 weeks 
(MDI 4.1 ± 1.6 vs CSII 4.2 ± 1.7, p=0.76).  Nor were there any differences in the 
secondary markers of glycaemic control including biochemical hypoglycaemia 
(% time spent ≤3.0 mmol/L: MDI 1.4 ± 2.5 vs CSII 2.0 ± 4.9, p=0.48), 8 point 
SMBG mean (MDI 8.9 ± 1.6 mmol/L vs CSII 8.7 ± 2.2 mmol/L, p=0.80) and 
HbA1c (MDI 67 ± 11 mmol/mol vs CSII 64 ± 9 mmol/L, p=0.26).  In keeping with 
other studies treatment satisfaction was higher in those randomised to pump 
therapy (DTSQ: MDI 29 ± 6 vs CSII 32 ± 3, p<0.001).  
5.4 Comparison of RT and SMBG 
The factorial design of the RCT in chapter 3 allowed for the comparison of RT 
and conventional SMBG.  Crucially, all participants randomised to these 
interventions were also given equivalent education and support with identical 
visit schedules and investigator contact time.  There was no difference in the 
primary endpoint of Gold scores at 24 weeks (SMBG 4.3 ± 1.6 vs RT 4.0 ±1.7, 
p=0.42).  There were no differences in the secondary endpoints of glycaemic 
control including biochemical hypoglycaemia (% time spent ≤ 3.0mmol/L SMBG 
1.3 ± 2.1 vs RT 2.1 ± 5.1, p=0.36), 8 point SMBG mean (SMBG 9.1 ± 2.2 
mmol/L vs RT 8.5 ± 1.6 mmol/L, p=0.80) and HbA1c (SMBG 65 ± 9 mmol/mol 
vs RT 66 ± 11 mmol/mol, p=0.80).  In contrast to the comparison between MDI 
and CSII treatment satisfaction scores were similar between these groups 
(SMBG 30 ± 5 vs RT 30 ± 5, p=0.79).  
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5.5 Improvement in awareness of hypoglycaemia and reduction in 
biochemical and severe hypoglycaemia 
While few differences were seen between the intervention arms of the study in 
chapter 3 the outcomes of the study population as a whole are striking.  There 
was a 10-fold reduction in severe hypoglycaemia events (baseline 8.9 ± 13.4 vs 
endpoint 0.8 ± 1.9 events/participant/year, p<0.001), with 20% of participants 
experiencing severe events during the RCT in comparison to 77% over the 
preceding 6 months and 92% in the preceding year.  All measures of 
hypoglycaemia awareness improved with the Gold score improving from 5.1 ± 
1.1 at baseline to 4.1 ± 1.6 at endpoint (p<0.001). Given the lack of a control 
group these findings need to be treated with some caution.  However the 
immediate and sustained reduction in biochemical hypoglycaemia (% time 
<3.0mmol/L) falling from 3.7 ± 4.4 at baseline to 1.7 ± 3.9 (p<0.01) and the 
reduction in severe hypoglycaemia events suggest that the improvement in IAH 
scores is real.  
5.6 Reduction in insulin doses 
Across the study population the total daily insulin dose (units/kg) fell from 0.64 ± 
0.23 at baseline to 0.53 ± 0.17 at endpoint (p<0.001).  Previous studies have 
reported a reduction in insulin dose with CSII compared to MDI to achieve 
equivalent glycaemic control (DeVries et al., 2002; Thomas et al., 2007).  
However a striking finding of the study in chapter 3 is that both the CSII and 
MDI groups showed equivalent reductions in insulin total daily dose.  At study 
endpoint the total daily insulin dose (units/kg) in the CSII group was 0.55 ± 0.18 
as compared to 0.51 ± 0.15 in the MDI group (p=0.31).  Importantly, these 
equivalent dose reductions were not associated with worsening of glycaemic 
control.  
5.7 Fear of hypoglycaemia 
While there was an overall significant reduction in Fear of Hypoglycaemia 
scores across the study population (baseline 58 ± 26 vs endpoint 45 ± 24, 
p<0.001), the study in chapter 3 demonstrated equivalent reduction in fear of 
hypoglycaemia in all groups.  This is a novel finding as previous studies have 
tended to favour technology over MDI / SMBG regimens (Rubin et al., 2012).  
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5.8 The Hypo awareness questionnaire 
Due to recognised relative insensitivity of the Gold score to change, a newly 
designed measure of awareness was included.  This showed a much greater 
magnitude of clinical improvement at study end-point with the score falling from 
13.4 ± 3.4 at baseline to 9.1 ± 4.2 at endpoint (p<0.001).  In keeping with the 
Gold score comparisons there was no difference in the Hypo-Q score between 
MDI and CSII (8.9 ± 4.3 vs 9.4 ± 4.2, p=0.601) or between SMBG and RT (9.2 ± 
4.1 vs 9.0 ± 4.4, p=0.83).  Validation studies for the HypoA-Q have been 
undertaken in Newcastle and in Edinburgh and once these are published this 
questionnaire may become more widely applicable.   
In the study in Chapter 4 the Gold score was used as a marker of response to 
intervention.  A one step improvement in Gold score cannot be a good 
discriminator, and therefore future analyses with a validated HypoA-Q score, 
which potentially will be more sensitive to change, is planned.  
5.9 My hypo compass 
The relative impact of the standardised education tool used in the study cannot 
be assessed.    However as discussed in chapter 1 much of the most 
convincing previous evidence for improved hypoglycaemia awareness has 
accrued from structured educational programmes (Hermanns et al., 2007; 
McIntyre et al., 2010).  As will be discussed in section 5.13.2 there have been 
new data recently published suggesting that both established structured 
educational interventions and novel psychosocial interventions may have a 
crucial role in reducing severe hypoglycaemia and improving IAH in high risk 
populations.  
5.10 Clinical characteristics of non-responders 
While there was a trend towards those with longer duration diabetes and higher 
age being less likely to demonstrate improved awareness of hypoglycaemia 
these findings were not significant.  It is known that people with chronic kidney 
disease are at higher risk of severe hypoglycaemia and again there was a trend 
towards higher creatinine indicating less chance of response.  While there   
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5.11 Autonomic symptoms and hyperglycaemia avoidance  
There is evidence that impaired awareness of hypoglycaemia is reversible even 
in long-standing type 1 diabetes (Cranston et al., 1994), but there may be sub-
groups in whom this is particularly difficult to achieve with conventional medical 
management.  One such sub-group includes those who are prepared to accept 
recurrent hypoglycaemia as a necessary encumbrance for avoiding high 
glucose levels and thus risk of chronic hyperglycaemia-induced complications. 
Another may include those with long-standing autonomic dysfunction in whom 
restoration of autonomic symptoms cannot be achieved solely by short-term 
absolute avoidance of hypoglycaemia.  Neither of these groups were identified 
in this study which used the autonomic symptom profile questionnaire and 
hyperglycaemia avoidance scale as outcomes.    
5.12 Optimised collection of biomedical glucose data 
In the design of the study paper diaries were used for SMBG recording.  This 
was to enable the glucose values to be collected in conjunction with data on 
what activity/task the glucose measurement related to (i.e. before meals, after 
meals and before bed).  While it may be considered a weakness not to have 
downloaded the blood glucose meters this would not have provided any context 
to why the blood glucose measurement was taken.  
While those participants randomised to RT were encouraged to use the sensors 
for at least 3 days every week, this was not mandated.  This was to improve the 
relevance of the results of the study to real life clinical practice.  However this 
may be deemed a limitation of the RCT in chapter 3.   While a potential 
weakness may have been not to collect all the data from the RT devices, a 
strength of the study was the equivalent methods of collecting continuous 
glucose monitoring data from all groups by use of the professional / blinded 
CGM.  In this way the burden of all biochemical hypoglycaemia could be 
assessed using % time under a range of values across the entire study 
population.  
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5.13 Advances in the field 
5.13.1 Real-time CGM 
As discussed in chapter 1 when these studies were initiated there was little 
evidence that RT significantly reduced severe hypoglycaemia.  Factors for this 
include the low baseline rates of hypoglycaemia amongst the participants 
randomised in previous trials, and in keeping with studies investigating the 
impact of analogue insulins, excluded those at highest risk.  There is also 
evidence from studies that participants have slept through the low glucose 
alarms on the RT CGM devices overnight (Buckingham et al., 2005).   
However since the studies in this thesis were undertaken the first two 
randomised control trials investigating the use of insulin pump therapy with 
automated insulin suspension (termed ‘low glucose suspend’) have been 
published (Bergenstal et al., 2013; Ly et al., 2013).  The low glucose 
suspension function enables insulin delivery to be stopped automatically for up 
to 2 hours when sensor glucose falls below a pre-set threshold.   
In the first study published by a group in Australia (Ly et al., 2013), which was 
partly funded by Medtronic, 95 individuals who were all pump users pre-study, 
were randomised to either continuing standard CSII therapy or to CSII therapy 
with the low glucose suspend feature (LGS).  As an example of the non-
standardised way hypoglycaemia is reported in clinical trials, in this study 
moderate hypoglycaemia was defined as an event requiring the assistance of 
another person whereas severe hypoglycaemia was classified as a 
hypoglycaemic seizure or coma. 
All individuals randomised to the LGS group received an additional education 
session before commencing this intervention, a visit not matched in the 
standard pump therapy arm.  Furthermore those using LGS system were 
advised to upload their data weekly to Medtronic’s online software for data 
analysis, whereas those randomised to standard pump therapy continued under 
their pre-study clinical team for standard clinical review.   
This study attempted to recruit those at high risk of severe hypoglycaemia by 
including the need for IAH as defined by the Gold score as an eligibility criteria.  
However although the participants recruited all had Gold and Clarke scores ≥ 4 
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at recruitment, unlike the participants of the studies in this thesis, the baseline 
rates of severe and moderate hypoglycaemia were low.  The reason for the low 
baseline rate of severe hypoglycaemia may be that the participants were all 
much younger (range 4-50 years, mean <20 years) and had shorter duration 
diabetes (mean <13 years) as compared to mean of 28.9 years in the studies of 
this thesis.  Of note, in each of the randomised groups fifteen of the participants 
were less than 12 years old.  The study did show a significantly bigger reduction 
in combined severe and moderate hypoglycaemia rates with LGS than with 
standard pump therapy.   
The second randomised controlled trial which has reported is the ASPIRE 
study, also published in 2013 (Bergenstal et al., 2013).  This multicentre study 
evaluated the effect of LGS compared to sensor augmented pump therapy 
(CSII with RT CGM).  Potential participants were excluded from this study if 
they had history of more than one episode of severe hypoglycaemia (defined as 
coma, or seizure or requiring medical assistance) within the previous six 
months.   Mean diabetes duration was longer than the Ly study at > 26 years 
and the visit schedule for the study was identical for both intervention groups.  
Of note, this study was also sponsored by Medtronic and representatives of the 
study performed data collection and provided editorial assistance to early 
versions of the manuscript.   
In this study there was a two-week run in phase, during which time participants 
had to use the sensors at least 80% of the time, and have at least 2 episodes of 
nocturnal hypoglycaemia to be eligible for randomisation.  Nocturnal 
hypoglycaemia was defined as 3.6 mmol per litre or less between 10pm and 
8am for more than 20 consecutive minutes.  247 patients were randomised and 
included in the intention to treat analysis.  The primary efficacy endpoint in the 
study was the area under the curve (AUC) for nocturnal hypoglycaemic events.  
The study reported that the AUC (mean ± SD) for nocturnal hypoglycaemia in 
the low glucose suspend group was 37.5% less than that of the control group 
(54.4 ± 66.6 mmol per litre x minutes vs 87.0 ± 110.7 mmol per litre x minutes, 
p<0.001).  There were no severe hypoglycaemia events in the low glucose 
suspend group and four severe hypoglycaemia events in the sensor augmented 
pump group. This was a relatively short study at 3 months duration and 
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therefore the long term outcomes of the low glucose suspend feature are not 
yet known.  
While these have been the first randomised studies evaluating LGS, non- 
randomised studies have shown reduced nocturnal hypoglycaemia with this 
technology.   
5.13.2 Structured education and motivational approaches  
The impact of the ‘my hypo compass’ tool (Little et al., 2012a) cannot be 
assessed in the these studies.  It was included as a way to ensure that all 
investigators were providing standardised advice on hypoglycaemia avoidance 
and treatment in a multicentre study.  However given the immediate reduction in 
biochemical hypoglycaemia upon randomisation it may be that this tool played a 
significant role.  Indeed as discussed in chapter 1 much of the most convincing 
previous evidence for improved hypoglycaemia awareness has accrued from 
structured educational programmes.  
Since these studies were undertaken the DAFNE group have published new 
data.  In an audit of participants attending courses in one year, 43% of those 
with impaired awareness at course entry (40% of the total) had restored 
awareness at one year (Hopkins et al., 2012).  In the same study there was also 
a significant reduction in the severe hypoglycaemia rate from 1.7 ± 8.5 to 0.6 ± 
3.7 episodes/person/year (p <0.001), within one year of undertaking the 
programme. 
Recently the DAFNE group have developed a new intervention which uses 
motivational interviewing and cognitive behavioural techniques to help 
individuals with impaired awareness of hypoglycaemia regain awareness.  
DAFNE HART is a 6 week course involving a 2 day workshop and weekly 
supervision which was in person, by telephone and by email, and involves input 
from a clinical psychologist.    
In a recent pilot study 23 participants with confirmed Gold score ≥4 and mean 
diabetes duration 30.7 ± 11.9 years completed the programme (de Zoysa et al., 
2014).  The severe hypoglycaemia rate (median, (range)) fell from 3.0 (0-104) 
to 0 (0-3) events per patient per year (p<0.0001).  There was also a significant 
reduction in the Gold score, which fell from 5.6 ± 1.4 at baseline to 4.5 ± 1.9 at 
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12 months (p<0.029).  It is notable that perhaps because the Gold score is 
insensitive to change, the 12-month mean Gold score was still within the 
‘unaware’ range despite the improvement.  There was a significant reduction in 
Clarke scores (mean ± SD) from 5.4 ± 1.2 at baseline to 3.8 ± 1.8 at 12 months 
(p<0.001).  The endpoint mean Clarke score was in the ‘aware’ range.  This 
pilot study also assessed hypoglycaemia avoidance scale (HAS) scores before 
and after the intervention.  There were significant reductions in the behaviour 
and worry sub scale scores 12 months following the intervention,   
This was an uncontrolled pilot study but the evidence of increased awareness, 
reduced severe hypoglycaemia events and interestingly reduced HAS scores 
suggest that the motivational approaches may be very relevant to this high risk 
population – a population very similar to that in HypoCOMPaSS.  
5.13.3 Islet cell transplantation 
Data has recently been published regarding the metabolic outcomes of the UK's 
nationally funded integrated islet transplant program (Brooks et al., 2013).  In 
this study the results of 20 individuals who had undergone a total of 25 islet cell 
infusions are provided.  Severe hypoglycemia was reduced from 20 (7-50) 
episodes/patient-year pre-transplant to 0.3 (0 - 1.6) episodes/patient-year post-
transplant (p<0.001).  Resolution of impaired hypoglycemia awareness was 
confirmed [pretransplant: Gold score 6 (5 - 7); 24 (13.5 - 36) months: 3 (1.5 -
4.5); p< 0.03].  Beta-cell replacement through transplantation of whole pancreas 
or isolated islets can undoubtedly prevent recurrent severe hypoglycaemia.  
Unfortunately, for as long as there is an on-going requirement for full systemic 
immunosuppression, transplantation can only be considered for the minority 
with truly life threatening hypoglycaemia or those who have previously had 
another type of transplant. 
5.14 Future work 
5.14.1 Follow up study 
An 18 month follow up study to the 24-week RCT is ongoing to assess the 
sustainability of the interventions.  At the end of the RCT participants returned 
to routine clinical care with those randomised to CSII able to continue using this 
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if they so wished as NICE criteria had been met upon recruitment.  Those 
randomised to RT were not provided with more sensors.  All participants of the 
RCT will be invited 6, 12 and 18 months after the end of the study for repeat 
blinded CGM profiles, data collection on severe hypoglycaemia incidence and 8 
point SMBG, repeat questionnaire completion including Gold, Clarke, Hypo-Q, 
DTSQ and HAS.   Given the relatively short 24-week duration of the RCT it 
crucial to assess the longer-term impact of the study interventions.  
5.14.2 Cardiac autonomic function data 
As part of the HypoCOMPaSS study cardiac autonomic function tests were 
undertaken.  This data will be analysed by colleagues in Sheffield.  I plan to 
investigate the correlation of the autonomic symptom profile questionnaire with 
the cardiac autonomic function test results in the unique HypoCOMPaSS study 
population.   
5.14.3 HypoCOMPaSS sub study 
The population in HypoCOMPaSS was a unique sub-group of the population 
with type 1 diabetes.  A control group is needed to compare the same outcomes 
in individuals with type 1 diabetes but with intact awareness.   This study is 
taking place with fellow investigators from Sheffield.  They are recruiting 
individuals with type 1 diabetes and intact awareness of hypoglycaemia as 
confirmed by a Gold score ≤ 3 at baseline.  The participants will be undertaking 
cardiac autonomic function testing, completing the ASP questionnaire and 
undertaking hypoglycaemic hyperinsulinaemic clamp studies.  
5.14.4 A study to investigate the impact of ‘my hypo compass’ 
The study undertaken in chapter 3 highlights the need to undertake a 
randomised control trial of impact of the ‘my hypo compass’ intervention in 
individuals with T1DM and IAH.  In the RCT ‘my hypo compass’ was carried out 
over a single 1-2 hour session and was facilitated by the site investigator.  
Although brief training on its use had been had been provided at the site 
initiation visit, educators did not have psychology qualifications.  It may 
therefore be a more accessible intervention than the 6-week DAFNE HART 
intervention (described in section 5.13.2).   
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5.14.5 Further analyses of psychosocial measures 
The hyperglycaemia avoidance scale was completed by all participants at 
baseline and at endpoint.  While the hypothesis in the study in Chapter 4 was 
driven by the baseline phenotype, I plan to investigate whether the use of the 
biomedical interventions in this thesis impacted on behaviours such as having a 
‘low glucose preference’ by analysing paired questionnaire scores.  
As part of the HypoCOMPaSS study a range of other validated and non-
validated psychosocial measures were recommended from Kings College 
London and included in the study protocol.  I plan to use these measures to 
further investigate whether there are any subtle correlates with non-response to 
the interventions studied.  
5.14.6 Correlating neuroimaging with phenotype 
The increasing body of literature assessing the neuroimaging with IAH and risk 
of severe hypoglycaemia are of great interest.  However it is yet to be seen how 
these people can be identified in routine clinical practice.  It would be of interest 
to undertake neuroimaging of the HypoCOMPaSS study population and 
correlate this with the phenotypes described in the study in chapter 4 of this 
thesis.  
5.14.7 Potential role of c-peptide microsecretion 
As discussed in chapter 1 the presence of c-peptide was shown in the DCCT 
study to protect against severe hypoglycaemia through an as yet unidentified 
mechanism (DCCT, 1997).  Recently there has been improvement in the 
sensitivity of c-peptide assays.  A recent study has shown that in a group of 74 
individuals with type 1 diabetes (as defined as diagnosis <30 years old or 
diagnosed >30 years old with positive islet autoantibodies), c-peptide was 
detectable (>3.3 pmol/L) in 54 (73%) (Oram et al., 2014).  The phenotype of this 
group including status of hypoglycaemia awareness is not known.  Therefore 
further research is needed to characterise apparent non-responders from 
responders in terms of c-peptide micro secretion.  A further study is planned to 
invite all HypoCOMPaSS participants for a mixed meal tolerance test to have c-
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peptide serum analysis using an electrochemiluminescence immunoassay with 
a reported limit of detection of 3.3 pmol/L.  
5.15 Conclusions 
Awareness of hypoglycaemia can be improved and recurrent severe 
hypoglycaemia prevented in people with long duration type 1 diabetes without 
relaxing HbA1c.  Similar biomedical outcomes can be attained with conventional 
MDI and SMBG regimens compared with CSII and RT.  All individuals may 
benefit from biomedical interventions aimed at improving awareness of 
hypoglycaemia.  Disease duration and age did not correlate with degree of 
autonomic dysfunction symptoms in this research, though there is a suggestion 
that those with the highest scores were less likely to respond.  This research 
provides a basis for further studies investigating impact of new technologies on 
IAH, severe hypoglycaemia and behaviour change.  This research underlines 
the importance of tailoring treatment to avoid biochemical hypoglycaemia 
without relaxing overall control.  
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6.1 Appendix 1: The hypoglycaemia awareness questionnaire (HypoA-Q) 
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6.2 
 171 
 172 
6.2 Appendix 2: Participant handbook for my hypo compass  
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6.3 Appendix 3: Facilitator handbook for ‘my hypo compass’  
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6.4 Appendix 4: Guy’s and St Thomas’ minimally modified Clarke 
hypoglycaemia survey 
Study Centre:  Today’s date:   /  /   (dd/mm/yy) 
Patient ID #:  Patient DOB:   /  /   (dd/mm/yy) 
Guy’s and St Thomas’ Minimally Modified Clarke Hypoglycaemia Survey 
1. Tick the category that best describes you (tick one only): 
0 I always have symptoms when my blood sugar is low  
0 I sometimes have symptoms when my blood sugar is low  
0 I no longer have symptoms when my blood sugar is low 
2. Have you lost some of the symptoms that used to occur when your blood sugar 
was low? 
0 Yes   0 No  
3. In the past 6 months, how often have you had hypoglycaemic episodes, where 
you might feel confused, disorientated, or lethargic and were unable to treat 
yourself? 
0 Never    0  Once or twice   0         Every other month 
0 Once a month  0  More than once a month  
4.  In the past year, how often have you had hypoglycaemic episodes, where you 
were unconscious or had a seizure and needed glucagon or intravenous 
glucose? 
0 Never   0 5 times  0 10 times  
0 1 time  0 6 times 0 11 times  
0 2 times 0 7 times  0 12 or more times  
0 3 times 0 8 times  
0  4 times  0 9 times  
5. How often in the last month have you had readings <3.5mmol/l with symptoms? 
0 Never  0 1-3 times  0 1 time/week 
0 2-3 times/week 0 4-5 times/week 0 Almost daily 
6. How often in the last month have you had readings <3.5mmol/l without any 
symptoms? 
0 Never  0 1-3 times  0 1 time/week 
0 2-3 times/week 0 4-5 times/week 0 Almost daily 
7. How low does your blood sugar need to go before you feel symptoms? 
0 3.4-3.9mmol/l 0 2.8-3.3mmol/l 0 2.2-2.7mmol/l  
0 <2.2 mmol/l 
8. To what extent can you tell by your symptoms that your blood sugar is low? 
0 Never   0 Rarely  0 Sometimes 0 Often 0 Always 
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 6.5 Appendix 5: Edinburgh hypoglycaemia survey including the Gold 
score 
1.  Please score the extent to which you experience the following symptoms 
during a typical daytime hypoglycaemic episode (circle a number for 
each symptom) 
 
           Not present      Present a great deal 
 
Confusion   1 2 3 4 5 6 7 
Sweating   1 2 3 4 5 6 7 
Drowsiness   1 2 3 4 5 6 7 
Weakness   1 2 3 4 5 6 7 
Dizziness   1 2 3 4 5 6 7 
Warmth   1 2 3 4 5 6 7 
Difficulty Speaking  1 2 3 4 5 6 7 
Pounding heart  1 2 3 4 5 6 7 
Inability to concentrate 1 2 3 4 5 6 7 
Blurred vision  1 2 3 4 5 6 7 
Hunger   1 2 3 4 5 6 7 
Nausea   1 2 3 4 5 6 7 
Anxiety   1 2 3 4 5 6 7 
Tiredness   1 2 3 4 5 6 7 
Tingling lips   1 2 3 4 5 6 7 
Trembling   1 2 3 4 5 6 7 
Headache   1 2 3 4 5 6 7 
2.  Do you know when your hypos are commencing?  Please circle a 
number: 
 
Always aware     Never aware 
 
Awareness   1 2 3 4 5 6 7 
Comments: 
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6.6 Appendix 6: Standard operating procedure for stepped 
hyperinsulinaemic hypoglycaemic clamp in the HypoCOMPaSS 
study 
 
Exclusion Criteria for clamp study 
All participants from the hypo COMPASS trial will be asked to consider 
participating in the clamp study unless they meet any of the following exclusion 
criteria: 
• Age >60 
• History of Epilepsy (seizures not primarily induced by hypoglycaemia) 
• Known Ischaemic Heart Disease 
• Other significant disease which in the judgement of the investigators 
which would increase the risks associated with taking part in the study 
Day before Study 
Subjects will have been fitted with a retrospective CGM sensor to be worn for 
the 7 days preceding the study day.  This will be downloaded on the morning of 
the study to determine whether any antecedent biochemical hypoglycaemia 
occurred over the 24-hour period prior to the clamp. Studies will be postponed 
to another day if any CGM and/or self-monitored capillary glucose below 
3.0mmol/l are detected during 24 hours prior to the study. If this is the case, 
participants will be asked to be fitted for a further 72 hours CGM and to reduce 
their basal insulin by 25% if on Detemir insulin (this applicable only to clamp 
studies carried out before the intervention period) and by 50% if on glargine on 
the night before the rescheduled clamp study, in addition to making other 
targeted self-management adjustments to absolutely prevent glucose levels 
<3.0mmol/L over the preceding 24 hours. 
Day of Study 
Participants will be admitted to the research unit at 0700Hrs on the study day 
following an overnight fast from 10 pm. An intravenous cannula will be inserted 
in the antecubital vein of the non-dominant arm and another retrogradely sited 
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in a vein on the dorsum of the hand on the same side using local anaesthetic. 
From 7am to 10. 30am, blood glucose will be stabilized with sliding scale insulin 
infusion aiming initially for blood glucose reading of 6.0 – 7.0 mmol/l, but 
bringing down to between 5 and 6 mmol/L between 10.30 and 11 am for start of 
clamp.  
The retrograde cannula will be used for sampling, both during initial stabilization 
and during clamp study. A slow intravenous infusion of saline will be used as 
needed to keep the sampling line patent.  During this period of stabilization, 
participants will be shown how to perform the brain (cognitive) function tests 
and asked to practice the tests till they achieve consistent results (typically 5 
practice sessions). The distal non-dominant hand will be heated using hot box 
starting at least 30 min prior to start of clamp (10.30 am at latest) and continued 
throughout study.  
Clamp 
At 11 am, a primed infusion of 60 mU/m-2 /min actrapid insulin will be started via 
the non-dominant antecubital vein catheter.  
To do this, insulin will made up between 10.00am and 11 am using either: 
1) total volume 50mls if using syringe driver: normal saline with 2mls of 
autologous blood (add saline first then blood and insulin last) 
2) total volume 100ml in bag if using infusion pump: remove volume of 
saline from 100 ml bag, add 4 mls of autologous blood then insulin last! 
 
The insulin dose will be calculated and will be  run through the side arm of a 3-
way tap. Priming rates are 
(i) insulin infusion at 48 mls/hr from 0 to 4 min 
(ii) insulin infusion at 32 ml/h from 4 to 7 min 
(iii) insulin infusion at 16 ml/hr from 7 min onwards 
 
20% glucose will also be infused via the same antecubital cannula (best through 
“straight” arm of 3 way tap at a variable rate to keep the blood glucose at the 
desired level. This is varied but a “typical” starting protocol might be: 
0 min   0   mg/kg/min 
4 min   2 mg/kg/min 
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7 min   2.5 mg/kg/min 
9 min   3 mg/kg/min 
11 min  4  mg/kg/min 
Plasma glucose will be sampled from sample drawn from retrograde cannula 
every 5 minutes (2ml dead space drawn, then the sample for analysis and then 
dead space sample returned), spun rapidly and assayed using Yellow Springs 
glucose analyzer. Dextrose infusion rates will be adjusted as needed aiming for 
stabilization at 5.0mmol/l at 40mins and lowered in a step wise manner by 
variable glucose infusion to 3.8mmol/L, 3.4mmol/l 2.8mmol/l and 2.4mmol/l. 
Each step will consist of 40 min allowing 20 minutes to fall to target and 20 
minutes for stabilization at that level.  Participants will be blinded to glucose 
levels throughout the study.  
In addition to samples for plasma glucose, additional arterialised venous blood 
samples for insulin, catecholamines, growth hormones, glucagon and cortisol 
will be drawn spun and stored at 0,10,20,30 and 40 minutes at start of clamp. 
Thereafter, these extra samples will be drawn at 20 minute intervals. Sampling 
details/ collection are detailed below. Also heart rate and BP recorded every 20 
minutes so easiest for timings to have a consistent time pattern of recording 
HR, draw samples and then inflate BP cuff as flushing line. Suggested pattern 
of activity for each glucose step (other than 0 to 40 min where additional basal 
hormone sampling) in figure 1 below: 
 
0 min +40 min+20
Heart rate/ 
Samples/ 
BP
Plasma glucose 
falling
Target Glucose
Cognitive 
function
Symptoms
+30
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 Figure 1: Pattern of activity for each clamp step 
Following Clamp 
At the end of the study, dextrose infusion will be increased to raise blood 
glucose to euglycaemia, and then tapered off gradually during meal (typically 
halved halfway through eating then discontinued at end of meal). For insulin;  
(1) for pump patients, the iv insulin infusion will be reduced to 
approximate basal infusion rates and pump reconnected with meal 
bolus as below but allowing 30 minutes overlap for pump site to 
kick in before stopping iv insulin (halve iv insulin infusion rate after 
15 minutes) 
(2) For MDI patients, iv insulin infusion will be reduced to approximate 
basal infusion rates and meal injection given as below. Allow 30 
mins overlap between bolus and stopping iv insulin (halve iv 
insulin infusion rate after 15 minutes). 
 
A carbohydrate rich meal will be consumed with 80% of usual prandial insulin 
bolus given. Frequent blood glucose measurements will be made (every 10 
minutes) until glucose levels are stable (at least 45 minutes after end of meal).  
Participants will be discharged home with advice about their subsequent insulin 
dose. Specifically (1) warned increased risk of hypo during subsequent 24-48 
hour period (2) MDI patients warned that it may take up to 3 days to restabilise 
baseline, to monitor frequently and to make small corrections only. 
 
Measures 
Blood: 
Plasma glucose will be analysed by Yellow Springs analyser (Yellow Springs, 
Ohio, USA).  
Hormone analysis of samples from all centres will be performed in the quality 
assured Diabetes Research Laboratory at Newcastle University.  
Blood samples for insulin will be collected as 3ml samples in EDTA tubes, and 
centrifuged at 2500 rpm for 2 minutes. Equal volumes of a polyethylene glycol 
(PEG) buffer will be added, samples vortexed and then spun for 30 minutes to 
remove the precipitated globulin fraction. The supernatant will be frozen for 
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assay (stored at -20) and free insulin measured by double-antibody 
immunoassay. 
For glucagon, 2.5ml blood will be collected in a tube containing 0.25ml aprotinin 
(trasylol) and EDTA which will have been stored in a refrigerator. A sequential 
radioimmunoassay will be used for Glucagon assay.  
Blood samples for cortisol will be collected as 2.5ml samples in glass white 
topped tubes.  ADVIA Centuar Cortisol assay will be used to measure cortisol in 
the serum samples. 
For catecholamines 4 mls of whole blood will be drawn into a Lithium Heparin 
tube. A non competitive enzyme linked immunosorbent assay kit will be used to 
measure epinephrine or norepinephrine in plasma.  
Blood samples for growth hormone assays will be collected as 3ml samples in 
EDTA tubes. GH will be measured using a Nichols Advantage assay using a 
two-site chemiuminescence immunoassay procedure.  
Physiological measurements 
Electrocardiograph monitoring will be performed continuously throughout the 
clamp studies using three electrodes. One electrode will be placed on either 
side of the sternum and one in the V5 position. The signal will be amplified and 
displayed on a monitor with the integrated heart rate displayed digitally.  
Heart Rate, blood pressure and 2 minutes ECG trace will be formally recorded 
every 20 minutes. 
In some studies, monitoring of skin perspiration and limb tremor will be 
undertaken intermittently using non-invasive previously validated sensors. This 
is not expected to cause any added discomfort or inconvenience for the 
recipient. 
Hypoglycaemia Symptom Score 
The participants will complete a symptom questionnaire at the end of each 
glucose step (i.e. every 40 minutes). Each symptom will be graded on a visual 
analogue scale (1-7). 
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Hypoglycaemia symptoms will be classified into 3 groups: 
Autonomic: palpitations, sweating, shaking and hunger 
Neuroglycopenic:  confusion, drowsiness, odd behaviour, speech difficulty and 
inco-ordination  
Non-specific: nausea and headache 
 
Cognitive function 
Participants will undertake three cognitive function tests at the end of each step 
of the clamp study (and practiced at least 5 times as described above prior to 
start of clamp between 7 and 11 am- the practice data will also be recorded to 
show that performance is stable), consisting of 4CRT (4 Choice Reaction Time), 
N-back and SWM (Spatial Working Memory) performed always in this order: 
 
Four choice reaction time: 
Four-choice reaction time is a test of attention, discrimination and motor speed 
reaction.  In this test, the subject is presented with a computer screen divided 
into four quadrants. A computer-generated signal appears randomly in one 
quadrant at a time and the subject has to clear it by pressing a corresponding 
button on a box. Up to 500 signals are presented in 5 min. The mean time of the 
reactions and accuracy (the percentage of correct responses) are recorded.  
The measures of speed and accuracy used in this test have previously been 
demonstrated to change by less than 1% on repeated measures at euglycaemia 
(Maran A, 1993) 
N-back:  
In this task, the subject is shown a rapid series of randomly chosen letters and 
responds when the letter presented is the same as either the last or the next to 
last or the previous to the next to last letter in the series. 
Spatial Working Memory: 
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Spatial Working Memory (SWM) task involves searching for a token hidden 
behind a circle by pressing a touch sensitive computer screen.  Once the token 
is found, a new trial will start and participants are informed that another token is 
hidden behind a different circle, therefore they should avoid touching the circle 
where the previous token was found.  The SWM test has been shown to be 
sensitive to hormonal manipulations.  For example, chronic administration of 
cortisol to healthy subjects leads to an increase in the within-search errors and 
impairs the use of appropriate cognitive strategies (Young, AH; Sahakian BJ; 
Robbins TW; Cowen PJ (1999). "The effects of chronic administration of 
hydrocortisone on cognitive function in normal male volunteers." 
Psychopharmacology 145(3): 260-266).   
More recently, a more challenging SWM test has been developed in Newcastle 
and this has been found to be sensitive to acute cortisol administration 
demonstrating a detrimental effect of cortisol on the within-search task, an effect 
that was attenuated by a selective serotonin reuptake inhibitor pre-treatment 
(Alhaj, HA; Arulnathan, VE; Gallagher, P; Marsh, RA; Massey, AE; Pariante, 
CM; McAllister-Williams, RH (2009). "Citalopram Modulation of the Effects of 
Cortisol on Attention and Memory." Journal of Psychopharmacology 23(6): 
TE18.).  
This is an in house adaptation of the SWM task from the CANTAB battery of 
cognitive tests.  See www.camcog.com/camcog/default.as 
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6.7 Appendix 7: Blood glucose targets 
The blood glucose targets (for all patients in both CSII and MDI groups) were as 
follows: 
 Fasting blood glucose (FBG):  5.0 - 7.0 mmol/l 
 Pre-prandial blood glucose:  4.5 - 7.0 mmol/l 
 Post-prandial glucose*:   6.0 – 8.0 mmol/l 
 Bedtime blood glucose**:   6.0 – 8.0 mmol/l 
 4am blood glucose:    5.0 – 7.0 mmol/l 
*postprandial blood glucose: measurement made 2 hours after the start of a 
meal 
**bedtime blood glucose: measurement made within 30 minutes of retiring to 
bed for the night. 
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6.8 Appendix 8: Glargine titration in MDI group 
Insulin glargine was self-administered and the following titration protocol was 
followed:  
• Take within 30 minutes of retiring to bed for night / no need for snack 
• Aim for stable (not falling) glucose through the night  
• Reduce dose if any hypoglycaemic episodes or glucose <5.0mmol/l 
between 4am and before breakfast 
• Target glucose of 5-7mmol/l before breakfast – adjust dose by 1-2 units 
to maintain target if necessary with primary aim being absolute 
avoidance of biochemical hypoglycaemia)  
• During periods of illness, basal insulin doses may need to be altered and 
this will be guided by SMBG levels. 
Introduction of twice daily glargine 
Participants randomised to MDI already on twice daily glargine continued on 
this from the outset of the RCT. In other MDI participants, if glucose was 
consistently >7mmol/l before evening meal or highly variable between breakfast 
and evening meal, a second dose of insulin glargine was added before 
breakfast. Initial dose was 4 units but was adjusted in light of participant’s 
insulin doses. If glucose had been falling through the night, a 2-4 unit reduction 
in evening glargine dose was actioned before bed on the day of commencing 
the morning dose.  The addition of a second daily glargine dose was considered 
for all participants in the MDI group.  This was initiated between study visits if 
necessary, e.g. after telephone advice.   
Morning insulin glargine was self-administered and adjusted as follows:   
• Take within 30 minutes of rising from bed for the morning 
• Aim for stable (not falling) glucose through the afternoon  
• Reduce dose if any hypoglycaemic episodes or glucose <5mmol/l 
between 2 hours after lunch and evening meal 
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• Target glucose of 5-7mmol/l before evening meal – adjust dose by 1-2 
units to maintain target if necessary with primary aim being absolute avoidance 
of biochemical hypoglycaemia  
 209 
6.9 Appendix 9: Basal insulin titration in CSII group 
The basal insulin delivery rate was titrated according to fasting, bedtime, pre-
prandial and 4am glucose levels ensuring absence of recurrent low glucose 
levels at these times (checkpoints).  Increased or decreased delivery was 
commenced from the previous basal insulin checkpoint level, i.e. if low at 4am – 
decreased from bedtime; if high fasting increased from 4am.   
Mean fasting; bedtime; 4am and pre-prandial blood glucose: 
• Within target: No change to basal delivery rate 
• Above target: Increase basal insulin by 0.1U/hr from previous check point 
• Below target or unexplained late post-prandial hypoglycaemia:
 Decrease basal insulin by 0.1U/hr from previous check point 
During periods of illness, basal insulin rates may need to be altered and this will 
be guided by SMBG levels. 
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6.10 Appendix 10: Meal-time insulin bolus in all groups (CSII and MDI) 
Carbohydrate counting skills and bolus dose adjustment in light of current blood 
glucose level / individualised insulin carbohydrate ratios was reviewed in all 
participants.  Aspart or lispro was delivered either by subcutaneous injection or 
as a subcutaneous pump bolus before all meals and snacks with substantial 
carbohydrate content.   
Insulin: carbohydrate ratios were calculated for all individuals using the ‘500 
rule’ and using total daily insulin doses pre-randomisation.  The ‘500 rule’ is:  
500 divided by the TDD (Total Daily Dose of insulin) = grams of carbohydrate 
covered by one unit of aspart or lispro 
In the event of high pre-prandial glucose levels corrective doses were also 
recommended with meals as part of the meal time bolus.  This was calculated 
using the ‘100 rule’ for estimation of Insulin Sensitivity Factor.  The ‘100 rule’ is  
100 divided by the TDD (Total daily Dose of insulin) = glucose drop in mmol/l 
per 1 unit of aspart or lispro   
This was presented to all participants as ‘1 unit of aspart/lispro will reduce your 
blood glucose by X mmol/l’. 
Corrective doses with all pre-main meal boluses / prandial insulin injections 
were encouraged according to the 100 rule when glucose level was above 
target.  
The insulin: carbohydrate ratio and Insulin Sensitivity Factor for that period of 
the day was adjusted accordingly in the event that: 
• The glucose level was consistently below or above target 2 hours after a 
bolus / prandial insulin injection. 
• If any unexplained hypoglycaemic event occurred 2 hours after a bolus / 
prandial insulin injection
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6.11 Appendix 11: Study flow chart 
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6.12 Appendix 12:  The diabetes treatment satisfaction questionnaire 
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6.13 Appendix 13: hyperglycaemia avoidance scale  
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6.14 Appendix 14: Hypoglycaemia fear survey 
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6.15 Appendix 15: Autonomic symptom profile questionnaire 
Answer every question by darkening the appropriate oval. If you are unsure about how to 
answer a question, please give the best answer you can.  Please darken the corresponding oval 
completely.  Fill in the number in the box if provided.  This is an American questionnaire – so 
some of the spellings are strange and the numbers erratic, please just ignore this and answer 
the questions as they appear.  Many thanks.  
 
18. In the past year, have you ever felt faint, dizzy or ‘goofy’ or had difficulty thinking soon 
after standing up from a sitting or lying position ? 
O 1    Yes  If you marked Yes go to question 19. 
O 2  No   If you marked No go to question 37. 
 
19. When standing up, how frequently do you get these feelings or symptoms ? 
O 1  Rarely 
O 2 Occasionally 
O 3 Frequently 
O 4  Almost always 
 
20. How would you rate the severity of these feelings or symptoms ? 
O 1  Mild 
O 2  Moderate 
O 3 Severe 
 
21. For how long have you been experiencing these feelings or symptoms ? 
O 1  Less than 3 months 
O 2    3-6 months 
O 3 7 to 12 months 
O 4 13 months to 5 years 
O 5 more than 5 years 
O 6 as long as I can remember. 
 
22. In the past year, how often have you ended up fainting soon after standing up from a 
sitting or lying position ? 
O 0  Never 
O 1 Once 
O 2 Twice 
O 3     Three times 
O 4 Four times 
O 5  Five or more times 
 
23. How cautious are you about standing up from a sitting or lying down position ? 
O 1  Not cautious at all 
O 2   Somewhat cautious 
O 3   Extremely cautious 
 
24. What part of the day are these feelings worst ? (check one only) 
O 1  Early morning  
O 2 Rest of the morning 
O 3 Afternoon 
O 4 Evening  
O 5  At night, when I get up after I’ve been sleeping 
O 6  No particular time is worst 
O 7  Other time, please specify ………………………………………… 
 
25. In the past year, have these feelings or symptoms that you have experienced: 
O 1  Got much worse 
O 2 Got somewhat worse 
O 3 Stayed about the same. 
O 4 Got somewhat better 
O 5 Got much better 
O 6  Completely gone. 
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Please rate the average severity you have experienced in the past year for each of the following 
symptoms.                        
            never had         Mild               Moderate     Severe 
 
26. Rapid or increased heart rate           O 1    O 2            O 3        O 4 
(palpitations) 
 
27.  Sickness to your stomach  (nausea)     O 1   O 2           O 3                    O 4 
or vomiting ?  
 
28. A spinning or swimming sensation ?    O 1              O 2            O 3                   O 4 
    
29. Dizziness ?                                    O 1   O 2            O 3                    O 4 
 
30. Blurred vision ?                                     O 1   O 2            O 3                    O 4 
 
31. Feeling of weakness ?                          O 1   O 2            O 3                    O 4 
 
32. Feeling shaky or shaking sensation?    O 1              O 2            O 3                    O 4 
 
33. Feeling anxious or nervous ?                O 1              O 2            O 3                    O 4 
 
34. Turning pale ?                            O 1   O 2            O 3                    O 4 
 
35. Clammy feeling to your skin ?               O 1              O 2            O 3                    O 4 
 
36. Do you have any biological (blood, natural) relatives among your patients, grand parents, brothers, 
sisters, or children who have frequent dizziness after standing from a sitting or lying position ? 
 
O 1 Yes    O 2 No                          If Yes, please list their names and relationships to you. 
 
Name     Relationship 
…………………….             ………………………………. 
…………………….             ………………………………. 
…………………….             ………………………………. 
 
In the past year, have you ever felt faint, dizzy, or ‘goofy’ or had difficulty thinking: 
 
37. soon after a meal ?       O 1 Yes  O 2 No  
 
38. after standing for a long time ?     O 1 Yes   O 2 No 
 
39. during or soon after physical activity or exercise ?  O 1 Yes   O 2 No  
 
40. during or soon after being in a hot bath, shower, tub or sauna ?O 1 Yes  O 2 No 
 
41. Have you ever felt dizzy or faint or actually fainted  
when you saw blood or had blood samples taken ?  O 1 Yes   O 2 No 
 
In the past year, have you fainted: 
 
42. while passing urine ?     O 1 Yes   O 2 No  
 
43. while coughing ?     O 1 Yes  O 2 No 
 
44. while pressing on your neck ?     O 1 Yes  O 2 No 
 
45. before a public speech ?      O 1 Yes   O 2 No 
 
46. any other time ?      O 1 Yes   O 2 No 
 
If you checked Yes to any of these questions on fainting please describe circumstances. 
…………………………………………………………………………. 
…………………………………………………………………………. 
 
47. In the past year, have you ever completely lost consciousness after a spell of dizziness ? 
 
O 1 Yes  O 2 No 
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48. In the past year, have you had any seizures or convulsions ? O 1 Yes  O 2 No           
please describe circumstances …………………………….. 
 
  
In the past 5 years how would you rate the amount of trouble, if any you have had: 
  
    None            Some           A lot  Constant 
 
49. with paralysis in parts of your face ?O 1             O 2         O 3                 O 4 
 
50. with feelings of complete weakness 
all over your body ?  O 1             O 2         O 3                 O 4 
 
51. with attacks of uncontrollable 
movements of your arms and legs ?O 1             O 2         O 3                 O 4 
 
52. with attacks in which you couldn’t 
control your speech ?  O 1             O 2         O 3                 O 4 
 
53.  Have you ever in your adult life had a spell of dizziness ?     O 1  Yes  O 2  No  
 
54. In the past year, have you ever noticed colour changes in your skin, such as red, white or purple ? 
 
O 1  Yes If yes, continue with question 55.            O 2  No If no, go to question 65. 
 
What colour skin changes have occurred (check all that apply) 
 
55. O My skin turns red. 
 
56. O My skin turns white. 
 
57. O My skin turns purple. 
 
58. O Other, please specify ………………………………………………… 
 
What parts of your body are affected by these colour changes ? (check all that apply) 
 
59. O  My hands. 
 
60. O  My feet. 
 
61. O  Other parts, please specify …………………………………………… 
 
62. O  Entire body. 
 
63. For how long have you been experiencing these changes in skin colour ? 
O 1 Less than 2 months 
O 2 3-6 months 
O 3 7-12 months 
O 4    13 months to 5 years 
O 5 More than 5 years 
O 6  As long as I can remember 
 
 
64. Are these changes in skin colour: 
   O 1 Getting much worse 
   O 2 Getting somewhat worse 
   O 3 Staying about the same 
   O 4 Getting somewhat better 
   O 5 Getting much better 
   O 6 Completely gone 
 
65. In the past year, after a long hot bath or shower, have you ever noticed the pads on the ends of 
your fingers wrinkle up ? 
O 1 Yes   O 2  No  
 
66. In the past 5 years, what changes, if any, have occurred in your general body sweating? 
O 1  I sweat much more than I used to. 
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O 2  I sweat somewhat more than I used to. 
O 3  I haven’t noticed any changes in my sweating. 
O 4  I sweat somewhat less than I used to. 
O 5  I sweat much less than I used to. 
 
67. In the past 5 years, what changes, if any, have occurred in the amount your feet sweat ? 
O 1  They sweat much more than they used to. 
O 2  They sweat somewhat more than they used to. 
O 3  I haven’t noticed any changes. 
O 4  They sweat somewhat less than they used to. 
O 5  They sweat much less than they used to. 
 
68. In the past 5 years, what changes, if any, have occurred in facial sweating after eating spicy 
foods ? 
O 1  I sweat much more than I used to. 
O 2  I sweat somewhat more than I used to. 
O 3  I haven’t noticed any changes in my sweating. 
O 4  I sweat somewhat less than I used to. 
O 5  I sweat much less than I used to. 
O 6  I avoid eating spicy foods because I sweat so much. 
O 7  I avoid eating spicy foods for other reasons. 
 
In the past 5 years, what changes, if any, have occurred in your ability to tolerate heat during a hot 
day, strenuous work or exercise, hot bath or shower, hot tub or sauna ? (check all that apply). 
 
69.  O I now get more overheated. 
 
70.  O I now get dizzy.  
 
71.  O I now get short of breath. 
 
72.  O Other changes, please specify ………………………………………….. 
 
73.  O No change. 
 
74.   Do your eyes feel excessively dry ?    
O  1  Yes  O  2  No 
 
75.   Does your mouth feel excessively dry ?             
O  1  Yes  O  2  No 
 
76.   Do you have excessive amounts of saliva formation ? 
 O  1  Yes  O 2   No 
 
77. What is the longest period of time that you have had any one of these symptoms: dry eyes, dry 
mouth, or increased saliva production ? 
O 0  I have not had any of these symptoms. 
O 1  Less than 3 months. 
O 2  3 to 6 months. 
O 3  7 to 12 months. 
O 4  13 months to 5 years. 
O 5  More than 5 years. 
O 6  As long as I can remember. 
 
78. For the symptom of dry eyes, dry mouth, or increased saliva production that you have had for 
the longest period of time, is this symptom: 
O 0  I have not had any of these symptoms. 
O 1  Getting worse. 
O 2  Getting somewhat worse. 
O 3  Staying about the same. 
O 4  Getting somewhat better. 
O 5  Getting much better. 
O 6  Completely gone. 
 
79. What weight changes, if any, have you had over the past year ? 
O 1  I have lost about ………………… pounds. 
O 2  My weight has not changed. 
O 3  I have gained about ……………..pounds. 
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80. In the past year, have you noticed any changes in how quickly you get full when eating a meal ? 
O 1  I get full a lot more quickly now than I used to. 
O 2  I get full more quickly now than I used to. 
O 3  I haven’t noticed any change. 
O 4  I get full less quickly now than I used to. 
O 5  I get full a lot less quickly now than I used to. 
 
81. In the past year, have you felt excessively full or persistently full (bloated feeling) after a meal ? 
O 1  Never  O 2 Sometimes        O 3 A lot of the time 
 
82. In the past year, have you felt like you had a persistent upset stomach (nausea) ? 
O 1  Never  O 2 Sometimes        O 3 A lot of the time 
 
83. In the past year, have you vomited after a meal ? 
O 1  Never  O 2 Sometimes        O 3 A lot of the time 
 
84. In the past year, have you had a cramping or colicky abdominal pain ? 
O 1  Never  O 2 Sometimes        O 3 A lot of the time 
 
85. Are these pains usually after a meal ?      O 1  Yes  O 2 No 
 
86. How long have you had these cramping or colicky abdominal pains ? 
O 1  Less than 3 months 
O 2  3 to 6 months 
O 3  7 to 12 months 
O 4  13 months to 5 years 
O 5  More than 5 years 
O 6  As long as I can remember 
 
87. In the past year, have you had any bouts of diarrhea ? 
O 1  Yes  If yes continue with question 88     O 2  No  If no go to question 94 
 
88. How frequently does this occur ? 
O 1  Rarely      O 2 Occasionally 
O 3  Frequently ………..times per month O 4 Constantly  
 
89. How severe are these bouts of diarrhoea ? 
O 1  Mild   O 2 Moderate  O 3 Severe  
 
90. What part of the day do they seem to be worse ? 
O 1  First thing in the morning 
O 2  Rest of the morning 
O 3  Afternoon 
O 4  Evening 
O 5  During the night 
O 6  No particular time 
 
91. Do these bouts of diarrhoea usually occur after meals   
O 1    Yes   O 2    No  
 
92. Are these bouts of diarrhoea accompanied with lots of rectal gas (flatus) 
O  1     Never O 2 Occasionally               O 3 Frequently   O 4  Always 
 
93. Are your bouts of diarrhea getting: 
O 1  Much worse 
O 2  Somewhat worse 
O 3  Staying the same 
O 4  Somewhat better 
O 5  Much better 
O 6  Completely gone 
 
94. In the past year, have you been constipated ?   
 O 1  Yes  If Yes continue below with question 95 O 2   No  If No go to question 98. 
 
95. How frequently are you constipated ? 
O 1  Rarely      O 2 Occasionally 
O 3  Frequently ………..times per month O 4 Constantly  
 
96. How severe are these bouts of constipation ? 
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O 1  Mild   O 2 Moderate  O 3 Severe  
 
97.  Is your constipation getting:          
O 1  Much worse 
O 2  Somewhat worse 
O 3  Staying the same 
O 4  Somewhat better 
O 5  Much better 
O 6  Completely gone 
 
98. Overall, are your abdominal symptoms of vomiting, diarrhoea, constipation, or weight loss getting: 
O 0  I have not had these symptoms. 
O 1  Much worse 
O 2  Somewhat worse 
O 3  Staying the same 
O 4  Somewhat better 
O 5  Much better 
O 6  Completely gone 
 
99. Which one of the following symptoms have been most troublesome for you (check only one). 
O 0  None 
O 1  Vomiting  
O 2  Diarrhoea 
O 3  Constipation 
O 4  Weight loss 
 
100.How long have you had this most troublesome symptom. 
O 0  I do not have any of these symptoms 
O 1  less than 3 months 
O 2  3 to 6 months 
O 3  7 to 12 months 
O 4  13 months to 5 years 
O 5  more than 5 years 
O 6  As long as I can remember 
 
101 Is this most troublesome symptom getting: 
O 0  I do not have any of these symptoms 
O 1  Much worse 
O 2  Somewhat worse 
O 3  Staying the same 
O 4  Somewhat better 
O 5  Much better 
O 6  Completely gone 
 
102 In the past 5 years, how would you rate the amount of trouble, if any, you have had with difficulty 
swallowing. 
O 1  No trouble 
O 2  Some trouble 
O 3  A lot of trouble 
O 4  Constant trouble 
 
103. In the past 5 years, how would you rate the amount of trouble, if any, you have had with 
everything you eat tasting the same. 
O 1  No trouble 
O 2  Some trouble 
O 3  A lot of trouble 
O 4  Constant trouble 
 
Have you ever in your life: 
104  Been nauseated or vomited   O 1  Yes   O 2    No 
 
105  had a bout of diarrhea   O 1  Yes   O 2    No 
 
106. lost your appetite for at least part of the day O 1  Yes   O 2    No 
 
107. Felt discomfort or pain in the pit of the stomachO 1  Yes   O 2    No 
 
108. In the past year, have you ever leaked urine or lost control of your bladder function ? 
O 1  Never      O 2 Occasionally 
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O 3  Frequently ………..times per month O 4 Constantly  
 
109. In the past, have you had difficulty passing urine ? 
O 1  Never      O 2 Occasionally 
O 3  Frequently ………..times per month O 4 Constantly  
 
110. In the past year, have you had trouble completely emptying your bladder ? 
O 1  Never      O 2 Occasionally 
O 3  Frequently ………..times per month O 4 Constantly  
 
111. How would you describe your current sexual desire ? 
O 1  Completely absent   O 2 Greatly reduced 
O 3  Somewhat reduced   O 4 About the same or more than in 
the past 
 
IF MALE COMPLETE QUESTIONS 112 -123 . FEMALES GO TO QUESTION 124  
 
112. Are you able to have a full erection ? 
O 1  Never, under any circumstances 
O 2  Much less frequently than in the past 
O 3  Somewhat less frequently than in the past 
O 4  The same, or more frequently, than in the past 
 
Which of the following statements apply to your situation ? (Fill in all that apply) 
 
113. O  1 My ability to have intercourse has not changed. 
 
114. O  1 I have erections but am unable to have intercourse. 
 
115. O  1 I can have intercourse only some of the time. 
 
116. O  1 My erections are definitely impaired. 
 
117. O  1 I am able to have intercourse, but am unable to ejaculate 
 
118.  O  1 I have ‘dry’ orgasms and afterward my urine looks milky. 
 
119.  O  1  I have been unable to have erections or they have been impaired since I started taking a 
medication called …………………………………………………………. 
 
120.  O  1 Other situation, please describe ………………………………………….. 
 
121.  O  1 None of the above apply. 
 
122. How long have you had difficulty with erectile function ? 
O 0  I do not have this difficulty 
O 1  Less than 3 months 
O 2  3 to 6 months 
O 3  7 to 12 months 
O 4  13 months to 5 years 
O 5  More than 5 years 
O 6  As long as I can remember 
 
123. Is this difficulty getting: 
O 0  I do not have difficulty 
O 1  Much worse 
O 2  Somewhat worse 
O 3  Staying the same 
O 4  Somewhat better 
O 5  Much better 
O 6  Completely gone 
 
124. In the past year, without sunglasses or tinted glasses, has bright light bothered your eyes ? 
O 1  Never         O 2 Occasionally 
O 3 Frequently     O 4 Constantly  
 
125. How severe is the sensitivity to light ? 
O 1    Mild    O 2  Moderate    O  3   Severe 
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126. In the past year, have you had trouble focussing your eyes ? 
O 1  Never      O 2 Occasionally 
O 3 Frequently    O 4 Constantly  
 
127. How severe is this focusing problem ? 
O 1    Mild    O 2  Moderate    O  3   Severe 
 
128. In the past year have you had blurred vision ? 
O 1  Never      O 2 Occasionally 
O 3 Frequently    O 4 Constantly  
 
129. How severe is the focusing problem 
O 1    Mild    O 2  Moderate    O  3   Severe 
 
130 In the past year, have you had difficulty seeing at night ? 
O 1  Never      O 2 Occasionally 
O 3 Frequently    O 4 Constantly  
 
131. How severe is the focusing problem 
O 1    Mild    O 2  Moderate    O  3   Severe 
 
132 In the past year, has the same degree of light seemed: 
O 1  Excessively dimmer  O 2 Much dimmer 
O 3  About the same   O 4 Much brighter 
O 5  Excessively brighter 
 
133. Which one of the following eye symptoms is the most troublesome for you ? 
O 0  None  O  1 Trouble focusing O 2 Blurred vision 
 O 3  Difficulty seeing at night. 
 
134. How long have you had this troublesome eye symptom ? 
O 0  I don’t have any of these symptoms 
O 1  Less than 3 months 
O 2  3 to 6 months 
O 3  7 to 12 months 
O 4  13 months to 5 years 
O 5  More than 5 years 
O 6  As long as I can remember 
 
135. Is this most troublesome symptom with your eyes getting: 
O 0  I don’t have any of these symptoms 
O 1  Much worse 
O 2  Somewhat worse 
O 3  Staying the same 
O 4  Somewhat better 
O 5  Much better 
O 6  Completely gone 
 
136. In the past year, have you ever noticed or been told that while sleeping you stop breathing for 
several seconds ? 
O 1   Yes   O 2  No  
 
137. In the past year, have you ever noticed or been told that while sleeping you snore loudly ? 
O 1   Yes   O 2  No  
 
Have you ever been told you have or been diagnosed as having : 
 
138. Narcolepsy     
O 1  Yes   O 2  No  O 3 Don’t know  
  
139. Obstructive sleep apnoea     
O 1  Yes   O 2  No  O 3 Don’t know 
 
140. Abnormal or disordered sleep 
Patterns      
O 1  Yes   O 2  No  O 3 Don’t know 
 
141. Currently, how refreshing and restorative is your sleep  
O 1  Not at all restorative – derive no benefit 
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O 2  Some slight restorative value 
O 3 Restorative, but not adequate 
O 4 Relatively satisfactory 
O 5 Very satisfactory – feel completely refreshed 
 
142. Compared with a year ago, how would you rate your own sleep over the last month ? 
O 1 Last month was much worse than a year ago 
O 2 Last month was slightly worse than a year ago 
O 3 Last month was about the same as a year ago 
O 4 Last month was slightly better than a year ago 
O 5 Last month was much better than a year ago 
 
143. Have you ever in your adult life had difficulty getting to sleep or staying asleep once you were 
asleep? 
O 1  Yes   O 2 No 
 
144. In the past year, have you ever noticed or been told that during the day you sometimes breathe 
very loudly (e.g. croup) ? 
 O 1 Yes   O 2 No 
 
How would you describe your alcohol use of the past year (check all that apply) 
145.  O 1  I have not drunk any alcohol over the last year 
 
146. O 1 I drink socially only. 
 
147. O 1 I have used alcohol excessively in the past year. 
 
148. O 1 I have been intoxicated one or more times in the past year. 
 
149. O 1 I have passed out from drinking too much alcohol one or more times in the past year. 
 
How would you describe your drug use over the past year ? (check all that apply) 
 
150.  O 1 I have not used any drugs in the last year 
 
151.  O 1 I have used drugs excessively in the last year 
 
152.  O 1 I have been intoxicated from drugs one or more times in the last year. 
 
153.  O 1 I have passed out from taking drugs one or more times in the last year. 
 
154. Have you ever felt that you have used alcohol or drugs excessively ?   O 1  Yes   O 1  
No 
 
155. Have you ever been told or have you been diagnosed as having alcohol of drug dependency ? 
O 1  Yes   O 2 No 
 
156. Have you received treatment for alcohol or other drug dependency 
O 1  Yes   O 2 No   Please list the drugs involved including alcohol 
     
 …………………………………………………………………….. 
Which of the following describe your cigarette smoking ? (check all that apply) 
157. O 1  I have never smoked cigarettes 
 
158. O 1 I have smoked cigarettes in the past but stopped: Date stopped : 
 
163.  O 1 I am currently smoking about ……………………… cigarettes per day. 
 
166. In the past 5 years, how would you rate the amount of trouble, if any you have had with over 
sensitive hearing ? 
O 1  None  O 2 Some   O 3 A lot   O 4 Constant 
 
167. Have you ever in your adult life had difficulty keeping your mind on your job or task ? 
O 1  Yes   O 2 No 
 
What medications have you taken in the past month ? 
 
Name of medication  How often do you take it   How much do you take 
each time 
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……………………..              ……………………………………               
………………………………………. 
……………………..              ……………………………………                
……………………………………… 
…………………….               ……………………………………               
………………………………………. 
……………………                ……………………………………               
………………………………………. 
…………………….               ……………………………………               
………………………………………. 
……………………..              ……………………………………               
………………………………………. 
……………………..              ……………………………………               
………………………….................. 
 
We welcome below (or on a separate sheet) any comments you might have about what might have 
caused or been associated with your current illness or anything that might be helpful to us in 
understanding your current condition. 
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